Urea compound having substituent

Abstract

An object of the present invention is to provide a compound that has a specific chemical structure having an activation effect on SIRT6 and is useful as an active component for preventing and treating inflammatory diseases. The present invention relates to a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof. (Each symbol in Formula (1) has the same definition as that described in the specification.)

Description

Substituent urea compounds The present invention provides compounds having a specific chemical structure that has an activating action of SIRT6 or pharmaceutically acceptable salts thereof. Sirtuins are nicotinamide-adenine dinucleotide (NAD)-dependent deacylation enzymes. It is highly conserved from prokaryotes to eukaryotes, and plays an important role in various life phenomena, such as DNA repair, energy metabolism control, aging and lifespan (Non-Patent Literature 1). Since ancient times, calorie restriction has been known to prolong lifespan and suppress various diseases called aging-related diseases (metabolic diseases, cancer, cardiac and neural diseases, inflammatory diseases, etc.), but it is thought that sirtuins play a central role in the mechanism of calorie restriction, as sirtuin is deficient in model organisms such as yeast and nematodes to prevent the prolongation of lifespan due to calorie restriction (Non-Patent Literature 2). There are seven sirtuins in mammals, including humans, up to SIRT1-7. SIRT1, SIRT6, and SIRT7 are mainly localized in the nucleus, SIRT1 is mainly localized to the nucleoplasm, SIRT6 is mainly localized to the heterochromatin region, and SIRT7 is mainly localized to the nucleolus. SIRT2 is localized in the cytoplasm, and SIRT3-5 is localized to mitochondria (Non-Patent Document 3). SIRT6 has deacylation and mono-ADP ribosylation activities. The deacetylation activity of histone H3K9 by SIRT6 has a higher substrate specificity than SIRT1, which is also localized in the nucleus, and since acetylation of H3K9 is increased in cells that knocked out SIRT6, it is thought to act as a major deacetylase (Non-patent literature 4 and 5). SIRT6 knockout mice develop normally until about 2-3 weeks after birth, but then rapidly develop premature aging-like symptoms such as a decrease in subcutaneous fat, a decrease in bone density, spinal cord cleft, and lymphocyte phenomena (Non-patent literature 6). SIRT6 regulates the transcription factor NF-κB, which is involved in the inflammatory and immune response, via deacetylation of H3K9, and in mice deficient in SIRT6, expression of inflammatory cytokines and other substances by NF-κB is constantly activated, resulting in a chronic inflammatory state. Premature aging-like symptoms in SIRT6 knockout mice are ameliorated by suppression of NF-κB (Non-patent literature 7). On the other hand, SIRT6 transgenic mice with high expression of SIRT6 become resistant to high-fat dietary load (HFD) in the same way as calorie restriction, and their lifespan is extended (Non-Patent Document 8). Research on sirtuins has progressed dramatically in recent years, and it has been suggested that SIRT6 in particular is responsible for a variety of functions, including telomere stabilizing effects, DNA repairing effects, anti-aging effects, anti-fatty liver effects, anti-obesity effects, antidiabetic effects, anti-atherosclerosis effects, anti-idiopathic pulmonary fibrosis (IPF) effects, cardioprotective effects, and anti-inflammatory and anti-rheumatic effects (Non-patent document 6-14). From these reasons, it is expected that compounds that increase the expression level of SIRT6 or enhance the activity of SIRT6 will become pharmaceuticals that exhibit medicinal efficacy against diseases including the above. The following compounds are known as compounds having inhibitory activity of phosphatidylinositol-3-kinase (Patent Documents 1 and 2). International Publication No. 2010 / 024258 International Publication No. 2010 / 125799 Imai S and Guarente L. Ten years of NAD-dependent SIR2 family deacetylases: implications for metabolic diseases. Trends Pharmacol Sci. 2010 31(5):212-220.Guarente L. Calorie restriction and sirtuins revisited. Genes Dev. 2013 27(19):2072-2085.Michishita E, Park JY, Burneskis JM, et al. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell. 2005 16(10):4623-4635.Michishita E, McCord RA, Berber E, et al. SIRT6 is a histone H3 lysine 9 deacetylase that modulates telemeric chromatin. Nature. 2008 452(7186):492-496.Michishita E, McCord RA, Boxer LD, et al. Cell cycle-dependent deacetylation of telemeric histone H3 lysine K56 by human SIRT6. Cell Cycle. 2009 8(16):2664-2666.Mostoslavsky R, Chua KF, Lombard DB, et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell. 2006 124(2):315-329Kawahara TL, Michishita E, Adler AS, et al. SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organic life span. Cell. 2009 136(1):62-74.Kanfi Y, Naiman S, Amir G, et al. The sirtuin SIRT6 regulates lifespan in male mice. Nature. 2012 483(7388):218-221McCord RA, Michishita E, Hong T, et al. SIRT6 stabilizes DNA-dependent protein kinase at chromatin for DNA double-strand break repair. Aging 2009 1(1):109-121Kim HS, Xiao C, Wang RH, et al. Hepatitic-specific disruption of SIRT6 in mice results in fatty liver Formation due to enhanced glycolysis and triglyceride synthesis. Cell Metab. 2010 12(3):224-236Kanfi Y, Peshti V, Gil R, et al. SIRT6 protects against pathological damage caused by diet-induced obesity. Aging Cell. 2010 9(2):162-173.Stohr R, Mavilio M, Marino A, et al. ITCH modulates SIRT6 and SREBP2 to influence lipid metabolism and atherosclerosis in ApoE null mice. Sci Rep. 2015 Mar 17; 5: 9023.Minagawa S, Araya J, Numata T, et al. Accelerated epithelial cell senscence in IPF and the inhibitory role of SIRT6 in TGF-β-induced senscence of human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2011 300(3): L391-401Sundaresan NR, Vasudevan P, Zhong L, et al. The sirtuin SIRT6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-Jun. Nat Med. 2012 18(11): 1643-1650 The present invention provides compounds that have a specific chemical structure that has an activating action of SIRT6 and are useful as active ingredients for the prevention and treatment of inflammatory diseases, pharmaceutically acceptable salts thereof, and the like, or novel methods of preparation and intermediates thereof. The compounds of the present invention, and pharmaceutically acceptable salts thereof, have different properties from anti-inflammatory agents in various aspects, and are considered useful as new pharmaceuticals. The present inventors have conducted intensive research into compounds useful as active ingredients for the prevention and treatment of inflammatory diseases, pharmaceutically acceptable salts, etc., and have found compounds of the present invention, pharmaceutically acceptable salts, etc. That is, the present invention is as described below. [1] A compound of formula (1) or a pharmaceutically acceptable salt thereof. The symbols in equation (1) have the following significance. R 1 , R 2 : Each independently, the same or different hydrogen atoms or C1-C6 alkyl groups; Or, R 1 and R 2 1, which are bonded to each other to form a substituent and represent any group selected from the following: R 12: C1-C6 alkyl group, hydroxyC1-C6 alkyl group, C1-C6 alkylcarbonyl group, Or, C1-C6 alkoxycarbonyl group R 6 : a C1-C6 alkyl group optionally substituted with one or two groups selected from the group G; a C3-C6 cycloalkyl group optionally substituted with one or two groups selected from the group G, or 4-7 membered saturated heterocyclic groups optionally substituted with one or two groups selected from the group G Group G: Hydroxy group, halogen atom, amino group, aminoC1-C6 alkyl group, C1-C6 alkylsulfonyl group, A carbamoyl group, optionally substituted with 1 or 2 groups selected from the group J; A C3-C6 cycloalkyl group optionally substituted with 1 or 2 groups selected from the group J; A 4-7-membered saturated heterocyclic group that may be substituted with one or two groups selected from the group J Group J: Amino C1-C6 alkyl groups, amino groups, C1-C6 alkyl groups R 7 : Hydrogen atom Or, R 6 and R 7 are bonded to each other to form a substituent, and represent the groups shown below. The group can be in either direction. R 67-1 , R 67-2 : Each independently, the same or different, is a hydrogen atom, a C1-C6 alkyl group, HydroxyC1-C6 alkyl group, C1-C4 alkylene group, or C1-C6 alkoxyC1-C6 alkyl group Q: Halogen atoms, R Q3 C1-C6 alkyl groups substituted from 1 to 3 with any group selected from R Q3 C3-C6 cycloalkyl groups substituted from 1 to 3 groups selected from R Q3 4-7-membered saturated heterocyclic groups substituted 1 to 3 with any group selected from; R Q3 an amino group substituted from 1 to 3 with any group selected from; Any of the following groups selected from R Q1 : Halogen atom, cyano group, C1-C6 alkyl group, C1-C6 alkoxy group, HaloC1-C6 alkyl group, haloC1-C6 alkoxy group, C3-C6 cycloalkylcarbonyl group, C1-C6 alkylcarbamoyl group, C1-C6 alkylsulfonyl group, or Mono(C1-C6 alkyl)aminosulfonyl group R Q2 : Hydrogen atom, hydroxyl group, or halogen atom Or, R Q1 and R Q2 are bonded to each other to form a substituent, and represent the groups shown below. R Q3 : Halogen atom, C1-C6 alkoxy group, haloC1-C6 alkyl group, HaloC1-C6 alkoxy group, C3-C6 cycloalkoxy group, phenoxy group, Benzyloxy group, C1-C6 alkylcarbamoyl group, or C1-C4 alkylene groups optionally substituted with halogen groups Y: Any group selected from the following, or a single bond The group can be in either direction. R Y1 : Hydrogen atom or C1-C6 alkyl group However, the following compounds, or pharmaceutically acceptable salts thereof, are excluded. [2] R 1 , R 2 is a hydrogen atom or R 1 and R 2 is any group that is bonded to each other to form a substituent and selected from: The compound according to [1], or a pharmaceutically acceptable salt thereof. R 12 : Methyl group, hydroxyethyl group, acetyl group, or methoxycarbonyl group [3] R 6 3. The compound according to [1] or [2], or a pharmaceutically acceptable salt thereof, wherein the compound according to [1] or [2] is any group selected from the following. C1-C6 alkyl groups, HydroxyC1-C6 alkyl groups, HydroxyC3-C6 cycloalkyl groups, Tetrahydrofuranyl group, 2-oxopyrrolidin-3-yl group [4] R 6 3. The compound according to [1] or [2], or a pharmaceutically acceptable salt thereof, wherein the compound according to [1] or [2] is any group selected from the following. Methyl group, Hydroxypropyl groups, 2-hydroxy-2-methylpropyl group, Hydroxycyclobutyl group, Tetrahydrofuranyl group [5] R 6 and R 7 is any group that binds to each other to form a substituent and is selected from: The compound according to [1] or [2], or a pharmaceutically acceptable salt thereof. The group can be in either direction. [6] Q is any of the groups selected from: R Q1 is any of the groups selected from: Halogen atom, C1-C6 alkyl group, C1-C6 alkoxy group, HaloC1-C6 alkyl groups, haloC1-C6 alkoxy groups R Q2 is any of the groups selected from: Hydrogen atoms, hydroxyl groups, fluorine atoms The compound according to any one of [1]-[5], or a pharmaceutically acceptable salt thereof. [7] Q is any of the groups selected from: R Q1 is any of the groups selected from: Fluorine atom, chlorine atom, methyl group, methoxy group, difluoromethyl group, Trifluoromethyl, difluoromethoxy, trifluoromethoxy groups R Q2 is any of the groups selected from: Hydrogen atom, hydroxyl group, or fluorine atom The compound according to any one of [1]-[5], or a pharmaceutically acceptable salt thereof. [8] Q is any of the groups selected from: R Q3 C3-C6 cycloalkyl groups substituted from 1 to 3 groups selected from R Q3 4-7-membered saturated heterocyclic groups substituted 1 to 3 with any group selected from R Q3 is any of the groups selected from: Fluorine atom, chlorine atom, methoxy group, difluoromethyl group, trifluoromethyl group, Difluoromethoxy, trifluoromethoxy, ethylene groups The compound according to any one of [1]-[5], or a pharmaceutically acceptable salt thereof. [9] Q is any of the groups selected from: The compound according to any one of [1]-[5], or a pharmaceutically acceptable salt thereof. HaloC1-C6 alkyl group, haloC1-C6 alkoxyC1-C6 alkyl group, C1-C6 alkoxyC1-C6 alkyl group

[0010] Q is any of the groups selected from: The compound according to any one of [1]-[5], or a pharmaceutically acceptable salt thereof. Fluorine atom, trifluoromethyl group, trifluoroethoxyethyl group, Ethoxyethyl group

[0011] Y is any of the groups selected from: The group can be either left or right, R Y1 is a hydrogen atom or a methyl group; The compound according to any one of [1]-

[0010] or a pharmaceutically acceptable salt thereof.

[0012] The compound according to [1] selected from the following compounds, or a pharmaceutically acceptable salt thereof. N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-methylurea N-methyl-N'-{5-[5-(trifluoromethyl)-1,3,4-oxazol-2-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}urea N-(5-{5-[(1R)-1-ethoxyethyl]-1,3,4-oxadiazol-2-yl}-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)-N'-methylurea N-methyl-N'-(5-{3-[1-(2,2,2-trifluoroethoxy)ethyl]-1,2,4-oxadiazol-5-yl}-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)urea N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(2R)-1-hydroxypropan-2-yl]urea N-methyl-N'-(10-{3-[cis-4-(trifluoromethyl)cyclohexyl]-1,2,4-oxadiazol-5-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl)urea N-{(4S,8S)-10-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea N-methyl-N'-(5-{3-[3-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)urea N-{5-[5-(4-fluoro-3-methylphenyl)-1,3,4-oxazol-2-yl]-4,5,6,7-tetrahydro[[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-methylurea N-{(5R * ,8S * )-9-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[d][1,3]thiazol-2-yl}-N'-methylurea N-{9-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[d][1,3]thiazol-2-yl}-N'-methylurea N-{(5R * ,9S * )-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-5,9-epiminocycloocta[d][1,3]thiazol-2-yl}-N'-methylurea N-{(4S,8S)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea N-(10-{5-[3-(difluoromethyl)phenyl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl)-N'-methylurea N-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea N-{10-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea N-{(4S,8S)-10-[4-(4-fluorophenyl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(2R)-1-hydroxypropan-2-yl]urea N-{6-acetyl-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl}-N'-methylurea (5R)-3-{(4S,8S)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-5-methylimidazolidine-2,4-dione

[0013] 1. A SIRT6 activator containing the compound according to any one of [1]-

[0012] or a pharmaceutically acceptable salt thereof as an active ingredient.

[0014] A pharmaceutical composition containing the compound according to any one of [1]-

[0012] or a pharmaceutically acceptable salt thereof as an active ingredient.

[0015] The pharmaceutical composition according to

[0014] , which is an oral agent.

[0016] The pharmaceutical composition according to

[0014] or

[0015] for treating and / or preventing peripheral inflammatory diseases.

[0017] The compound according to any one of [1]-

[0012] , or a pharmaceutically acceptable salt thereof, for use in the treatment and / or prevention of peripheral inflammatory diseases.

[0018] Peripheral inflammatory diseases include rheumatoid arthritis, systemic lupus erythematosus, scleroderma, bronchial asthma, asthmatic bronchitis, diffuse interstitial pneumonia, chronic obstructive pulmonary disease, ulcerative colitis, Crohn's disease, acute hepatitis, chronic hepatitis, fulminant hepatitis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerotic cholangitis, alcoholic hepatitis, non-alcoholic steatohepatitis, liver cirrhosis, peripheral neuritis, ankylosing spondylitis, acute eczema, subacute eczema, chronic eczema, contact dermatitis, sunlight and / or ultraviolet rays, radiation dermatitis, atopic dermatitis, seborrheic dermatitis, psoriasis vulgaris, The pharmaceutical composition according to

[0016] , which is selected from the group consisting of: psoriatic arthritis, erythroderma, pustular psoriasis, lichen planus, erythema, rosacea, urticaria, alopecia areata, pemphigoid group, erythema, acne vulgaris, bed ulcer, wound, burn, conjunctivitis, keratitis, scleritis, acute / chronic otitis media, perennial allergic rhinitis, hay fever, sinusitis, laryngitis, esophagitis, refractory stomatitis, glossitis, acute / chronic salivation, angular antitis, cheilitis, Behcet's disease, multiple sclerosis, type I diabetes, type II diabetes, atherosclerosis, pancreatitis, and chronic heart failure.

[0019] Peripheral inflammatory diseases include rheumatoid arthritis, systemic lupus erythematosus, scleroderma, bronchial asthma, acute hepatitis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerotic cholangitis, alcoholic hepatitis, non-alcoholic steatohepatitis, ankylosing spondylitis, contact dermatitis, sunlight and / or ultraviolet rays, radiation dermatitis, atopic dermatitis, seborrheic dermatitis, psoriasis vulgaris 可以上文帳に行します。 0016, any of the pharmaceutical compositions selected from the group consisting of: psoriasis, erythroderma psoriasis, pustular psoriasis, lichen planus, erythema, rosacea, urticaria, alopecia areata, pemphigoid group, erythema, acne vulgaris, bed ulcer, wounds, burns, sinusitis, laryngitis, esophagitis, refractory stomatitis, glossitis, acute / chronic salivary anodic anodic anodic anodic anodic anodic anodic anodic anodic anodic anodic cheilitis, and Behcet's disease.

[0020] 可以上这种用方法合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物

[0021] A method for treating and / or preventing a peripheral inflammatory disease, in which an effective amount of the pharmaceutical composition described in

[0014] or

[0015] is administered. Another aspect of the present invention relates to the following [1A]-[32A]. [1A] A compound of formula (1) or a pharmaceutically acceptable salt thereof. The symbols in equation (1) have the following significance. R 1 , R 2 : Each independently, the same or different hydrogen atoms or C1-C6 alkyl groups; Or, R 1 and R 2 1, which are bonded to each other to form a substituent and represent any group selected from the following: R 12 : C1-C6 alkyl group, hydroxyC1-C6 alkyl group, C1-C6 alkylcarbonyl group, C1-C6 alkoxycarbonyl group or C1-C6 alkylsulfonyl group R 3 : It represents a hydrogen atom or a C1-C6 alkyl group. R 6 : C1-C6 alkyl groups optionally substituted with 1 to 3 groups selected from the group G; a C3-C6 cycloalkyl group optionally substituted with one or two groups selected from the group G, or 固合物分合物分合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物合物。 Specific examples of 4-7-membered heterocyclic groups optionally substituted with one or two groups selected from the group G. Group G: Hydroxy group, halogen atom, amino group, haloC1-C6 alkyl group, HydroxyC1-C6 alkyl group, aminoC1-C6 alkyl group, C1-C6 alkoxy group, C1-C6 alkylsulfonyl group, hydroxyC1-C6 alkoxy group, C1-C6 alkylcarbonyl group, A carbamoyl group, optionally substituted with one or two groups selected from the group J; a C3-C6 cycloalkyl group optionally substituted with one or two groups selected from the group J; A 4-7-membered heterocyclic group, optionally substituted with one or two groups selected from the group J, or 5-6-membered heteroaryl groups optionally substituted with 1 or 2 groups selected from the group J Group J: Hydroxy group, oxo group, aminoC1-C6 alkyl group, amino group, C1-C6 alkyl group, or C1-C6 alkylcarbonyl group R 7 : It represents a hydrogen atom. Or, R 6 and R 7 are bonded to each other to form a substituent, and represent the groups shown below. The group can be in either direction. R 67-1 , R 67-2 : Each of them independently, the same or different, is a hydrogen atom, a C1-C6 alkyl group, HydroxyC1-C6 alkyl group, C1-C4 alkylene group, or C1-C6 alkoxyC1-C6 alkyl group Q: Halogen atoms, R Q3 C1-C6 alkyl groups substituted from 1 to 3 with any group selected from R Q3 C3-C6 cycloalkyl groups substituted from 1 to 3 groups selected from R Q3 4-7-membered saturated heterocyclic groups substituted 1 to 3 with any group selected from; R Q3 an amino group substituted one or two with any group selected from Any of the groups selected from the following are indicated. R Q1 : Halogen atom, cyano group, C1-C6 alkyl group, C1-C6 alkoxy group, HaloC1-C6 alkyl group, haloC1-C6 alkoxy group, C3-C6 cycloalkylcarbonyl group, C1-C6 alkylcarbamoyl group, C1-C6 alkylsulfonyl group, mono(C1-C6 alkyl)amino group, Di(C1-C6 alkyl)amino group, mono(C1-C6 alkyl)aminosulfonyl group, Or a tetrahydropyranyl group R Q2 : Hydrogen atom, hydroxyl group, C1-C6 alkyl group, or halogen atom Or, R Q1 and R Q2 are bonded to each other to form a substituent, and represent the groups shown below. R Q3 : Halogen atom, C1-C6 alkoxy group, haloC1-C6 alkyl group, HaloC1-C6 alkoxy group, C3-C6 cycloalkoxy group, phenoxy group, Benzyloxy group, C1-C6 alkylcarbamoyl group, or C1-C4 alkylene groups that may be substituted with halogen groups Y: Any group selected from the following, or a single bond is represented. The group can be in either direction. R Y1 : Hydrogen atom or C1-C6 alkyl group However, the following compounds, or pharmaceutically acceptable salts thereof, are excluded. [2A]R 1 and R 2 However, both are hydrogen atoms or R 1 and R 2 1, and are bonded to each other to form a substituent, indicating any group selected from the following, R 12 : methyl group, hydroxyethyl group, acetyl group, methoxycarbonyl group, or Methanesulfonyl group R 3 is a hydrogen atom or a methyl group; The compound according to [1A] or a pharmaceutically acceptable salt thereof. [3A]R 1 and R 2 However, both are hydrogen atoms or R 1 and R 2 1, and are bonded to each other to form a substituent, indicating any group selected from the following, R 13 :Acetyl group or methoxycarbonyl group R 3 indicates a hydrogen atom, The compound according to [1A] or a pharmaceutically acceptable salt thereof. [4A]R 1 and R 3 However, both have methyl groups, and 2 1A, wherein the compound according to [1A], which indicates a hydrogen atom, or a pharmaceutically acceptable salt thereof. [5A]R 6 indicates any group selected from: C1-C6 alkyl groups, HydroxyC1-C6 alkyl groups, HydroxyC3-C6 cycloalkyl group, C1-C6 alkoxyC1-C6 alkyl group, Tetrahydrofuranyl group, Tetrahydropyranyl group, or Dioxanylmethyl group R 7 but indicates a hydrogen atom, The compound according to any one of [1A] to [4A], or a pharmaceutically acceptable salt thereof. [6A]R 6 is any of the groups selected from: Methyl group, isobutyl group, 2-hydroxy-1-methylethyl group, 2-hydroxy-2-methylpropyl group, 3-hydroxybutyl group, 2-hydroxycyclopentyl group, 4-hydroxycyclohexyl group, 2-methoxypropyl group, 3-tetrahydrofuranyl group, 4-tetrahydropyranyl group, or 1,4-dioxan-2ylmethyl group R 7 is a hydrogen atom, The compound according to any one of [1A] to [4A], or a pharmaceutically acceptable salt thereof. [7A] The compound according to any one of [1A] to [6A], in which Q represents any group selected from the following, or a pharmaceutically acceptable salt thereof. R Q4C3-C6 cycloalkyl groups substituted from 1 to 3 groups selected from R Q4 phenyl groups substituted from 1 to 3 with any group selected from; R Q4 or a pyridyl group substituted from 1 to 3 groups selected from R Q4 1,3-benzoxazol-2-yl groups substituted 1 to 3 with any group selected from R Q4 : Halogen atom, cyano group, C1-C6 alkyl group, C1-C6 alkoxy group, HaloC1-C6 alkyl group, haloC1-C6 alkoxy group, C1-C6 alkylsulfonyl groups, diC1-C6 alkylamino groups, Alternatively, C3-C6 cycloalkylcarbonyl group [8A] The compound according to any one of [1A] to [6A], in which Q represents any group selected from the following, or a pharmaceutically acceptable salt thereof. A cyclohexyl group substituted with two fluorine atoms; A phenyl group substituted with a fluorine atom or a cyclopropylcarbonyl group; A pyridyl group substituted with a single group selected from the group consisting of a methoxy group, an ethoxy group, and a difluoromethoxy group, or 1,3-benzoxazol-2-yl group substituted with one or two groups independently selected from the group consisting of a fluorine atom, a methyl group, a methoxy group, an ethoxy group, a dimethylamino group, and a methanesulfonyl group [9A]Y represents a single bond or any group selected from: The group can be in either direction, The compound according to any one of [1A] to [8A], or a pharmaceutically acceptable salt thereof. [10A]Q represents a 1,3-benzoxazol-2-yl group, substituted with one or two groups independently selected from the group consisting of a fluorine atom, a methyl group, a methoxy group, an ethoxy group, a dimethylamino group, and a methanesulfonyl group; The compound according to any one of [1A] to [6A], wherein Y is a single bond, or a pharmaceutically acceptable salt thereof. [11A]Q is a cyclohexyl group in which Q is substituted with two fluorine atoms; A phenyl group substituted with a fluorine atom or a cyclopropylcarbonyl group, 固化合物分化合物分化合物用方法。 固合物用方法合物的合物的合物的合物的合物的合物的合物的合物的合物的合物的合物的合物的合物的合物的合物的合物的合物的合物的合物的合物的合物的 Y represents any group selected from: The compound according to any one of [1A] to [6A], or a pharmaceutically acceptable salt thereof. [12A] The compound according to [1A] selected from the following compounds, or a pharmaceutically acceptable salt thereof. N-[(4S,8S)-10-{5-[3-(cyclopropanecarbonyl)phenyl]-1,3,4-oxadiazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-methylurea, (-)-N-{(4R * ,8R * )-6-acetyl-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl}-N'-methylurea, (-)-Methyl (4R * ,8R * )-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate, N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(1R,2R)-2-hydroxycyclopentyl]urea, N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(1r,4r)-4-hydroxycyclohexyl]urea, N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-(3-methoxypropyl)urea, N-{[(2S)-1,4-dioxan-2-yl]methyl}-N'-{(4S,8S)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}urea, N-[(2R)-1-hydroxypropan-2-yl]-N'-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-[(4S,8S)-10-(5-fluoro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminoxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-[(4S,8S)-10-(5-ethoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-(2-hydroxy-2-methylpropyl)urea, N-{(4S,8S)-10-[5-(dimethylamino)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(2-hydroxy-2-methylpropyl)urea, N-[(4S,8S)-10-(5,6-difluoro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-{(4S,8S)-10-[5-(methanesulfonyl)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(2-methylpropyl)urea, N-(2-hydroxy-2-methylpropyl)-N'-[(4S,8S)-10-(5-methoxy-6-methyl-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-[(4S,8S)-10-(5-methoxy-6-methyl-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(3R)-oxolan-3-yl]urea, N-(2-hydroxy-2-methylpropyl)-N'-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(3R)-oxolan-3-yl]urea, N-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-methylurea, N-methyl-N'-[(4S,8S)-10-(5-methyl-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-(2-hydroxy-2-methylpropyl)-N'-[(4S,8S)-10-{5-[( 2 H 3 )Methyloxy]-1,3-benzoxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-{(4S,8S)-10-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(1s,4s)-4-hydroxycyclohexyl]urea, N-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-oxan-4-ylurea, N-[(4S,8S)-10-{5-[6-(difluoromethoxy)pyridin-2-yl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-[(2R)-1-hydroxypropan-2-yl]-N'-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}urea, N-{(4S,8S)-10-[5-(6-ethoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-[(2R)-1-hydroxypropan-2-yl]-N'-{5-[5-(methanesulfonyl)-1,3-benzoxazol-2-yl]-6,6-dimethyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}urea, N-(2-hydroxy-2-methylpropyl)-N'-{5-[5-(methanesulfonyl)-1,3-benzoxazol-2-yl]-6,6-dimethyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}urea, N-[(2R)-1-hydroxypropan-2-yl]-N'-[(4S,8S)-10-{5-[( 2 H 3 )Methyloxy]-1,3-benzoxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-[(4S,8S)-10-{5-[( 2 H 3 )methyloxy]-1,3-benzoxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(3R)-oxolan-3-yl]urea, N-[(1r,3S)-3-hydroxycyclobutyl]-N'-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}urea, N-{(4S,8S)-10-[5-(6-ethoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(2-hydroxy-2-methylpropyl)urea, N-{(4S,8S)-10-[5-(6-ethoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(1r,3S)-3-hydroxycyclobutyl]urea, N-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-oxan-4-ylurea [12A-1]N-[(4S,8S)-10-{5-[3-(cyclopropanecarbonyl)phenyl]-1,3,4-oxadiazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-methylurea, or a pharmaceutically acceptable salt thereof. [12A-2] (-)-N-{(4R) * ,8R * )-6-acetyl-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl}-N'-methylurea, or a pharmaceutically acceptable salt thereof. [12A-3] (-)-Methyl (4R * ,8R * )-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate, or a pharmaceutically acceptable salt thereof. [12A-4]N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(1R,2R)-2-hydroxycyclopentyl]urea, or a pharmaceutically acceptable salt thereof. [12A-5]N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(1r,4r)-4-hydroxycyclohexyl]urea, or a pharmaceutically acceptable salt thereof. [12A-6]N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-(3-methoxypropyl)urea, or a pharmaceutically acceptable salt thereof. [12A-7]N-{[(2S)-1,4-dioxan-2-yl]methyl}-N'-{(4S,8S)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}urea, or a pharmaceutically acceptable salt thereof. [12A-8]N-[(2R)-1-hydroxypropan-2-yl]-N'-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, or a pharmaceutically acceptable salt thereof. [12A-9]N-[(4S,8S)-10-(5-fluoro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea, or a pharmaceutically acceptable salt thereof. [12A-10]N-[(4S,8S)-10-(5-ethoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminoxocino[5,4-d][1,3]thiazol-2-yl]-N'-(2-hydroxy-2-methylpropyl)urea, or a pharmaceutically acceptable salt thereof. [12A-11]N-{(4S,8S)-10-[5-(dimethylamino)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(2-hydroxy-2-methylpropyl)urea, or a pharmaceutically acceptable salt thereof. [12A-12]N-[(4S,8S)-10-(5,6-difluoro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea, or a pharmaceutically acceptable salt thereof. [12A-13]N-{(4S,8S)-10-[5-(methanesulfonyl)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(2-methylpropyl)urea, or a pharmaceutically acceptable salt thereof. [12A-14]N-(2-hydroxy-2-methylpropyl)-N'-[(4S,8S)-10-(5-methoxy-6-methyl-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, or a pharmaceutically acceptable salt thereof. [12A-15]N-[(4S,8S)-10-(5-methoxy-6-methyl-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(3R)-oxolan-3-yl]urea, or a pharmaceutically acceptable salt thereof. [12A-16]N-(2-hydroxy-2-methylpropyl)-N'-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, or a pharmaceutically acceptable salt thereof. [12A-17]N-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(3R)-oxolan-3-yl]urea, or a pharmaceutically acceptable salt thereof. [12A-18]N-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-methylurea, or a pharmaceutically acceptable salt thereof. [12A-19]N-methyl-N'-[(4S,8S)-10-(5-methyl-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, or a pharmaceutically acceptable salt thereof. [12A-20]N-(2-hydroxy-2-methylpropyl)-N'-[(4S,8S)-10-{5-[( 2 H 3 ) Methyloxy]-1,3-benzoxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, or a pharmaceutically acceptable salt thereof. [12A-21]N-{(4S,8S)-10-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(1s,4s)-4-hydroxycyclohexyl]urea, or a pharmaceutically acceptable salt thereof. [12A-22]N-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-oxan-4-ylurea, or a pharmaceutically acceptable salt thereof. [12A-23]N-[(4S,8S)-10-{5-[6-(difluoromethoxy)pyridin-2-yl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea, or a pharmaceutically acceptable salt thereof. [12A-24]N-[(2R)-1-hydroxypropan-2-yl]-N'-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}urea, or a pharmaceutically acceptable salt thereof. [12A-25]N-{(4S,8S)-10-[5-(6-ethoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(2R)-1-hydroxypropan-2-yl]urea, or a pharmaceutically acceptable salt thereof. [12A-26]N-[(2R)-1-hydroxypropan-2-yl]-N'-{5-[5-(methanesulfonyl)-1,3-benzoxazol-2-yl]-6,6-dimethyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}urea, or a pharmaceutically acceptable salt thereof. [12A-27]N-(2-hydroxy-2-methylpropyl)-N'-{5-[5-(methanesulfonyl)-1,3-benzoxazol-2-yl]-6,6-dimethyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}urea, or a pharmaceutically acceptable salt thereof. [12A-28]N-[(2R)-1-hydroxypropan-2-yl]-N'-[(4S,8S)-10-{5-[(( 2 H 3 ) Methyloxy]-1,3-benzoxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, or a pharmaceutically acceptable salt thereof. [12A-29]N-[(4S,8S)-10-{5-[( 2 H 3 )methyloxy]-1,3-benzoxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(3R)-oxolan-3-yl]urea, or a pharmaceutically acceptable salt thereof. [12A-30]N-[(1r,3S)-3-hydroxycyclobutyl]-N'-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}urea, or a pharmaceutically acceptable salt thereof. [12A-31]N-{(4S,8S)-10-[5-(6-ethoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(2-hydroxy-2-methylpropyl)urea, or a pharmaceutically acceptable salt thereof. [12A-32]N-{(4S,8S)-10-[5-(6-ethoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(1r,3S)-3-hydroxycyclobutyl]urea, or a pharmaceutically acceptable salt thereof. [12A-33]N-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-oxan-4-ylurea, or a pharmaceutically acceptable salt thereof. [13A] A SIRT6 activator containing the compound according to any one of [1A] to [12A] or a pharmaceutically acceptable salt thereof as an active ingredient. [14A] A pharmaceutical composition containing the compound according to any one of [1A] to [12A] or a pharmaceutically acceptable salt thereof as an active ingredient. [15A] The pharmaceutical composition according to [14A], which is an oral agent. [16A] The pharmaceutical composition according to [14A], which is a topical agent. [17A] The pharmaceutical composition according to any one of [14A] to [16A] for treating and / or preventing peripheral inflammatory diseases. [18A] Peripheral inflammatory diseases include rheumatoid arthritis, systemic lupus erythematosus, scleroderma, bronchial asthma, asthmatic bronchitis, diffuse interstitial pneumonia, chronic obstructive pulmonary disease, ulcerative colitis, Crohn's disease, acute hepatitis, chronic hepatitis, fulminant hepatitis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerotic cholangitis, alcoholic hepatitis, nonalcoholic steatohepatitis, liver cirrhosis, peripheral neuritis, ankletic Spondylitis, acute eczema, subacute eczema, chronic eczema, contact dermatitis, sunlight dermatitis due to sunlight and / or ultraviolet rays, radiation dermatitis, atopic dermatitis, seborrheic dermatitis, psoriasis vulgaris, psoriatic arthritis, erythroderma, psoriatic erythroderma, pustular psoriasis, lichen planus, erythema, rosacea, urticaria, alopecia areata, pemphigoid group, erythema, acne vulgaris, bed ulcer, wound, burn, conjunctivitis, keratitis, scleritis, acute / chronic otitis media, year-round Sexual allergic rhinitis, hay fever, sinusitis, laryngitis, esophagitis, refractory stomatitis, glossitis, acute / chronic salivatitis, cheilitis, Behcet's disease, multiple sclerosis, type I diabetes, type II diabetes, atherosclerosis, pancreatitis, chronic heart failure, vitiligo vulgaris, wart vulgaris, diabetic ulcer, lower leg ulcer, keloid, hypertrophic scar, seborrheic keratosis, male pattern baldness, female pattern baldness, elderly 17A, the pharmaceutical composition selected from the group consisting of: Sexual alopecia, acne scars, pigmentation, sunlight keratosis, gray hair, chronic hand eczema, chronic pruritus, generalized skin pruritus, glaucoma, cataracts, age-related macular degeneration, idiopathic pulmonary fibrosis, acute glomerulonephritis, chronic glomerulonephritis, diabetic nephritis, hypertrophic cardiomyopathy, osteoporosis, neurogenic myopathy, myogenic myopathy, and hypertension. [19A] Peripheral inflammatory diseases include rheumatoid arthritis, systemic lupus erythematosus, scleroderma, bronchial asthma, acute hepatitis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerotic cholangitis, alcoholic hepatitis, non-alcoholic steatohepatitis, ankylosing spondylitis, contact dermatitis, sunlight and / or ultraviolet rays, radiation dermatitis, atopic dermatitis, seborrheic dermatitis, psoriasis vulgaris, psoriatic psoriasis, erythrodermatitis, pustular psoriasis, lichen planus, erythema, rosacea, urticaria, alopecia areata, pemphigoid group, erythema vulgaris, bedded The pharmaceutical composition according to [17A], which is selected from the group consisting of acne, wounds, burns, sinusitis, laryngitis, esophagitis, refractory stomatitis, glossitis, acute / chronic salivation, cheilitis, Behcet's disease, vitiligo vulgaris, wart vulgaris, vitiligo vulgaris, diabetic ulcers, lower leg ulcers, keloids, hypertrophic scars, seborrheic keratosis, male pattern alopecia, female pattern alopecia, senile alopecia, acne scars, pigmentation, sun keratosis, gray hair, chronic hand eczema, chronic pruritus, general skin pruritus, and idiopathic pulmonary fibrosis. [20A] Peripheral inflammatory diseases include rheumatoid arthritis, systemic lupus erythematosus, alcoholic hepatitis, non-alcoholic steatohepatitis, contact dermatitis, sunlight and / or ultraviolet rays, radiation dermatitis, atopic dermatitis, seborrheic dermatitis, psoriasis vulgaris, psoriatic erythroderma, psoriatic erythroderma, pustular psoriasis, lichen planus, erythema, rosacea, urticaria, alopecia areata, pemphigoid group, erythroderma, acne vulgaris, bedsores, wounds The pharmaceutical composition according to [17A], which is selected from the group consisting of wounds, burns, refractory stomatitis, glossitis, Behcet's disease, vitiligo vulgaris, wart vulgaris, diabetic ulcers, lower leg ulcers, keloids, hypertrophic scars, seborrheic keratosis, male pattern alopecia, female pattern alopecia, senile alopecia, acne scars, pigmentation, sun keratosis, gray hair, chronic hand eczema, chronic pruritus, general skin pruritus, and idiopathic pulmonary fibrosis. [21A] A method for treating and / or preventing a peripheral inflammatory disease, in which an effective amount of the pharmaceutical composition according to any one of [14A] to [16A] is administered. [22A] Peripheral inflammatory diseases include rheumatoid arthritis, systemic lupus erythematosus, scleroderma, bronchial asthma, asthmatic bronchitis, diffuse interstitial pneumonia, chronic obstructive pulmonary disease, ulcerative colitis, Crohn's disease, acute hepatitis, chronic hepatitis, fulminant hepatitis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerotic cholangitis, alcoholic hepatitis, nonalcoholic steatohepatitis, liver cirrhosis, peripheral neurotis, traction Spondylitis, acute eczema, subacute eczema, chronic eczema, contact dermatitis, sunlight dermatitis due to sunlight and / or ultraviolet rays, radiation dermatitis, atopic dermatitis, seborrheic dermatitis, psoriasis vulgaris, psoriatic arthritis, erythroderma, psoriatic erythroderma, pustular psoriasis, lichen planus, erythema, rosacea, urticaria, alopecia areata, pemphigoid group, erythema, acne vulgaris, bed ulcer, wound, burn, conjunctivitis, keratitis, scleritis, acute / chronic otitis media, Perennial allergic rhinitis, hay fever, sinusitis, laryngitis, esophagitis, refractory stomatitis, glossitis, acute / chronic salivatitis, cheilitis, Behcet's disease, multiple sclerosis, type I diabetes, type II diabetes, atherosclerosis, pancreatitis, chronic heart failure, vitiligo vulgaris, wart vulgaris, diabetic ulcer, lower leg ulcer, keloid, hypertrophic scar, seborrheic keratosis, male pattern alopecia, female pattern alopecia , the method according to [21A], which is selected from the group consisting of senile alopecia, acne scars, pigmentation, sunlight keratosis, gray hair, chronic hand eczema, chronic pruritus, generalized skin pruritus, glaucoma, cataracts, age-related macular degeneration, idiopathic pulmonary fibrosis, acute glomerulonephritis, chronic glomerulonephritis, diabetic nephritis, hypertrophic cardiomyopathy, osteoporosis, neurogenic myopathy, myogenic myopathy, and hypertension. [23A] Peripheral inflammatory diseases include rheumatoid arthritis, systemic lupus erythematosus, scleroderma, bronchial asthma, acute hepatitis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerotic cholangitis, alcoholic hepatitis, non-alcoholic steatohepatitis, ankylosing spondylitis, contact dermatitis, sunlight and / or ultraviolet rays, radiation dermatitis, atopic dermatitis, seborrheic dermatitis, plaque psoriasis, psoriasis, erythroderma vulgaris, psoriasis, pustular psoriasis, lichen planus, erythema, rosacea, urticaria, alopecia areata, pemphigoid group, erythema, erythema, rosacea, urticaria, alopecia areata, pemphigoid group, erythema , the method according to [21A], which is selected from the group consisting of acne vulgaris, bed ulcers, wounds, burns, sinusitis, laryngitis, esophagitis, refractory stomatitis, glossitis, acute / chronic salivation, cheilitis, Behcet's disease, vitiligo vulgaris, wart vulgaris, diabetic ulcers, lower leg ulcers, keloids, hypertrophic scars, seborrheic keratosis, male pattern alopecia, female pattern alopecia, senile alopecia, acne scars, pigmentation, sun keratosis, gray hair, chronic hand eczema, chronic pruritus, general skin pruritus, and idiopathic pulmonary fibrosis. [24A] Peripheral inflammatory diseases include rheumatoid arthritis, systemic lupus erythematosus, alcoholic hepatitis, non-alcoholic steatohepatitis, contact dermatitis, sunlight and / or ultraviolet rays, radiation dermatitis, atopic dermatitis, seborrheic dermatitis, psoriasis vulgaris, psoriatic erythroderma, psoriatic erythroderma, pustular psoriasis, lichen planus, erythema, rosacea, urticaria, alopecia areata, pemphigoid group, erythroderma, acne vulgaris, bedsorum, 3. The method according to [21A], which is selected from the group consisting of wounds, burns, refractory stomatitis, glossitis, Behcet's disease, vitiligo vulgaris, wart vulgaris, diabetic ulcers, lower leg ulcers, keloids, hypertrophic scars, seborrheic keratosis, male pattern alopecia, female pattern alopecia, senile alopecia, acne scars, pigmentation, sun keratosis, gray hair, chronic hand eczema, chronic pruritus, general skin pruritus, and idiopathic pulmonary fibrosis. [25A] A compound according to any one of [1A] to [12A], or a pharmaceutically acceptable salt thereof, for use in the treatment and / or prevention of peripheral inflammatory diseases. [26A] Peripheral inflammatory diseases include rheumatoid arthritis, systemic lupus erythematosus, scleroderma, bronchial asthma, asthmatic bronchitis, diffuse interstitial pneumonia, chronic obstructive pulmonary disease, ulcerative colitis, Crohn's disease, acute hepatitis, chronic hepatitis, fulminant hepatitis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerotic cholangitis, alcoholic hepatitis, nonalcoholic steatohepatitis, liver cirrhosis, peripheral neuritis, ankylosing spondylitis , acute eczema, subacute eczema, chronic eczema, contact dermatitis, sunlight dermatitis due to sunlight and / or ultraviolet rays, radiation dermatitis, atopic dermatitis, seborrheic dermatitis, psoriasis vulgaris, psoriatic arthritis, erythroderma, psoriatic erythroderma, pustular psoriasis, lichen planus, erythema, rosacea, urticaria, alopecia areata, pemphigoid group, erythema, acne vulgaris, bed ulcer, wound, burn, conjunctivitis, keratitis, scleritis, acute / chronic otitis media, perennial allergies Sexual rhinitis, hay fever, sinusitis, laryngitis, esophagitis, refractory stomatitis, glossitis, acute / chronic salivatitis, cheilitis, Behcet's disease, multiple sclerosis, type I diabetes, type II diabetes, atherosclerosis, pancreatitis, chronic heart failure, vitiligo vulgaris, wart vulgaris, diabetic ulcer, lower leg ulcer, keloid, hypertrophic scar, seborrheic keratosis, male pattern alopecia, female pattern alopecia, senile alopecia, acne scar , or a pharmaceutically acceptable salt thereof, which is selected from the group consisting of pigmentation, sunlight keratosis, gray hair, chronic eczema, chronic pruritus, generalized cutaneous pruritus, glaucoma, cataracts, age-related macular degeneration, idiopathic pulmonary fibrosis, acute glomerulonephritis, chronic glomerulonephritis, diabetic nephritis, hypertrophic cardiomyopathy, osteoporosis, neurogenic myopathy, myogenic myopathy, and hypertension. [27A] Peripheral inflammatory diseases include rheumatoid arthritis, systemic lupus erythematosus, scleroderma, bronchial asthma, acute hepatitis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerotic cholangitis, alcoholic hepatitis, non-alcoholic steatohepatitis, ankylosing spondylitis, contact dermatitis, sunlight and / or ultraviolet rays, radiation dermatitis, atopic dermatitis, seborrheic dermatitis, psoriasis vulgaris, psoriatic psoriasis, erythrodermatitis, pustular psoriasis, lichen planus, erythema, rosacea, urticaria, alopecia areata, pemphigoid group, erythema vulgaris, bedded 合方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方法方 [28A] Peripheral inflammatory diseases include rheumatoid arthritis, systemic lupus erythematosus, alcoholic hepatitis, non-alcoholic steatohepatitis, contact dermatitis, sunlight and / or ultraviolet rays, radiation dermatitis, atopic dermatitis, seborrheic dermatitis, psoriasis vulgaris, psoriatic psoriasis, erythrodermatitis, pustular psoriasis, lichen planus, erythema, rosacea, urticaria, alopecia areata, pemphigoid group, erythema, acne vulgaris, bedsorption, wounds, burns, curative treatment 3. The compound according to [25A], or a pharmaceutically acceptable salt thereof, which is selected from the group consisting of stomatitis, glossitis, Behcet's disease, vitiligo vulgaris, warts vulgaris, diabetic ulcers, lower leg ulcers, keloids, hypertrophic scars, seborrheic keratosis, male pattern alopecia, female pattern alopecia, senile alopecia, acne scars, pigmentation, sunlight keratosis, gray hair, chronic hand eczema, chronic pruritus, generalized skin pruritus, and idiopathic pulmonary fibrosis. [29A] The use of the compound according to any one of [1A] to [12A], or a pharmaceutically acceptable salt thereof, in the manufacture of a pharmaceutical composition for use in the treatment and / or prevention of peripheral inflammatory diseases. [30A] Peripheral inflammatory diseases include rheumatoid arthritis, systemic lupus erythematosus, scleroderma, bronchial asthma, asthmatic bronchitis, diffuse interstitial pneumonia, chronic obstructive pulmonary disease, ulcerative colitis, Crohn's disease, acute hepatitis, chronic hepatitis, fulminant hepatitis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerotic cholangitis, alcoholic hepatitis, non-alcoholic steatohepatitis, liver cirrhosis, peripheral neurotis, traction Spondylitis, acute eczema, subacute eczema, chronic eczema, contact dermatitis, sunlight dermatitis due to sunlight and / or ultraviolet rays, radiation dermatitis, atopic dermatitis, seborrheic dermatitis, psoriasis vulgaris, psoriatic arthritis, erythroderma, psoriatic erythroderma, pustular psoriasis, lichen planus, erythema, rosacea, urticaria, alopecia areata, pemphigoid group, erythema, acne vulgaris, bed ulcer, wound, burn, conjunctivitis, keratitis, scleritis, acute / chronic otitis media, Perennial allergic rhinitis, hay fever, sinusitis, laryngitis, esophagitis, refractory stomatitis, glossitis, acute / chronic salivatitis, cheilitis, Behcet's disease, multiple sclerosis, type I diabetes, type II diabetes, atherosclerosis, pancreatitis, chronic heart failure, vitiligo vulgaris, wart vulgaris, diabetic ulcer, lower leg ulcer, keloid, hypertrophic scar, seborrheic keratosis, male pattern alopecia, female pattern alopecia , the use according to [29A], which is selected from the group consisting of senile alopecia, acne scars, pigmentation, sunlight keratosis, gray hair, chronic hand eczema, chronic pruritus, generalized skin pruritus, glaucoma, cataracts, age-related macular degeneration, idiopathic pulmonary fibrosis, acute glomerulonephritis, chronic glomerulonephritis, diabetic nephropathy, hypertrophic cardiomyopathy, osteoporosis, neurogenic myopathy, myogenic myopathy, and hypertension. [31A] Peripheral inflammatory diseases include rheumatoid arthritis, systemic lupus erythematosus, scleroderma, bronchial asthma, acute hepatitis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerotic cholangitis, alcoholic hepatitis, non-alcoholic steatohepatitis, ankylosing spondylitis, contact dermatitis, sunlight and / or ultraviolet rays, radiation dermatitis, atopic dermatitis, seborrheic dermatitis, plaque psoriasis, psoriasis, erythrodermatitis, psoriasis, pustular psoriasis, lichen planus, erythema, rosacea, urticaria, alopecia areata, pemphigoid group, erythema, erythema, rosacea, urticaria, alopecia areata, pemphigoid group, erythema , any of the following is selected from the group consisting of acne vulgaris, bed ulcers, wounds, burns, sinusitis, laryngitis, esophagitis, refractory stomatitis, glossitis, acute / chronic salivation, cheilitis, Behcet's disease, vitiligo vulgaris, wart vulgaris, diabetic ulcers, lower leg ulcers, keloids, hypertrophic scars, seborrheic keratosis, male pattern alopecia, female pattern alopecia, senile alopecia, acne scars, pigmentation, sun keratosis, gray hair, chronic hand eczema, chronic pruritus, general skin pruritus, and idiopathic pulmonary fibrosis. [32A] Peripheral inflammatory diseases include rheumatoid arthritis, systemic lupus erythematosus, alcoholic hepatitis, non-alcoholic steatohepatitis, contact dermatitis, sunlight and / or ultraviolet rays, radiation dermatitis, atopic dermatitis, seborrheic dermatitis, psoriasis vulgaris, psoriatic erythroderma, psoriatic erythroderma, pustular psoriasis, lichen planus, erythema, rosacea, urticaria, alopecia areata, pemphigoid group, erythroderma, acne vulgaris, bedsorption, The use according to [29A] is selected from the group consisting of wounds, burns, refractory stomatitis, glossitis, Behcet's disease, vitiligo vulgaris, wart vulgaris, diabetic ulcers, lower leg ulcers, keloids, hypertrophic scars, seborrheic keratosis, male pattern alopecia, female pattern alopecia, senile alopecia, acne scars, pigmentation, sun keratosis, gray hair, chronic hand eczema, chronic pruritus, general skin pruritus, and idiopathic pulmonary fibrosis. The compounds having a specific chemical structure having an anti-inflammatory effect of the present invention or pharmaceutically acceptable salts thereof have different properties from the anti-inflammatory agents that have existed in various aspects, and are considered useful as new pharmaceuticals. Furthermore, the compounds of the present invention and their pharmaceutically acceptable salts have excellent properties in terms of anti-inflammatory activity, bioavailability, solubility, cell membrane permeability, oral absorption, blood concentration, metabolic stability, tissue migration, in vitro activity, in vivo activity, ex vivo activity, speed of drug efficacy, sustained drug efficacy, physical stability, drug interaction, safety (for example, cardiotoxicity or hepatotoxicity), and are considered to be useful as pharmaceuticals. The present invention will be described in detail below. (Substituents, explanations of terms, etc.) One aspect of the present invention is a compound of formula (1) or a pharmaceutically acceptable salt thereof. (The symbols in formula (1) representing each substituent group have the same meaning as above.) Suitable aspects of the compounds of formula (1) of the present invention include the following: ・R 1 and R 2 As R 1 and R 2 However, each of these groups is preferably a hydrogen atom or any group selected from the following, which is bonded to each other to form a substituent. R 12 : Methyl group, hydroxyethyl group, acetyl group, or methoxycarbonyl group, or methanesulfonyl group ・R 3 Suitable examples include a hydrogen atom or a C1-C6 alkyl group. ・R 1 , R 2 and R 3 Suitable combinations of R 1 , R 2 and R 3 However, they are both hydrogen atoms. ・R 1 , R 2 and R 3 Another suitable combination of R 1 and R 3 However, both are methyl groups, and 2 is a hydrogen atom. ・R 1 , R 2 and R 3 Another suitable combination of R 1 and R 2 is any group that binds to each other to form a substituent, and is selected from: R 3 is a hydrogen atom. ・R 6 As such, groups represented by any of (1)-(2) below are suitable. (1) Any of the following selected groups C1-C6 alkyl groups, HydroxyC1-C6 alkyl groups, HydroxyC3-C6 cycloalkyl groups, Tetrahydrofuranyl group, Tetrahydropyranyl group (2) Any of the following groups selected from: Methyl group, Hydroxypropyl groups, 2-hydroxy-2-methylpropyl group, Hydroxycyclobutyl group, Tetrahydrofuranyl group, Tetrahydropyranyl group ・R 7 As such, hydrogen atoms are preferred. ・R 6 and R 7 Another aspect of the R 6 and R 7 It is preferred that they bond together to form any substituent selected from: The group can be in either direction. ・R 6 and R 7 Another suitable combination of R 6 is a methyl group, and 7 is a hydrogen atom. ・R 6 and R 7 Another suitable combination of R 6 is a 2-hydroxy-2-methylpropyl group, 7 is a hydrogen atom. ・R 6 and R 7 Another suitable combination of R 6 is a 2-hydroxy-1-methylethyl group, 7 is a hydrogen atom. ・R 6 and R 7 Another suitable combination of R 6 is a 4-tetrahydropyranyl group, 7 is a hydrogen atom. - Suitable groups shown in any of (1)-(4) below are: (1) Any of the following selected groups R Q1 is any of the groups selected from: Halogen atom, C1-C6 alkyl group, C1-C6 alkoxy group, HaloC1-C6 alkyl groups, haloC1-C6 alkoxy groups R Q2 is one of the following groups selected from: Hydrogen atoms, hydroxyl groups, fluorine atoms (2) Any of the following groups selected from: R Q1 is any of the groups selected from: Fluorine atom, chlorine atom, methyl group, methoxy group, difluoromethyl group, Trifluoromethyl, difluoromethoxy, trifluoromethoxy groups R Q2 is one of the following groups selected from: Hydrogen atom, hydroxyl group, or fluorine atom (3) Any of the following groups selected from: R Q3 C3-C6 cycloalkyl groups substituted from 1 to 3 groups selected from R Q3 4-7-membered saturated heterocyclic groups substituted 1 to 3 with any group selected from R Q3 is one of the following groups selected from: Fluorine atom, chlorine atom, methoxy group, difluoromethyl group, trifluoromethyl group, Difluoromethoxy, trifluoromethoxy, ethylene groups (4) Any of the following groups selected from: HaloC1-C6 alkyl group, haloC1-C6 alkoxyC1-C6 alkyl group, C1-C6 alkoxyC1-C6 alkyl group Another preferred embodiment of Q is a group shown in any of the following: -A suitable group is any of the following selected groups: -Y. The group can be in either direction. R Y1 is a hydrogen atom or a methyl group; Another preferred embodiment of Y is the group shown in any of the following: Suitable combinations of Q and Y are groups shown in any of the following: Another suitable combination of Q and Y is that Y is a single bond and Q is a group represented by any of the following: Another aspect of the present invention is a compound selected from the following or a pharmaceutically acceptable salt thereof. N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-methylurea, N-methyl-N'-{5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}urea, N-(5-{5-[(1R)-1-ethoxyethyl]-1,3,4-oxadiazol-2-yl}-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)-N'-methylurea, N-methyl-N'-(5-{3-[1-(2,2,2-trifluoroethoxy)ethyl]-1,2,4-oxadiazol-5-yl}-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)urea, N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-methyl-N'-(10-{3-[(1s,4s)-4-(trifluoromethyl)cyclohexyl]-1,2,4-oxadiazol-5-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl)urea, N-{(4S,8S)-10-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea, N-methyl-N'-(5-{3-[3-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)urea, N-{5-[5-(4-fluoro-3-methylphenyl)-1,3,4-oxadiazol-2-yl]-4,5,6,7-tetrahydro[[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-methylurea, N-{(5R * ,8S * )-9-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[d][1,3]thiazol-2-yl}-N'-methylurea, N-{9-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[d][1,3]thiazol-2-yl}-N'-methylurea, N-{(5R * ,9S * )-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-5,9-epiminocycloocta[d][1,3]thiazol-2-yl}-N'-methylurea, N-{(4S,8S)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea, N-(10-{5-[3-(difluoromethyl)phenyl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl)-N'-methylurea, N-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea, N-{10-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea, N-{(4S,8S)-10-[4-(4-fluorophenyl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea, N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-{6-acetyl-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl}-N'-methylurea, (5R)-3-{(4S,8S)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-5-methylimidazolidine-2,4-dione, N-[(4S,8S)-10-{5-[3-(cyclopropanecarbonyl)phenyl]-1,3,4-oxadiazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-methylurea, N-[(4S,8S)-10-{5-[3-(difluoromethoxy)phenyl]-1,3,4-oxadiazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-methylurea, (-)-N-{(4R * ,8R * )-6-acetyl-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl}-N'-methylurea, (-)-Methyl (4R * ,8R * )-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate, N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(1R,2R)-2-hydroxycyclopentyl]urea, N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(1r,4r)-4-hydroxycyclohexyl]urea, N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-(3-methoxypropyl)urea, N-{5-[3-(3,3-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-(2-hydroxy-2-methylpropyl)urea, N-{[(2S)-1,4-dioxan-2-yl]methyl}-N'-{(4S,8S)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}urea, N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-6-(methanesulfonyl)-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl}-N'-oxan-4-ylurea, N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-6-(methanesulfonyl)-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl}-N'-methylurea, Propan-2-yl 10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate, Methyl (4R) *,8R * )-2-{[(2-hydroxy-2-methylpropyl)carbamoyl]amino}-10-{3-[1-(trifluoromethyl)cyclopropyl]-1,2,4-oxadiazol-5-yl}-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate, N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[2-(2-hydroxyethoxy)ethyl]urea, N-{5-[3-(3,3-difluorocyclopentyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(1r,3r)-3-hydroxycyclobutyl]urea, N-{5-[3-(3,3-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-methylurea, N-[(3R)-oxolan-3-yl]-N'-[(4S,8S)-10-{3-[1-(trifluoromethyl)cyclopropyl]-1,2,4-oxadiazol-5-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-[(2R)-1-hydroxypropan-2-yl]-N'-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-[(4S,8S)-10-(5-fluoro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminoxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-[(4S,8S)-10-(5-ethoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-(2-hydroxy-2-methylpropyl)urea, N-{(4S,8S)-10-[5-(dimethylamino)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(2-hydroxy-2-methylpropyl)urea, N-[(4S,8S)-10-(5,6-difluoro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-{(4S,8S)-10-[5-(methanesulfonyl)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(2-methylpropyl)urea, N-(2-hydroxy-2-methylpropyl)-N'-[(4S,8S)-10-(5-methoxy-6-methyl-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-[(4S,8S)-10-(5-methoxy-6-methyl-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(3R)-oxolan-3-yl]urea, N-(2-hydroxy-2-methylpropyl)-N'-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(3R)-oxolan-3-yl]urea, N-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-methylurea, N-methyl-N'-[(4S,8S)-10-(5-methyl-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-{(4S,8S)-10-[5-(methanesulfonyl)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminoxocino[5,4-d][1,3]thiazol-2-yl}-N'-propan-2-ylurea, N-[(4S,8S)-10-(6-cyano-5-methyl-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-(2-hydroxy-2-methylpropyl)urea, N-[(4S,8S)-10-(5-ethoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-{(4S,8S)-10-[5-(difluoromethyl)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(2-hydroxy-2-methylpropyl)urea, N-[(1r,3S)-3-hydroxycyclobutyl]-N'-[(4S,8S)-10-(5-trifluoromethoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-{(4S,8S)-10-(5-cyano-6-fluoro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-(2-hydroxy-2-methylpropyl)urea, N-{(4S,8S)-10-[5-(difluoromethyl)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(2R)-1-hydroxypropan-2-yl)urea, N-{(4S,8S)-10-[5-(fluoromethoxy)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(2-hydroxy-2-methylpropyl)urea, N-(1-hydroxy-2-methylpropan-2-yl)-N'-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-[(4S,8S)-10-(5-chloro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-(2-hydroxy-2-methylpropyl)-N'-[(4S,8S)-10-{5-[( 2 H 3 )Methyloxy]-1,3-benzoxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-{(4S,8S)-10-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(1s,4s)-4-hydroxycyclohexyl]urea, N-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-oxan-4-ylurea, N-{(4S,8S)-10-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(2-hydroxy-2-methylpropyl)urea, Methyl 10-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate, N-{(4S,8S)-10-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazolo-2-yl}-N'-[(2R)-2-hydroxypropyl]urea, N-[(4S,8S)-10-{5-[6-(difluoromethoxy)pyridin-2-yl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-[(2R)-1-hydroxypropan-2-yl]-N'-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}urea, N-{(4S,8S)-10-[5-(6-ethoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-[(4S,8S)-10-{5-[3-(difluoromethyl)phenyl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-(1-hydroxy-2-methylpropan-2-yl)urea, N-[(4S,8S)-10-{5-[3-(difluoromethoxy)phenyl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-[(4S,8S)-10-{5-[3-(difluoromethyl)phenyl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-[(4S,8S)-10-{5-[3-(difluoromethyl)phenyl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-2-hydroxypropyl]urea, N-[(4S,8S)-10-{5-[3-(difluoromethoxy)phenyl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(3R)-oxolan-3-yl]urea, N-[(2R)-1-hydroxypropan-2-yl]-N'-{5-[5-(methanesulfonyl)-1,3-benzoxazol-2-yl]-6,6-dimethyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}urea, N-(2-hydroxy-2-methylpropyl)-N'-{5-[5-(methanesulfonyl)-1,3-benzoxazol-2-yl]-6,6-dimethyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}urea, N-[(2R)-1-hydroxypropan-2-yl]-N'-[(4S,8S)-10-{5-[( 2 H 3 )Methyloxy]-1,3-benzoxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-[(4S,8S)-10-{5-[( 2 H 3 )methyloxy]-1,3-benzoxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(3R)-oxolan-3-yl]urea, N-[(1r,3S)-3-hydroxycyclobutyl]-N'-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}urea, N-{(4S,8S)-10-[5-(6-ethoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(2-hydroxy-2-methylpropyl)urea, N-{(4S,8S)-10-[5-(6-ethoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(1r,3S)-3-hydroxycyclobutyl]urea, N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(2S)-2-hydroxypropyl]urea, N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(2R)-2-hydroxypropyl]urea, N-{10-[3-(4-fluoro-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(1r,3r)-3-(hydroxymethyl)cyclobutyl]urea, N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(1s,3s)-3-hydroxycyclobutyl]urea, N-{(4S,8S)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(1r,3S)-3-hydroxycyclobutyl]urea, N-{5-[3-(3,3-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-(2-hydroxy-2-methylpropyl)urea, N-[(2R)-1-hydroxypropan-2-yl]-N'-(5-{3-[1-(2,2,2-trifluoroethoxy)ethyl]-1,2,4-oxadiazol-5-yl}-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)urea, N-{(4S,8S)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(1-hydroxy-2-methylpropan-2-yl)urea, N-[(2R)-1-hydroxypropan-2-yl]-N'-(5-{3-[2-(2,2,2-trifluoroethoxy)propan-2-yl]-1,2,4-oxadiazol-5-yl}-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)urea, N-(2-hydroxy-2-methylpropyl)-N'-(5-{3-[1-(trifluoromethyl)cyclopropyl]-1,2,4-oxadiazol-5-yl}-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)urea, N-{5-[3-(4-fluorobicyclo[2.2.1]heptan-1-yl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-methylurea, N-{5-[3-(3,3-difluorocyclopentyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-(2-hydroxy-2-methylpropyl)urea, N-{5-[3-(4,4-difluorooxan-2-yl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(3R)-oxolan-3-yl]urea, N-(5-{3-[3-(difluoromethyl)bicyclo[1.1.1]pentan-1-yl]-1,2,4-oxadiazol-5-yl}-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)-N'-(2-hydroxy-2-methylpropyl)urea, N-[(1r,3r)-3-hydroxycyclobutyl]-N'-(5-{3-[1-(trifluoromethyl)cyclopropyl]-1,2,4-oxadiazol-5-yl}-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)urea, N-{5-[3-(4,4-difluorooxan-2-yl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-(2-methoxyethyl)urea, N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(pyrimidin-5-yl)methyl]urea, N-{5-[3-(4-fluoro-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(1-methyl-1H-imidazol-2-yl)methyl]urea, N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(2-oxo-1,2-dihydropyridin-4-yl)methyl]urea, N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(4H-1,2,4-triazol-3-yl)methyl]urea, N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(2-oxo-1,2-dihydropyridin-3-yl)methyl]urea, N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(1-hydroxycyclopropyl)methyl]urea, N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[1-(hydroxymethyl)cyclopropyl]urea, N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]urea, N-{5-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-oxan-4-ylurea, N-{5-[3-(3-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-oxan-4-ylurea, N-(10-{5-[3-(difluoromethyl)phenyl]-1,3,4-oxadiazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl)-N'-methylurea, N-methyl-N'-(10-{5-[3-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl)urea, N-{10-[5-(3-tert-butoxyphenyl)-1,3,4-oxadiazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea, N-(10-{3-[3-(cyclopropanecarbonyl)phenyl]-1,2,4-oxadiazol-5-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl)-N'-methylurea, N-(10-{5-[3-(cyclobutanecarbonyl)phenyl]-1,3,4-oxadiazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl)-N'-methylurea, N-(10-{5-[3-((cyclopropanecarbonyl)phenyl]-1,3,4-oxadiazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl)-N'-(2,2,2-trifluoroethyl)urea, N-(10-{5-[3-(difluoromethoxy)phenyl]-1,3,4-oxadiazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl)-N'-[(3S)-oxolan-3-yl]urea, N-(10-{5-[3-(cyclopropanecarbonyl)-2-fluorophenyl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl)-N'-methylurea, N-[(4S,8S)-10-{5-[3-(cyclopropanecarbonyl)phenyl]-1,3,4-oxadiazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-propan-2-ylurea, N-{(4S,8S)-10-[5-(3-ethylphenyl)-1,3,4-oxadiazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea, N-methyl-N'-[(4S,8S)-10-{5-[3-(propan-2-yl)phenyl]-1,3,4-oxadiazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-{(4S,8S)-10-[5-(3-methoxyphenyl)-1,3,4-oxadiazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea, N-{(4S,8S)-10-[5-(3-ethoxyphenyl)-1,3,4-oxadiazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea, N-methyl l-N'-[(4S,8S)-10-(5-{3-[(propan-2-yl)oxy]phenyl}-1,3,4-oxadiazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, Methyl 10-{5-[3-(cyclopropanecarbonyl)phenyl]-1,3,4-oxadiazol-2-yl}-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate, N-(10-{3-[3-(difluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl)-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-[(4R,8R)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-6-(2-methylpropanoyl)-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl]-N'-methylurea, N-{6-acetyl-10-[5-(6-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl}-N'-methylurea, N-[(4R,8R)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-6-(2-hydroxyethyl)-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl]-N'-methylurea, N-(6-acetyl-10-{5-[6-(difluoromethoxy)pyridin-2-yl]-1,3-oxazol-2-yl}-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl)-N'-methylurea, N-{6-acetyl-10-[5-(6-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl}-N'-methylurea, N-[6-acetyl-10-(5-fluoro-1,3-benzoxazol-2-yl)-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl]-N'-methylurea, Methyl 10-[3-(3,3-difluorocyclopentyl)-1,2,4-oxadiazol-5-yl]-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate, Methyl 10-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate, Methyl 10-[3-(4-fluorobicyclo[2.2.1]heptan-1-yl)-1,2,4-oxadiazol-5-yl]-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate, Ethyl 2-[(methylcarbamoyl)amino]-10-{3-[1-(trifluoromethyl)cyclopropyl]-1,2,4-oxadiazol-5-yl}-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate, Methyl 10-{3-[3-(difluoromethyl)bicyclo[1.1.1]pentan-1-yl]-1,2,4-oxadiazol-5-yl}-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate, N-{6-acetyl-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl}-N'-ethylurea, N-{6-acetyl-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl}-N'-propan-2-ylurea, N-{6-acetyl-10-[3-(3-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl}-N'-methylurea, N-{6-acetyl-10-[5-(3-chlorophenyl)-1,3-oxazol-2-yl]-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl}-N'-methylurea, N-{6-acetyl-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl}-N'-[(3R)-oxolan-3-yl]urea, Methyl 10-(5-methoxy-1,3-benzoxazol-2-yl)-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate, Methyl 10-[3-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-5-yl]-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate, Propan-2-yl 10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-{[(oxan-4-yl)carbamoyl]amino}-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate, N-(2-hydroxy-2-methylpropyl)-N'-{(4S,8S)-10-[5-(trifluoromethyl)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}urea, N-(2-hydroxy-2-methylpropyl)-N'-[(4S,8S)-10-(5-methyl-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-[(4S,8S)-10-(5,6-difluoro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-(2-hydroxy-2-methylpropyl)urea, N-[(4S,8S)-10-(5,7-difluoro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-[(4S,8S)-10-(5,6-dimethyl-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-[(4S,8S)-10-(5-chloro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(1r,4r)-4-hydroxycyclohexyl]urea, N-[(4S,8S)-10-(5-chloro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminoxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(4-hydroxyoxan-4-yl)methyl]urea, N-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(3S)-oxolan-3-yl]urea, N-[(2R)-1-hydroxypropan-2-yl]-N'-{9-[5-(methanesulfonyl)-1,3-benzoxazol-2-yl]-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[d][1,3]thiazol-2-yl}urea, N-{5-[5-(4,4-difluorocyclohexyl)-1,2-oxazol-3-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(2R)-2-hydroxypropyl]urea, N-{(4S,8S)-10-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-{(4S,8S)-10-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-[(4S,8S)-10-{5-[3-(difluoromethyl)phenyl]-1,2-oxazol-3-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-{(4S,8S)-10-[5-(4,4-difluorocyclohexyl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(3R)-oxolan-3-yl]urea, N-{(4S,8S)-10-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(1s,3R)-3-hydroxycyclobutyl]urea, N-{(4S,8S)-10-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(1r,4r)-4-hydroxycyclohexyl]urea, N-{(4S,8S)-10-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(1-hydroxy-2-methylpropan-2-yl)urea, N-{(4S,8S)-10-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-oxan-4-ylurea, N-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(3S)-oxolan-3-yl]urea, N-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(3R)-oxolan-3-yl]urea, N-{(4S,8S)-10-[5-(3-methoxyphenyl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(3R)-oxolan-3-yl]urea, N-(1,1-dioxo-1λ 6 -thian-4-yl)-N'-{(4S,8S)-10-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}urea, N-(10-{5-[3-(difluoromethyl)phenyl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl)-N'-[(1r,3r)-3-hydroxycyclobutyl]urea, N-[(4S,8S)-10-{5-[3-(difluoromethoxy)phenyl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(1r,3S)-3-hydroxycyclobutyl]urea, N-[(4S,8S)-10-{5-[3-(difluoromethyl)phenyl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2S)-1-hydroxypropan-2-yl]urea, N-[(4S,8S)-10-{5-[6-(difluoromethoxy)pyridin-2-yl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2S)-1-hydroxypropan-2-yl]urea, N-[(4S,8S)-10-{5-[3-(difluoromethoxy)phenyl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-(1-hydroxy-2-methylpropan-2-yl)urea, N-[(4S,8S)-10-{5-[3-(difluoromethoxy)phenyl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-2-hydroxypropyl]urea, N-[(4S,8S)-10-{5-[3-(difluoromethoxy)phenyl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-(2-hydroxy-2-methylpropyl)urea, N-[(4S,8S)-10-{5-[3-(difluoromethoxy)phenyl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2S)-1-hydroxypropan-2-yl]urea, N-[(4S,8S)-10-{5-[6-(difluoromethoxy)pyridin-2-yl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2S)-2-hydroxypropyl]urea, N-[(4S,8S)-10-{5-[6-(difluoromethoxy)pyridin-2-yl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(3R,4S)-4-hydroxyoxolan-3-yl]urea, N-[(4S,8S)-10-{5-[6-(difluoromethoxy)pyridin-2-yl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(1r,4r)-4-hydroxycyclohexyl]urea, N-[(4S,8S)-10-{5-[6-(difluoromethoxy)pyridin-2-yl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2-hydroxypyridin-4-yl)methyl]urea, N-[(4S,8S)-10-{5-[6-(difluoromethoxy)pyridin-2-yl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)methyl]urea, N-[(4S,8S)-10-{5-[6-(difluoromethoxy)pyridin-2-yl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(1-hydroxycyclopropyl)methyl]urea, N-[(4S,8S)-10-{5-[6-(difluoromethoxy)pyridin-2-yl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-(1,1-dioxo-1λ 6 Chian-4-il) Urea, N-[(4S,8S)-10-{5-[6-(difluoromethoxy)pyridin-2-yl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[1-(hydroxymethyl)cyclopropyl]urea, N-[(3R)-1-acetylpyrrolidin-3-yl]-N'-[(4S,8S)-10-{5-[6-(difluoromethoxy)pyridin-2-yl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-(1-acetylazetidin-3-yl)-N'-[(4S,8S)-10-{5-[6-(difluoromethoxy)pyridin-2-yl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-(2-hydroxy-2-methylpropyl)-N'-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}urea, N-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(3R)-oxolan-3-yl]urea, N-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminoxocino[5,4-d][1,3]thiazol-2-yl}-N'-oxan-4-ylurea, N-[(1s,4s)-4-hydroxycyclohexyl]-N'-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}urea, N-[(1r,4r)-4-hydroxycyclohexyl]-N'-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}urea, N-[(2R)-1-hydroxypropan-2-yl]-N'-[5-(5-methoxy-1,3-benzoxazol-2-yl)-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl]urea, N-(2-hydroxy-2-methylpropyl)-N'-[5-(5-methoxy-1,3-benzoxazol-2-yl)-6,6-dimethyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl]urea, N-[(2R)-1-hydroxypropan-2-yl]-N'-{5-[4-(oxan-3-yl)pyrimidin-2-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}urea, N-[(1r,3r)-3-hydroxycyclobutyl]-N'-{5-[4-(oxan-3-yl)pyrimidin-2-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}urea, N-[(2R)-1-hydroxypropan-2-yl]-N'-{(4S,8S)-10-[5-(6-methoxy-5-methylpyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}urea A preferred embodiment of the present invention is a compound selected from the following or a pharmaceutically acceptable salt thereof. N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-methylurea, N-methyl-N'-{5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}urea, N-(5-{5-[(1R)-1-ethoxyethyl]-1,3,4-oxadiazol-2-yl}-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)-N'-methylurea, N-methyl-N'-(5-{3-[1-(2,2,2-trifluoroethoxy)ethyl]-1,2,4-oxadiazol-5-yl}-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)urea, N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-methyl-N'-(10-{3-[(1s,4s)-4-(trifluoromethyl)cyclohexyl]-1,2,4-oxadiazol-5-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl)urea, N-{(4S,8S)-10-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea, N-methyl-N'-(5-{3-[3-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)urea, N-{5-[5-(4-fluoro-3-methylphenyl)-1,3,4-oxadiazol-2-yl]-4,5,6,7-tetrahydro[[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-methylurea, N-{(5R * ,8S * )-9-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[d][1,3]thiazol-2-yl}-N'-methylurea, N-{9-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[d][1,3]thiazol-2-yl}-N'-methylurea, N-{(5R * ,9S * )-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-5,9-epiminocycloocta[d][1,3]thiazol-2-yl}-N'-methylurea, N-{(4S,8S)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea, N-(10-{5-[3-(difluoromethyl)phenyl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl)-N'-methylurea, N-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea, N-{10-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea, N-{(4S,8S)-10-[4-(4-fluorophenyl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea, N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-{6-acetyl-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl}-N'-methylurea, (5R)-3-{(4S,8S)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-5-methylimidazolidine-2,4-dione, N-[(4S,8S)-10-{5-[3-(cyclopropanecarbonyl)phenyl]-1,3,4-oxadiazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-methylurea, N-[(4S,8S)-10-{5-[3-(difluoromethoxy)phenyl]-1,3,4-oxadiazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-methylurea, (-)-N-{(4R * ,8R * )-6-acetyl-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl}-N'-methylurea, (-)-Methyl (4R * ,8R * )-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate, N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(1R,2R)-2-hydroxycyclopentyl]urea, N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(1r,4r)-4-hydroxycyclohexyl]urea, N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-(3-methoxypropyl)urea, N-{5-[3-(3,3-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-(2-hydroxy-2-methylpropyl)urea, N-{[(2S)-1,4-dioxan-2-yl]methyl}-N'-{(4S,8S)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}urea, N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-6-(methanesulfonyl)-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl}-N'-oxan-4-ylurea, N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-6-(methanesulfonyl)-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl}-N'-methylurea, Propan-2-yl 10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate, Methyl (4R) * ,8R * )-2-{[(2-hydroxy-2-methylpropyl)carbamoyl]amino}-10-{3-[1-(trifluoromethyl)cyclopropyl]-1,2,4-oxadiazol-5-yl}-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate, N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[2-(2-hydroxyethoxy)ethyl]urea, N-{5-[3-(3,3-difluorocyclopentyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(1r,3r)-3-hydroxycyclobutyl]urea, N-{5-[3-(3,3-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-methylurea, N-[(3R)-oxolan-3-yl]-N'-[(4S,8S)-10-{3-[1-(trifluoromethyl)cyclopropyl]-1,2,4-oxadiazol-5-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-[(2R)-1-hydroxypropan-2-yl]-N'-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-[(4S,8S)-10-(5-fluoro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminoxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-[(4S,8S)-10-(5-ethoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-(2-hydroxy-2-methylpropyl)urea, N-{(4S,8S)-10-[5-(dimethylamino)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(2-hydroxy-2-methylpropyl)urea, N-[(4S,8S)-10-(5,6-difluoro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-{(4S,8S)-10-[5-(methanesulfonyl)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(2-methylpropyl)urea, N-(2-hydroxy-2-methylpropyl)-N'-[(4S,8S)-10-(5-methoxy-6-methyl-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-[(4S,8S)-10-(5-methoxy-6-methyl-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(3R)-oxolan-3-yl]urea, N-(2-hydroxy-2-methylpropyl)-N'-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(3R)-oxolan-3-yl]urea, N-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-methylurea, N-methyl-N'-[(4S,8S)-10-(5-methyl-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-{(4S,8S)-10-[5-(methanesulfonyl)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminoxocino[5,4-d][1,3]thiazol-2-yl}-N'-propan-2-ylurea, N-[(4S,8S)-10-(6-cyano-5-methyl-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-(2-hydroxy-2-methylpropyl)urea, N-[(4S,8S)-10-(5-ethoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-{(4S,8S)-10-[5-(difluoromethyl)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(2-hydroxy-2-methylpropyl)urea, N-[(1r,3S)-3-hydroxycyclobutyl]-N'-[(4S,8S)-10-(5-trifluoromethoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-{(4S,8S)-10-(5-cyano-6-fluoro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-(2-hydroxy-2-methylpropyl)urea, N-{(4S,8S)-10-[5-(difluoromethyl)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(2R)-1-hydroxypropan-2-yl)urea, N-{(4S,8S)-10-[5-(fluoromethoxy)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(2-hydroxy-2-methylpropyl)urea, N-(1-hydroxy-2-methylpropan-2-yl)-N'-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-[(4S,8S)-10-(5-chloro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-(2-hydroxy-2-methylpropyl)-N'-[(4S,8S)-10-{5-[( 2 H 3 )Methyloxy]-1,3-benzoxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-{(4S,8S)-10-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(1s,4s)-4-hydroxycyclohexyl]urea, N-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-oxan-4-ylurea, N-{(4S,8S)-10-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(2-hydroxy-2-methylpropyl)urea, Methyl 10-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate, N-{(4S,8S)-10-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazolo-2-yl}-N'-[(2R)-2-hydroxypropyl]urea, N-[(4S,8S)-10-{5-[6-(difluoromethoxy)pyridin-2-yl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-[(2R)-1-hydroxypropan-2-yl]-N'-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}urea, N-{(4S,8S)-10-[5-(6-ethoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-[(4S,8S)-10-{5-[3-(difluoromethyl)phenyl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-(1-hydroxy-2-methylpropan-2-yl)urea, N-[(4S,8S)-10-{5-[3-(difluoromethoxy)phenyl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-[(4S,8S)-10-{5-[3-(difluoromethyl)phenyl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-[(4S,8S)-10-{5-[3-(difluoromethyl)phenyl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-2-hydroxypropyl]urea, N-[(4S,8S)-10-{5-[3-(difluoromethoxy)phenyl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(3R)-oxolan-3-yl]urea, N-[(2R)-1-hydroxypropan-2-yl]-N'-{5-[5-(methanesulfonyl)-1,3-benzoxazol-2-yl]-6,6-dimethyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}urea, N-(2-hydroxy-2-methylpropyl)-N'-{5-[5-(methanesulfonyl)-1,3-benzoxazol-2-yl]-6,6-dimethyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}urea, N-[(2R)-1-hydroxypropan-2-yl]-N'-[(4S,8S)-10-{5-[( 2 H 3 )Methyloxy]-1,3-benzoxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-[(4S,8S)-10-{5-[( 2 H 3 )methyloxy]-1,3-benzoxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(3R)-oxolan-3-yl]urea, N-[(1r,3S)-3-hydroxycyclobutyl]-N'-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}urea, N-{(4S,8S)-10-[5-(6-ethoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(2-hydroxy-2-methylpropyl)urea, N-{(4S,8S)-10-[5-(6-ethoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(1r,3S)-3-hydroxycyclobutyl]urea, A more preferred embodiment of the present invention is a compound selected from the following or a pharmaceutically acceptable salt thereof. N-[(4S,8S)-10-{5-[3-(cyclopropanecarbonyl)phenyl]-1,3,4-oxadiazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-methylurea, (-)-N-{(4R * ,8R * )-6-acetyl-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl}-N'-methylurea, (-)-Methyl (4R * ,8R * )-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate, N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(1R,2R)-2-hydroxycyclopentyl]urea, N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(1r,4r)-4-hydroxycyclohexyl]urea, N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-(3-methoxypropyl)urea N-{[(2S)-1,4-dioxan-2-yl]methyl}-N'-{(4S,8S)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}urea, N-[(2R)-1-hydroxypropan-2-yl]-N'-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-[(4S,8S)-10-(5-fluoro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminoxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-[(4S,8S)-10-(5-ethoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-(2-hydroxy-2-methylpropyl)urea, N-{(4S,8S)-10-[5-(dimethylamino)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(2-hydroxy-2-methylpropyl)urea, N-[(4S,8S)-10-(5,6-difluoro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-{(4S,8S)-10-[5-(methanesulfonyl)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(2-methylpropyl)urea, N-(2-hydroxy-2-methylpropyl)-N'-[(4S,8S)-10-(5-methoxy-6-methyl-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-[(4S,8S)-10-(5-methoxy-6-methyl-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(3R)-oxolan-3-yl]urea, N-(2-hydroxy-2-methylpropyl)-N'-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(3R)-oxolan-3-yl]urea, N-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-methylurea, N-methyl-N'-[(4S,8S)-10-(5-methyl-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-(2-hydroxy-2-methylpropyl)-N'-[(4S,8S)-10-{5-[( 2 H 3 )Methyloxy]-1,3-benzoxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-{(4S,8S)-10-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(1s,4s)-4-hydroxycyclohexyl]urea, N-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-oxan-4-ylurea, N-[(4S,8S)-10-{5-[6-(difluoromethoxy)pyridin-2-yl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-[(2R)-1-hydroxypropan-2-yl]-N'-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}urea, N-{(4S,8S)-10-[5-(6-ethoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-[(2R)-1-hydroxypropan-2-yl]-N'-{5-[5-(methanesulfonyl)-1,3-benzoxazol-2-yl]-6,6-dimethyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}urea, N-(2-hydroxy-2-methylpropyl)-N'-{5-[5-(methanesulfonyl)-1,3-benzoxazol-2-yl]-6,6-dimethyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}urea, N-[(2R)-1-hydroxypropan-2-yl]-N'-[(4S,8S)-10-{5-[( 2 H 3 )Methyloxy]-1,3-benzoxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-[(4S,8S)-10-{5-[( 2 H 3 )methyloxy]-1,3-benzoxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(3R)-oxolan-3-yl]urea, N-[(1r,3S)-3-hydroxycyclobutyl]-N'-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}urea, N-{(4S,8S)-10-[5-(6-ethoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(2-hydroxy-2-methylpropyl)urea, N-{(4S,8S)-10-[5-(6-ethoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(1r,3S)-3-hydroxycyclobutyl]urea The substituents and terms used to represent the compound of formula (1) or a pharmaceutically acceptable salt thereof will be explained below. In this specification, "C1-C6 alkyl group" refers to a linear or branched chain alkyl group having 1-6 carbon atoms, such as methyl, ethyl, 1-propyl, isopropyl, 1-butyl, 2-butyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 1-pentyl, 2-pentyl, 3 Examples include a pentyl group, a 2-methyl-2-butyl group, a 3-methyl-2-butyl group, a 1-hexyl group, a 2-hexyl group, a 3-hexyl group, a 2-methyl-1-pentyl group, a 3-methyl-1-pentyl group, a 2-ethyl-1-butyl group, a 2,2-dimethyl-1-butyl group, or a 2,3-dimethyl-1-butyl group. In this specification, the "C1-C6 alkoxy group" refers to a group in which an oxy group is bound to a C1-C6 alkyl group, and examples include a methoxy group, an ethoxy group, a 1-propoxy group, a 2-propoxy group, a 1-butoxy group, a 2-butoxy group, a 2-methyl-1-propoxy group, a 2-methyl-2-propoxy group, a 1-pentyloxy group, a 2-pentyloxy group, a 3-pentyloxy group, a 2-methyl-2-butoxy group, a 3-methyl-2-butoxy group, a 1-hexyloxy group, a 2-hexyloxy group, a 3-hexyloxy group, a 3-hexyloxy group, a 2-methyl-1-pentyloxy group, or a 3-methyl-1-pentyloxy group. In this specification, a "hydroxyC1-C6 alkyl group" refers to a group in which any number of hydroxyl groups are attached to a C1-C6 alkyl group. It is preferably a group in which one to three hydroxyl groups are bonded, and more preferably a group in which one hydroxyl group is bonded. Specific groups include, for example, hydroxymethyl group, hydroxyethyl group, hydroxypropyl group, hydroxyisopropyl group, or hydroxyisobutyl group. In this specification, the "C1-C6 alkylcarbonyl group" refers to a group in which a C1-C6 alkyl group is bound to a carbonyl group, and examples include an acetyl group, an ethylcarbonyl group, or a propylcarbonyl group. In this specification, the "C1-C6 alkylcarbamoyl group" refers to a group in which a C1-C6 alkyl group is attached to a carbamoyl group, and examples include a methylcarbamoyl group, an ethylcarbamoyl group, or a propylcarbamoyl group. In this specification, the "C1-C6 alkylsulfonyl group" refers to a group in which a C1-C6 alkyl group is bound to a sulfonyl group, and examples include a methanesulfonyl group, an ethanesulfonyl group, or a butanesulfonyl group. In this specification, the "C1-C6 alkoxycarbonyl group" refers to a group in which a C1-C6 alkoxy group is bound to a carbonyl group, and examples include a methoxycarbonyl group, an ethoxycarbonyl group, or a t-butoxycarbonyl group. In this specification, a "hydroxyC1-C6 alkoxy group" refers to a group in which any number of hydroxyl groups are attached to a C1-C6 alkoxy group. It is preferably a group with one to three hydroxyl groups attached, and more preferably a group with one hydroxyl group attached. Specific groups include, for example, hydroxymethoxy, hydroxyethoxy, hydroxypropoxy, hydroxyisopropoxy, or hydroxyisobutoxy. In this specification, the "C3-C6 cycloalkyl group" refers to a cyclic alkyl group having 3-6 carbon atoms, and examples thereof include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, or a cyclohexyl group. In this specification, the "C3-C6 cycloalkoxy group" refers to a group in which an oxy group is attached to a C3-C6 cycloalkyl group, and examples include a cyclopropoxy group, a cyclobutoxy group, a cyclopentyloxy group, or a cyclohexyloxy group. In this specification, the "C3-C6 cycloalkylcarbonyl group" refers to a group in which a carbonyl group has 3-6 carbon atoms is bonded to a carbonyl group, and examples include a cyclopropylcarbonyl group, a cyclobutylcarbonyl group, a cyclopentylcarbonyl group, or a cyclohexylcarbonyl group. In this specification, a "hydroxyC3-C6 cycloalkyl group" refers to a group in which any number of hydroxyl groups are attached to a C3-C6 cycloalkyl group. It is preferably a group with one to three hydroxyl groups attached, and more preferably a group with one hydroxyl group attached. Specific groups include, for example, hydroxycyclopropyl, hydroxycyclobutyl, hydroxycyclopentyl, or hydroxycyclohexyl. As used herein, a "4-7-membered heterocyclic group" refers to a monocyclic 4-7-membered heterocyclic group containing 1-3 atoms selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom, and may contain one or two unsaturated bonds in the ring. Examples include an azetidyl group, a pyrrolidyl group, an imidazolyl group, a pyrazolyl group, an oxazolyl group, a thiazolyl group, a piperidinyl group, azepanyl group, a piperazinyl group, a hexahydropyrimidinyl group, morpholyl group, thiomorpholyl group, oxetanyl group, tetrahydrofuranyl group, tetrahydropyranyl group, dioxanyl group, thioxanyl group, oxepanyl group, dihydropyridyl group, and the like. Suitable rings such as the ones shown below are: In this specification, the "5-6-membered heterocyclic group" refers to a monocyclic 5-6-membered aromatic heterocyclic group containing 1-3 atoms selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom, and examples thereof include an imidazolyl group, a triazolyl group, a pyridyl group, or a pyrimidyl group. In this specification, "halogen atom" includes, for example, a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom. In this specification, a "haloC1-C6 alkyl group" refers to a group in which an arbitrary number of halogen atoms is substituted by a C1-C6 alkyl group. It is preferably a group in which one to three halogen atoms are bonded. Specific groups include, for example, difluoromethyl, trifluoromethyl, or difluoroethyl. In this specification, a "haloC1-C6 alkoxy group" refers to a group in which an arbitrary number of halogen atoms is substituted by a C1-C6 alkoxy group. It is preferably a group in which one to three halogen atoms are bonded. Specific groups include, for example, difluoromethoxy, trifluoromethoxy, or difluoroethoxy. In this specification, the "C1-C6 alkoxyC1-C6 alkyl group" refers to a group in which one C1-C6 alkoxy group is bound to a C1-C6 alkyl group, and examples include a methoxymethyl group, an ethoxymethyl group, or an ethoxyethyl group. In this specification, the "haloC1-C6 alkoxyC1-C6 alkyl group" refers to a group in which one haloC1-C6 alkoxy group is bound to a C1-C6 alkyl group, and examples include a difluoromethoxymethyl group, a trifluoromethoxymethyl group, or a difluoroethoxyethyl group. In this specification, the "mono(C1-C6 alkyl)amino group" refers to a group in which one C1-C6 alkyl group is attached to an amino group, and examples include a methylamino group, an ethylamino group, or a propylamino group. In this specification, the "di(C1-C6 alkyl)amino group" refers to a group in which two C1-C6 alkyl groups identical or different to the amino group, and examples include a dimethylamino group, a diethylamino group, or a dipropylamino group. In this specification, the "aminoC1-C6 alkyl group" refers to a group in which one amino group is attached to a C1-C6 alkyl group, and examples include an aminomethyl group, an aminoethyl group, or an aminopropyl group. In this specification, the "mono(C1-C6 alkyl)aminosulfonyl group" refers to a group in which a mono(C1-C6 alkyl)amino group is a group in which a sulfonyl group is bound, and examples include a methylaminosulfonyl group or an ethylaminosulfonyl group. In this specification, the "C1-C4 alkylene group" refers to a saturated chain alkylene group having two bonds and having 1-4 carbon atoms, including, for example, a methylene group, an ethylene group, a propylene group, or a butylene group. "Pharmaceutically acceptable salts" refer to salts that can be used as pharmaceuticals. In the compound, when an acidic group or basic group is present, the compound can be made into a basic salt or an acid salt by reacting it with a base or acid, and therefore it is a salt thereof. Pharmacologically acceptable "basic salts" of the compounds are suitably alkali metal salts such as sodium, potassium, and lithium salts; alkaline earth metal salts such as magnesium, and calcium salts; alkaline earth metal salts such as N-methylmorpholine, triethylamine, tributylamine, diisopropylethylamine, dicyclohexylamine, N-methylpiperidine, pyridine, 4-pyrrolidinopyridine, and picoline salts, and amino acid salts such as glycine, lysine, arginine, ornithine, glutamate, and aspartate, and are preferably alkali metal salts. The pharmacologically acceptable "acidic salts" of the compounds are suitably inorganic acid salts such as hydrofluorides, hydrochlorides, hydrobromides, hydroiodides, nitrates, perchlorates, sulfates, phosphates, and the like; lower alkanesulfonates such as methanesulfonates, trifluoromethanesulfonates, ethanesulfonates, benzenesulfonates, p-toluenes Organic acid salts such as aryl sulfonates, acetates, malates, fumarates, succinates, citrates, ascorbates, tartrates, oxalates, maleates, and the like; or amino acid salts such as glycine, lysine, arginine, ornithine, glutamate, aspartate, and most preferably hydrohalides (particularly hydrochlorides). The compounds of the present invention or pharmaceutically acceptable salts thereof may be left in the atmosphere or recrystallized to absorb water, and may be hydrated, and the present invention also includes a variety of such hydrates, solvates and polycrystalline compounds. The compounds of the present invention, pharmaceutically acceptable salts or solvates thereof, may include various isomers such as geometric isomers such as cis and trans, tautomers, rotomers, or optical isomers such as d and l (including enantiomers and diastereomers), depending on the type and combination of substituents. The compounds of the present invention include, where not particularly limited, all of these isomers, stereoisomers, and any proportion of these isomers and mixtures of stereoisomers. Mixtures of these isomers can be separated by known resolution means. The compounds of the present invention also include labels, ie, compounds in which one or more atoms of the compound are replaced with isotopes (for example, 2H, 3H, 13C, 14C, 35S, etc.). The compounds of the present invention are generally named according to the nomenclature of International Union of Pure and Applied Chemistry (IUPAC). In the compound name of the present invention, when an atom that is an asymmetric center in the structure of the compound, the absolute configuration of the compound may be indicated by R and S (indicated together with the position number). Relative arrangements are marked with * marks on the arrangement indication when the initial arrangement of the asymmetric center is R or S (R) * And S * ) or a prefix (symbol) rel- (meaning relative) may be preceded by the name. Racemic mixtures usually show their absolute configurations without using R and S, * And S * The symbols RS and SR may be used instead, or the name may be prefixed with a prefix (symbol) rac- (meaning racemic). The present invention also includes so-called prodrugs. A prodrug is a compound having a group capable of converting the compound into an amino group, a hydroxyl group, a carboxyl group, etc. by hydrolysis or under physiological conditions, and the group that forms such a prodrug is a group described in Prog. Med., Vol. 5, pp. 2157-2161, 1985, etc. More specifically, as the prodrug, (1) If an amino group is present in the compound, Examples of compounds in which the amino group is acylated, alkylated, or phosphorylated (for example, compounds in which the amino group is eicosanoylated, alanylated, pentylaminocarbonylated, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxycarbonylated, tetrahydrofuranylated, pyrrolidylmethylated, pivaloyloxymethylated, tert-butylated, etc.) can be mentioned, (2) If a hydroxyl group is present in the compound, Examples of compounds in which the hydroxyl group is acylated, alkylated, phosphorylated, or booxidized (for example, compounds in which the hydroxyl group is acetylated, palmitoylated, propanoylated, pivaloylated, succinylated, fumarylated, alanylated, dimethylaminomethylcarbonylated, etc.) can be mentioned, (3) Furthermore, if a carboxy group is present in the compound, Examples include compounds in which the carboxy group is esterified or amidated (for example, compounds in which the carboxy group is ethyl esterified, phenyl esterified, carboxymethyl esterified, dimethylaminomethyl esterified, pivaloyloxymethyl esterified, ethoxycarbonyloxyethyl esterified, amidated or methylamidated). (Manufacturing method) The manufacturing method is described below. However, the method for producing the compound or its salt is not limited to the following methods. [Method A] Method A is a method for producing compound (A-V). [wherein, Bn represents a benzyl group, and R 1 and R 2 1, which are bonded to each other to form a substituent and represent any group selected from the following: R 12 : C1-C6 alkyl group, hydroxyC1-C6 alkyl group, C1-C6 alkylcarbonyl group, or C1-C6 alkoxycarbonyl group] (Step A1) Step of performing oxidative cleavage (When using ozone) This is a step of carrying out a reaction from compound (A-I) using ozone and a reducing agent to obtain compound (A-II). Examples of reducing agents include triphenylphosphine, dimethylsulfide, and the like. Solvents include methanol, dichloromethane, or mixtures thereof. The reaction temperature is usually around -78°C to room temperature, and the reaction time is usually around 0.25 to 24 hours. (When using an oxidizing agent) This is a step of carrying out a reaction from compound (A-I) using an oxidizing agent to obtain compound (A-II). The oxidizing agent may include potassium permanganate, osmium tetroxide, sodium periodate, and the like, or mixtures thereof. Solvents include tetrahydrofuran, acetonitrile, water, dichloromethane, and the like, or mixtures thereof. The reaction temperature is usually about 0°C to room temperature, and the reaction time is usually about 0.5 to 24 hours. (Step A2) Step to carry out epoxidation This is a step of carrying out a reaction from compound (A-I) using an oxidizing agent in the presence or absence of a base to obtain compound (A-III). Examples of the base include sodium bicarbonate and pyridine. Examples of the oxidizing agent include 3-chloroperbenzoic acid (mCPBA), hydrogen peroxide, and the like. Solvents include dichloromethane, acetonitrile, methanol, water, and the like, or mixtures thereof. The reaction temperature is usually about 0°C to 60°C, and the reaction time is usually about 0.25 to 24 hours. (A3 step) Step to open the epoxy This is a step of carrying out a reaction from compound (A-III) in the presence or absence of an acid or base using an aqueous solvent to obtain compound (A-IV). Examples of the acid include sulfuric acid. Examples of the base include sodium hydroxide. Solvents include tetrahydrofuran, methanol, water, and the like, or mixtures thereof. The reaction temperature is usually about room temperature to 100°C, and the reaction time is usually about 0.25 to 24 hours. (A4 step) Step to carry out oxidative cleavage This is a step of carrying out a reaction from the compound (A-IV) using an oxidizing agent to obtain the compound (A-II). Examples of the oxidizing agent include sodium periodate. The solvent may include tetrahydrofuran, acetonitrile, methanol, water, or mixtures thereof. The reaction temperature is usually about 0°C to room temperature, and the reaction time is usually about 0.5 to 24 hours. (A5 step) Step to form rings This is a step of carrying out a reaction from compound (A-II) using benzylamine or 1,3-acetone dicarboxylic acid in the presence of an acid to obtain compound (A-V). Examples of the acid include hydrochloric acid. The solvent may include tetrahydrofuran, acetonitrile, methanol, water, or mixtures thereof. The reaction temperature is usually about 0°C to 60°C, and the reaction time is usually about 0.5 to 24 hours. [Method B] Method B is a method for producing compound (B-III). [wherein, Bn represents a benzyl group, and R 1 and R 2 1, which are bonded to each other to form a substituent and represent any group selected from the following: R 12 : C1-C6 alkyl group, hydroxyC1-C6 alkyl group, C1-C6 alkylcarbonyl group, or C1-C6 alkoxycarbonyl group P a1 1 shows a commonly used protecting group of an amino group. ] (Step B1) Deprotection process This is a step of carrying out a reaction from compound (B-I) in a hydrogen atmosphere, in the presence or absence of acid, using a transition metal catalyst to obtain compound (B-II). Examples of the acid include hydrochloric acid, hydrogen chloride-1,4-dioxane, hydrogen chloride-ethyl acetate, and the like. Examples of transition metal catalysts include palladium-carbon, palladium-carbon, Raney-nickel, and the like. Examples of the solvent include methanol, ethanol, ethyl acetate, chloroform, and the like, or mixtures thereof. The reaction temperature is usually around 0 to 100°C, and the reaction time is usually around 0.5 to 24 hours. (Step B2)Protection process (For carbamate groups) This is a step of carrying out a reaction from compound (B-II) using a carbamate reagent in the presence of a base to obtain compound (B-III). In this step, a carbamate group refers to a carbamate group that is generally used as a protecting group for an amino group in synthesis, such as a t-butoxycarbonyl (Boc), 2-(trimethylsilyl)ethoxycarbonyl (Teoc), allyloxycarbonyl (Alloc), benzyloxycarbonyl (Cbz) group. Examples of the bases include triethylamine, diisopropylethylamine, sodium hydrogen carbonate, 4-dimethylaminopyridine, and the like. Examples of carbamate reagents include chloroformate, dicarbonate, succinimidyl carbonate, and the like. Solvents include tetrahydrofuran, dichloromethane, N,N-dimethylformamide, water, and the like, or mixtures thereof. The reaction temperature is usually about 0 to 80°C, and the reaction time is usually about 0.5 to 24 hours. [Method C] Method C is a method for producing compound (C-II). [In the ceremony, R 1 and R 2 has the same meaning as in the case of the compound of formula (1) above, and P a1 has the same meaning as above. ] (Step C1) Deprotection process (For t-butoxycarbonyl (Boc) group) This is a step of carrying out a reaction from a compound (C-I) containing an amino group protected by a t-butoxycarbonyl group using an acid to obtain compound (C-II). Examples of the acid include hydrochloric acid, hydrogen chloride-1,4-dioxane, hydrogen chloride-ethyl acetate, trifluoroacetic acid, p-toluenesulfonic acid, and the like. Solvents include methanol, ethanol, tetrahydrofuran, dichloromethane, water, and the like, or mixtures thereof. The reaction temperature is usually about 0 to 100°C, and the reaction time is usually about 0.5 to 24 hours. (For benzyl (Bn) groups) This is a step of obtaining compound (C-I) containing an amino group protected by a benzyl group is reacted using a transition metal catalyst in the presence or absence of acids in the hydrogen atmosphere, using a transition metal catalyst. This step can be carried out by the same method as in step B1. [D Method] Method D is a method for producing compound (D-III). [In the ceremony, R 1 , R 2 and R 3 has the same meaning as in the case of the compound of formula (1) above, and P a1 has the same meaning as above. ] (Step D1) Step to form a thiazole ring (When using sulfur) This is a step of carrying out a reaction from the compound (D-I) using a base, sulfur, cyanamide, and an acid to obtain the compound (D-II). Examples of the bases include pyrrolidine, piperidine, diethylamine, pyridine, and the like. Examples of the acid include hydrogen chloride-1,4-dioxane, p-toluenesulfonic acid, and the like. Examples of the solvent include methanol, ethanol, isopropanol, toluene, and the like. The reaction temperature is usually about 0 to 130°C, and the reaction time is usually about 0.5 to 24 hours. (When using thiourea) This is a step of obtaining compound (D-I) by carrying out a reaction using a halogenating reagent or thiourea in the presence or absence of a base. Examples of the halogenating reagents include N-bromosuccinimide, bromine, bromine-1,4-dioxane complex, pyridinium bromide perbromide, iodine, N-iodosuccinimide, and the like. Examples of the base include sodium bicarbonate. Solvents include chloroform, ethanol, and the like, or mixtures thereof. The reaction temperature is usually about 0 to 100°C, and the reaction time is usually about 0.5 to 24 hours. (Step D2) Deprotection process (For t-butoxycarbonyl (Boc) group) This is a step of carrying out a reaction from a compound (D-II) containing an amino group protected by a t-butoxycarbonyl group using an acid to obtain compound (D-III). Examples of the acid include hydrochloric acid, hydrogen chloride-1,4-dioxane, hydrogen chloride-ethyl acetate, trifluoroacetic acid, p-toluenesulfonic acid, and the like. Solvents include methanol, ethanol, tetrahydrofuran, dichloromethane, water, and the like, or mixtures thereof. The reaction temperature is usually about 0 to 100°C, and the reaction time is usually about 0.5 to 24 hours. [Method E] Method E is a method for producing compound (E-IV). [In the ceremony, R 1 and R 2 has the same meaning as in the case of the compound of formula (1) above, and P a1 indicates the same meaning as above, and P a2 Is P a1 固合物分化合物分化合物分化合物分化合物合物的化合物的化合物的化合物的化合物的化合物。 � ] (Step E1) Step to form a thiazole ring This is a step of obtaining compound (E-II) from compound (E-I). This step can be carried out by the same method as (Step D1). (E2 step)Protection process (For carbamate groups) This is a step of carrying out a reaction from compound (E-II) using a base and a carbamate reagent to obtain compound (E-III). This step can be carried out by the same method as in (Step B2). In this step, a carbamate group refers to a carbamate group that is generally used as a protecting group for an amino group in synthesis, such as a t-butoxycarbonyl (Boc), 2-(trimethylsilyl)ethoxycarbonyl (Teoc), allyloxycarbonyl (Alloc), benzyloxycarbonyl (Cbz) group. (For acyl groups) This is a step of carrying out a reaction from compound (E-II) using a base and an acylating reagent to obtain compound (E-III). In this step, an acyl group refers to an acyl group that is generally used as a protecting group for an amino group, such as an acetyl group, a trifluoroacetyl group, or a benzoyl group. Examples of the bases include triethylamine, diisopropylethylamine, pyridine, 4-dimethylaminopyridine, and the like. Examples of the acylating reagent include acyl chloride, acid anhydride, and the like. Examples of the solvent include tetrahydrofuran, dichloromethane, N,N-dimethylformamide, and the like. The reaction temperature is usually about 0 to 80°C, and the reaction time is usually about 0.5 to 24 hours. (E3 step) Deprotection process (For t-butoxycarbonyl (Boc) group) This is a step of carrying out a reaction from a compound (E-III) containing an amino group protected by a t-butoxycarbonyl group using an acid to obtain compound (E-IV). This step can be carried out by the same method as in (step C1). (For 2-(trimethylsilyl)ethoxycarbonyl (Teoc) group) This is a step of carrying out a reaction from a compound (E-III) containing an amino group protected by a 2-(trimethylsilyl)ethoxycarbonyl group using a desilylating reagent or an acid to obtain compound (E-IV). Examples of the desilylating reagent include tetrabutylammonium fluoride (TBAF), hydrogen fluoride, pyridine hydrogen fluoride, and the like. Examples of the acids include hydrochloric acid, sulfuric acid, hydrochloric acid-methanol, hydrochloric acid-1,4-dioxane, hydrochloric acid-ethyl acetate, acetic acid, p-toluenesulfonic acid, trifluoroacetic acid, and the like, and in this case the reaction can be carried out in a catalytic amount. Solvents include methanol, ethanol, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, acetonitrile, water, and the like, or mixtures thereof. The reaction temperature is usually about 0 to 60°C, and the reaction time is usually about 0.5 to 24 hours. [F Method] The F method is a method for producing a compound (F-IV). [In the ceremony, R 1 , R 2 , R 6 and R 7 has the same meaning as in the case of the compound of formula (1) above, and P a1 has the same meaning as above. ] (F1 step) Step to form a thiazole ring This is a step of obtaining compound (F-II) from compound (F-I). This step can be carried out by the same method as (Step D1). (F2 step) Step to carry out ureaization This is a step of obtaining compound (F-II) by carrying out a reaction from compound (F-II) in the presence or absence of a base using a ureaing reagent, the corresponding amine or a hydrochloride salt thereof. Examples of ureaing reagents include carbonyldiimidazole, triphosgene, phenyl chloroformate, 4-nitrophenyl chloroformate, and the like. Examples of the bases include toriethylamine, diisopropylethylamine, and the like. Examples of the solvent include N,N-dimethylformamide, dichloromethane, tetrahydrofuran, and the like. The reaction temperature is usually about 0 to 60°C, and the reaction time is usually about 1 to 48 hours. (F3 step) Deprotection process This is a step of obtaining compound (F-IV) from compound (F-III). This step can be carried out by the same method as (E3 step). [G Method] The G method is a method for producing the compound (G-VI). [In the ceremony, R 6 and R 7 has the same meaning as in the case of the compound of formula (1) above, and P a1 has the same meaning as above. R 1’ and R 2’ are bonded to each other to form a substituent, and represent the groups shown below. P a3 Is P a1 ,P a2 固合物分化合物分化合物分化合物分化合物合物的化合物的化合物的化合物的化合物的化合物。 � R 1’’ and R 2’’ are bonded to each other to form a substituent, and represent the following groups: R 1’’’ and R 2’’’ are bonded to each other to form a substituent, and represent the groups shown below. R 12 is a C1-C6 alkyl group, a hydroxyC1-C6 alkyl group, a C1-C6 alkylcarbonyl group, Alternatively, it represents a C1-C6 alkoxycarbonyl group. ] (G1 step) Step to form a thiazole ring This is a step of obtaining compound (G-II) from compound (G-I). This step can be carried out by the same method as (Step D1). (G2 step) Step to carry out ureaization This is a step of obtaining compound (G-III) from compound (G-II). This step can be carried out by the same method as (F2 step). (G3 step) Deprotection process This is a step of obtaining compound (G-IV) from compound (G-III). This step can be carried out by the same method as (E3 step). (G4 step) Step to modify the amino group (In the case of carbamate) This is a step of carrying out a reaction from the compound (G-IV) using a base and a carbamate reagent to obtain the compound (G-V). Examples of the bases include triethylamine, diisopropylethylamine, sodium hydrogen carbonate, 4-dimethylaminopyridine, and the like. Examples of carbamate reagents include chloroformate, dicarbonate, and the like. Examples of the solvent include tetrahydrofuran, dichloromethane, N,N-dimethylformamide, and the like. The reaction temperature is usually about 0 to 80°C, and the reaction time is usually about 0.5 to 24 hours. (In the case of acylation) This is a step of carrying out a reaction from the compound (G-IV) using a base and an acylating reagent to obtain the compound (G-V). Examples of the bases include triethylamine, diisopropylethylamine, pyridine, 4-dimethylaminopyridine, and the like. Examples of the acylating reagent include acyl chloride, acid anhydride, and the like. Examples of the solvent include tetrahydrofuran, dichloromethane, N,N-dimethylformamide, and the like. The reaction temperature is usually about 0 to 80°C, and the reaction time is usually about 0.5 to 24 hours. (In the case of alkylation) (When using alkyl halide) This is a step of carrying out a reaction from the compound (G-IV) using the corresponding alkylation reagent in the presence of a base to obtain the compound (G-V). Examples of the alkylation reagent include alkyl halides such as alkyl iodides and alkyl bromides, and sulfonic acid esters such as alkyl tosylates and alkyl mesylates. Examples of the bases include toriethylamine, diisopropylethylamine, potassium carbonate, and the like. Examples of the solvent include tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, and the like. The reaction temperature is usually about 0 to 100° C., and the reaction time is usually about 0.5 to 24 hours. (When using a reductive amination reaction) This is a step of obtaining compound (G-V) by carrying out a reaction from compound (G-IV) in the presence or absence of acid using a reducing agent and the corresponding aldehyde. Examples of reducing agents include sodium triacetoxyborohydride and sodium cyanoborohydride. Examples of the acid include acetic acid, tetraisopropyl orthotitanate, and zinc chloride. Solvents include methanol, acetonitrile, tetrahydrofuran, dichloromethane, and the like, or mixtures thereof. The reaction temperature is usually about 0 to 80°C, and the reaction time is usually about 0.5 to 24 hours. (G5 step) Deprotection process This is a step of obtaining compound (G-VI) from compound (G-V). This step can be carried out by the same method as (E3 step). Note that, for the following methods of manufacturing using the following compounds as starting materials, methods H, methods I, methods J, methods K, methods L, methods M, methods N, methods X, methods Y, and methods Z are described as production methods for convenience. [In the ceremony, R 1 , R 2 , R 6 and R 7 1. The meaning is the same as that of the compound of formula (1). ] However, in the methods of the H, I, J, K, L, M, N, X, Y, and Z, the following necessary compounds can be prepared as starting materials to obtain the desired compound of the present invention. [In the ceremony, R 1 , R 2 and R 3 has the same meaning as in the case of the compound of formula (1) above, and P a2 has the same meaning as above. ] [Method H] Method H is a method for producing the compound (H-II) of the present invention. [In the ceremony, R 1 , R 2 , R 6 , R 7 , Q and Y have the same meaning as in the case of the compound of formula (1). ] (Step H1) Step to perform coupling with a heterocycle This is a step of carrying out a reaction from compound (H-I) using Q-Y-Cl in the presence of a base to obtain compound (H-II). Examples of the bases include triethylamine, diisopropylethylamine, sodium bicarbonate, potassium carbonate, and the like. Examples of the solvent include N,N-dimethylformamide, dimethylsulfoxide, and the like. The reaction temperature is usually about 0 to 140°C, and the reaction time is usually about 0.5 to 48 hours. [Method I] Method I is a method for producing the compound (I-II) of the present invention. [In the ceremony, R 1 , R 2 , R 6 , R 7 and Q have the same meaning as in the case of the compound of formula (1). ] (Step I1) Step to perform coupling with a heterocycle This is a step of carrying out a reaction from compound (I-I) using a condensing agent in the presence of a base to obtain compound (I-II). Examples of the bases include toriethylamine, diisopropylethylamine, and the like. Examples of the condensation agent include phosphorus nitride chloride (trimer). Examples of the solvent include N,N-dimethylformamide, dimethylsulfoxide, and the like. The reaction temperature is usually about 0 to 140°C, and the reaction time is usually about 0.5 to 48 hours. [J Method] The J method is a method for producing the compound (J-III) of the present invention. [In the ceremony, R 1 , R 2 , R 6 , R 7 and Q have the same meaning as in the case of the compound of formula (1). ] (J1 step) Steps to carry out cyanamide formation This is a step of carrying out a reaction from compound (J-I) using cyanide halide in the presence or absence of base to obtain compound (J-II). Examples of the bases include toriethylamine, diisopropylethylamine, sodium hydrogen carbonate, and potassium carbonate. Examples of the solvent include acetonitrile, acetone, dichloromethane, tetrahydrofuran, and the like. The reaction temperature is usually about 0°C to room temperature, and the reaction time is usually about 0.5 to 48 hours. (J2 step) Step to form rings This is a step of carrying out a reaction from compound (J-II) using a metal halide, an acid, and the corresponding amide oxime to obtain compound (J-III). Examples of the metal halide include zinc chloride, zinc bromide, and the like. Examples of the acids include p-toluenesulfonic acid, sulfuric acid, hydrochloric acid, and the like. The solvent may include diethyl ether, tetrahydrofuran, ethyl acetate, ethanol, water, and the like, or a mixture thereof. The reaction temperature is usually about 0 to 100°C, and the reaction time is usually about 0.5 to 48 hours. [K Method] The K method is a method for producing the compound (K-V) of the present invention. [In the ceremony, R 1 , R 2 , R 6 , R 7 and Q have the same meaning as in the case of the compound of formula (1) above, and R k1 represents a phenoxy group that may have a substituent or an imidazolyl group. ] (Step K1) Process for carbonylation This is a step of carrying out a reaction from the compound (K-I) using a carbonylating agent in the presence of a base to obtain the compound (K-II). Examples of the bases include toriethylamine, diisopropylethylamine, sodium hydrogen carbonate, and the like. Examples of the carbonylating agent include carbonyldiimidazole, phenyl chloroformate, 4-nitrophenyl chloroformate, and the like. Solvents include tetrahydrofuran, dichloromethane, water, and the like, or mixtures thereof. The reaction temperature is usually about 0°C to room temperature, and the reaction time is usually about 0.5 to 24 hours. (Step K2) Step of performing amidation using hydrazine This is a step of carrying out a reaction from compound (K-II) using hydrazine hydrate in the presence or absence of base to obtain compound (K-III). Examples of the bases include toriethylamine, diisopropylethylamine, dimethylaminopyridine, and the like. Solvents include ethanol, tetrahydrofuran, acetonitrile, and the like, or mixtures thereof. The reaction temperature is usually about room temperature to 100°C, and the reaction time is usually about 1 to 24 hours. (Step K3) Step to amidate acylhydrazine (When using the corresponding carboxylic acid and condensation agent) This is a step of carrying out a reaction from compound (K-III) using a condensing agent and the corresponding carboxylic acid in the presence of a base to obtain compound (K-IV). Examples of the condensation agent include O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethylronium hexafluorophosphate (HATU), 4-(4,6-dimethoxy-1,3,5-toriazin-2-yl)-4-methylmorpholine (DMT-MM), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (WSC, or EDCI), 1H-benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP reagent), and the like. Examples of the bases include toriethylamine, diisopropylethylamine, dimethylaminopyridine, and the like. As the additives, N-hydroxysuccinimide (HOSu), 1-hydroxybenzotriazole (HOBt), 1-hydroxy-7-azabenzotriazole (HOAt), and the like can be added. The additives may allow the reaction to proceed smoothly. Examples of the solvent include tetrahydrofuran, N,N-dimethylformamide, dichloromethane, and the like, or a mixed solvent thereof. The reaction temperature is usually about 0°C to room temperature, and the reaction time is usually about 0.5 to 24 hours. (When the corresponding carboxylic acid is passed through an acid chloride) This is a step of carrying out a reaction from compound (K-III) using a carboxylic acid chloride prepared from the corresponding carboxylic acid using a dehydrated chlorinating agent in the presence of a base to obtain compound (K-IV). Examples of the dehydrated chlorinating agent include oxalyl chloride, thionyl chloride, sulfuryl chloride, phosphorus pentachloride, and the like. Examples of the bases include toriethylamine, diisopropylethylamine, pyridine, dimethylaminopyridine, and the like. Examples of the solvent include tetrahydrofuran, dichloromethane, N,N-dimethylformamide, and the like, or a mixed solvent thereof. The reaction temperature is usually about 0 to 100°C, and the reaction time is usually about 0.5 to 24 hours. (When using the corresponding acid chloride) This is a step of carrying out a reaction from compound (K-III) using the corresponding carboxylic acid chloride in the presence of a base to obtain compound (K-IV). Examples of the bases include toriethylamine, diisopropylethylamine, pyridine, dimethylaminopyridine, and the like. Examples of the solvent include tetrahydrofuran, dichloromethane, N,N-dimethylformamide, and the like, or a mixed solvent thereof. The reaction temperature is usually about 0 to 100°C, and the reaction time is usually about 0.5 to 24 hours. (K4 step) Step to form rings This is a step of carrying out a reaction from the compound (K-IV) using a dehydrating agent to obtain the compound (K-V). Examples of dehydrating agents include (methoxycarbonylsulfamoyl)triethylammonium hydroxide intramolecular salts, tosyl chloride, and the like. Examples of the solvent include toluene, acetonitrile, dichloromethane, and the like. The reaction temperature is usually about 0 to 100°C, and the reaction time is usually about 0.5 to 24 hours. [L Method] The L method is a method for producing the compound (L-V) of the present invention. [In the ceremony, R 1 , R 2 , R 6 , R 7 and Q have the same meaning as in the case of the compound of formula (1). ] (Step L1) Step to carry out thiourea This is a step of carrying out a reaction from compound (L-I) using 1,1'-thiocarbonyldiimidazole in the presence or absence of a base to obtain compound (L-II). Examples of the bases include toriethylamine, 1,8-diazabicyclo[5.4.0]-7-undecene, sodium carbonate, and the like. Solvents include tetrahydrofuran, dichloromethane, N,N-dimethylformamide, acetonitrile, water, and the like, or mixtures thereof. The reaction temperature is usually about 0°C to 80°C, and the reaction time is usually about 0.5 to 24 hours. (Step L2) Step of performing amidation using hydrazine This is a step of carrying out a reaction from compound (L-II) using hydrazine hydrate in the presence or absence of base to obtain compound (L-III). Examples of the bases include toriethylamine, diisopropylethylamine, dimethylaminopyridine, and the like. Solvents include ethanol, tetrahydrofuran, acetonitrile, and the like, or mixtures thereof. The reaction temperature is usually about room temperature to 100°C, and the reaction time is usually about 1 to 24 hours. (Step L3) Step to amidate carbothiohydrazide This is a step of obtaining compound (L-IV) from compound (L-III). This step can be carried out by the same method as (K3 step). (L4 step) Step to form rings (When using condensation agent) This is a step of carrying out a reaction from the compound (L-IV) using a condensing agent in the presence or absence of a base to obtain the compound (L-V). Examples of the condensation agent include 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (WSC, or EDCI), 1H-benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP reagent), and the like. Examples of the bases include toriethylamine, diisopropylethylamine, dimethylaminopyridine, and the like. Examples of the solvent include dimethyl sulfoxide, tetrahydrofuran, N,N-dimethylformamide, and the like, or a mixed solvent thereof. The reaction temperature is usually about room temperature to 100°C, and the reaction time is usually about 0.5 to 24 hours. (When using a dehydrating agent) This is a step of carrying out a reaction from the compound (L-IV) using a dehydrating agent to obtain the compound (L-V). Examples of dehydrating agents include (methoxycarbonylsulfamoyl)triethylammonium hydroxide intramolecular salts, tosyl chloride, and the like. Examples of the solvent include toluene, acetonitrile, dichloromethane, and the like. The reaction temperature is usually about 0 to 100°C, and the reaction time is usually about 0.5 to 24 hours. [M Method] The M method is a method for producing the compound (M-II) of the present invention. [In the ceremony, R 1 , R 2 , R 6 , R 7 and Q have the same meaning as in the case of the compound of formula (1). ] (M1 step) Step to form rings This is a step of carrying out a reaction from compound (M-I) using 1,1-dibromoformaldoxime and the corresponding alkyne in the presence of a base to obtain compound (M-II). Examples of the bases include toriethylamine, diisopropylethylamine, and the like. Solvents include tetrahydrofuran, N,N-dimethylformamide, and the like, or mixtures thereof. The reaction temperature is usually about 0°C to room temperature, and the reaction time is usually about 0.5 to 48 hours. [X Method] Method X is a method for preparing the compound (X-VI) of the present invention. [In the ceremony, R 1 , R 2 , R 6 , R 7 , Q has the same meaning as in the case of the compound of general formula (1), Ph represents a phenyl group, Imd represents an imidazolyl group, and R x1 indicates OPh or Imd. ] (X1 step) Process for coupling This is a step of carrying out a reaction from compound (X-I) using 1,1'-thiocarbonyldiimidazole or phenyl chlorothionoformate in the presence of a base to obtain compound (X-II). Examples of the base include sodium tert-butoxide, lithium bis(trimethylsilyl)amide, and the like. Solvents include tetrahydrofuran, N,N-dimethylformamide, and the like, or mixtures thereof. The reaction temperature is usually about 0°C to 60°C, and the reaction time is usually about 0.5 to 24 hours. (X2 step) Process for coupling This is a step of obtaining compound (X-IV) by carrying out a coupling reaction using compound (X-III) in the presence or absence of base. Examples of the bases include toriethylamine, 1,8-diazabicyclo[5.4.0]-7-undecene, sodium carbonate, and the like. Solvents include tetrahydrofuran, N,N-dimethylformamide, ethanol, and the like, or mixtures thereof. The reaction temperature is usually about 0°C to 100°C, and the reaction time is usually about 0.5 to 24 hours. (Step X3) Step to carry out methylation This is a step of carrying out a reaction from compound (X-IV) using a methylation reagent in the presence of a base to obtain compound (X-V). Examples of the methylation reagent include iodomethane, dimethylsulfuric acid, and the like. Examples of the bases include toriethylamine, diisopropylethylamine, potassium carbonate, and the like. Solvents include tetrahydrofuran, acetonitrile, N,N-dimethylformamide, or mixtures thereof. The reaction temperature is usually about 0 to 100°C, and the reaction time is usually about 0.5 to 24 hours. (X4 step) Process for cyclization This is a step of carrying out a reaction from compound (X-V) using hydroxylamine or a hydrochloride salt thereof in the presence or absence of a base to obtain compound (X-VI). Examples of the bases include triethylamine, sodium acetate, sodium hydrogen carbonate, and the like. Examples of the solvent include methanol, ethanol, water, or a mixed solvent of these. The reaction temperature is usually about room temperature to 100°C, and the reaction time is usually about 0.5 to 24 hours. [N Law] The N method is a method for producing the compound (N-III) of the present invention. [In the ceremony, R 1 , R 2 , R 6 , R 7 and Q have the same meaning as in the case of the compound of formula (1). ] (N1 step) Step to carry out ureaization This is a step of obtaining compound (N-II) from compound (N-I). This step can be carried out by the same method as (F2 step). (N2 step) Step to carry out ring formation This is a step of carrying out a reaction from compound (N-II) using a dehydrating agent in the presence or absence of a base to obtain compound (N-III). Examples of dehydrating agents include trifluoroacetic anhydride, phosphorus oxychloride, and the like. Examples of the bases include toriethylamine, diisopropylethylamine, dimethylaminopyridine, and the like. Solvents include dichloromethane, tetrahydrofuran, and the like, or solvent-free. The reaction temperature is usually about 0 to 100°C, and the reaction time is usually about 0.5 to 24 hours. [Y Method] The Y method is a method for producing the compound (Y-II) of the present invention. [In the ceremony, R 1 , R 2 , R 6 , R 7 , Q has the same meaning as in the case of the compound of general formula (1) above, and Ph represents a phenyl group. ] (Y1 step) Step to form a benzoxazole ring This is a step of carrying out a reaction from compound (Y-I) in the presence of an acid or a base, and in the presence of tetramethoxymethane or dichlorodiphenoxymethane, to obtain compound (Y-II). Examples of the acid include acetic acid. Examples of the base include toriethylamine. Examples of the solvent include chloroform and toluene. The reaction temperature is usually about 0 to 100°C, and the reaction time is usually about 0.5 to 48 hours. [Z Method] The Z method is a method for producing the compound (Z-II) of the present invention. [In the ceremony, R 1 , R 2 , R 6 , R 7 , Q has the same meaning as in the case of the compound of general formula (1) above, and LG represents a leaving group. ] (Step Z1) Step of carrying out coupling reaction using a transition metal catalyst This is a step of carrying out a reaction from compound (Z-I) using a copper or palladium catalyst in the presence or absence of a base and ligand to obtain compound (Z-II). Examples of copper catalysts include copper iodide, copper chloride, copper acetate, copper sulfate, and the like. Examples of the palladium catalyst include tetrakis (triphenylphosphine)palladium, trilith (dibenzylideneacetone)dipalladium, palladium acetate, bis (triphenylphosphine)palladium dichloride, and the like. Examples of the bases include triethylamine, diisopropylethylamine, potassium carbonate, cesium carbonate, and the like. Examples of the solvent include tetrahydrofuran, 1,4-dioxane, water, N,N-dimethylformamide, dimethylsulfoxide, tolene, and the like, or mixtures thereof. The reaction temperature is usually about room temperature to 150°C, and the reaction time is usually about 0.5 to 48 hours. [O Method] Method O is a method for producing the compound (O-III) of the present invention. [In the ceremony, R 1 , R 2 , R 6 , R 7 , Q and Y have the same meaning as in the case of the compound of formula (1). ] (O1 step) Step to form a thiazole ring This is a step of obtaining compound (O-II) from compound (O-I). This step can be carried out by the same method as (Step D1). (O2 step) Step to carry out ureaization This is a step of obtaining compound (O-III) from compound (O-II). This step can be carried out by the same method as (F2 step). [Q Method] The Q method is a method for producing the compound (Q-III) of the present invention. [In the ceremony, R 1 , R 2 , R 6 , R 7 , Q and Y have the same meaning as in the case of the compound of formula (1) above, and P a2 has the same meaning as above. ] (Q1 step) Deprotection process (For t-butoxycarbonyl (Boc) group) This is a step of carrying out a reaction from a compound (Q-I) containing an amino group protected by a t-butoxycarbonyl group using an acid to obtain compound (Q-II). This step can be carried out by the same method as in (step C1). (For 2-(trimethylsilyl)ethoxycarbonyl (Teoc) group) This is a step of carrying out a reaction from a compound (Q-I) containing an amino group protected by a 2-(trimethylsilyl)ethoxycarbonyl group using a desilylating reagent or an acid to obtain compound (Q-II). This step can be carried out by the same method as (E3 step). (For allyloxycarbonyl (Alloc) groups) This is a step of obtaining compound (Q-I) containing an amino group protected by an allyloxycarbonyl (Alloc) group, a reaction is carried out using an amine in the presence of a palladium catalyst and a phosphine ligand to obtain compound (Q-II). Examples of the palladium catalyst include tetrakis(triphenylphosphine)palladium, [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium, trolith(dibenzylideneacetone)dipalladium, palladium acetate, acetylacetonepalladium, bis(triphenylphosphine)palladium dichloride, and the like. Examples of phosphine ligands used simultaneously with the palladium catalyst include 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (xantphos), 1,1'-bis(diphenylphosphino)ferrocene (dppf), 2,2'-bis(diphenylphosphino)-1,1-binaphthyl (BINAP), bis(diphenylphosphino)methane (DPPM), triphenylphosphine or 1,2-bis(diphenylphosphino)ethane (DPPE), and the like. Examples of the base include diethylamine and morpholine. Solvents include acetonitrile, tetrahydrofuran, dichloromethane, water, and the like, or mixtures thereof. The reaction temperature is usually about room temperature to 60°C, and the reaction time is usually about 0.5 to 48 hours. (For benzyloxycarbonyl (Cbz) group) This is a step of obtaining compound (Q-I) containing an amino group protected by a benzyloxycarbonyl (Cbz) group is reacted using a transition metal catalyst in the presence or absence of acids in the hydrogen atmosphere, using a transition metal catalyst. Examples of the acid include hydrochloric acid, hydrogen chloride-1,4-dioxane, hydrogen chloride-ethyl acetate, and the like. Examples of the transition metal catalyst include palladium-carbon, palladium-hydroxy-carbon, or Raney nickel. Examples of the solvent include methanol, ethanol, ethyl acetate, chloroform, and the like, or mixtures thereof. The reaction temperature is usually about 0 to 100°C, and the reaction time is usually about 0.5 to 24 hours. (Q2 step) Step to carry out ureaization This is a step of obtaining compound (Q-III) from compound (Q-II). This step can be carried out by the same method as (F2 step). [R method] The R method is a method for producing the compound (R-II) of the present invention. [In the ceremony, R 1 , R 2 , R 67-1 , R 67-2 , Q and Y have the same meaning as in the case of the compound of formula (1). ] (Step R1) Step to form a hydantoin ring This is a step of obtaining compound (R-I) by carrying out a reaction from compound (R-I) in the presence or absence of a base using a ureaing reagent, the corresponding amine or a hydrochloride salt thereof. Examples of ureaing reagents include carbonyldiimidazole, triphosgene, phenyl chloroformate, 4-nitrophenyl chloroformate, and the like. Examples of the bases include toriethylamine, diisopropylethylamine, and the like. Examples of the solvent include N,N-dimethylformamide, dichloromethane, tetrahydrofuran, and the like. The reaction temperature is usually about 0 to 100°C, and the reaction time is usually about 1 to 48 hours. [S Method] The S-method is a method for producing the compound (S-III) of the present invention. [In the ceremony, R 1 , R 2 , R 67-1 , R 67-2 , Q and Y have the same meaning as in the case of the compound of formula (1) above, and R s1 represents a C1-C6 alkyl group. ] (S1 step) Step to carry out ureaization This is a step of obtaining compound (S-II) from compound (S-I). This step can be carried out by the same method as (F2 step). (S2) Step to form rings This is a step of obtaining compound (S-III) from compound (S-II) in the presence or absence of base using a condensing agent. Examples of the condensation agent include 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (WSC, or EDCI), 1H-benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP reagent), and the like. Examples of the bases include toriethylamine, diisopropylethylamine, dimethylaminopyridine, and the like. Examples of the solvent include N,N-dimethylformamide, tetrahydrofuran, and the like, or a mixed solvent of these. The reaction temperature is usually about room temperature to 100°C, and the reaction time is usually about 0.5 to 24 hours. [T Method] The T method is a method for producing the compound (T-IV) of the present invention. [In the ceremony, R 1 , R 2 , R 67-1 , R 67-2 , Q and Y have the same meaning as in the case of the compound of formula (1) above, and P a4 denotes a commonly used protecting group of an amino group. ] (T1 step) Step of performing amidation This is a step of carrying out a reaction from compound (T-I) using a condensing agent and corresponding amino acids in the presence of a base to obtain compound (T-II). Examples of the condensation agent include O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethylronium hexafluorophosphate (HATU), 4-(4,6-dimethoxy-1,3,5-toriazin-2-yl)-4-methylmorpholine (DMT-MM), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (WSC, or EDCI), 1H-benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP reagent), and the like. Examples of the bases include toriethylamine, diisopropylethylamine, dimethylaminopyridine, and the like. As the additives, N-hydroxysuccinimide (HOSu), 1-hydroxybenzotriazole (HOBt), 1-hydroxy-7-azabenzotriazole (HOAt), and the like can be added. The additives may allow the reaction to proceed smoothly. Examples of the solvent include tetrahydrofuran, N,N-dimethylformamide, dichloromethane, and the like, or a mixed solvent thereof. The reaction temperature is usually about 0°C to room temperature, and the reaction time is usually about 0.5 to 24 hours. (T2 step) Deprotection process (For t-butoxycarbonyl (Boc) group) This is a step of carrying out a reaction from a compound (T-II) containing an amino group protected by a t-butoxycarbonyl group using an acid to obtain compound (T-III). This step can be carried out by the same method as in (step C1). (T3 step) Step to form rings This is a step of carrying out a reaction from compound (T-III) using a ureaing reagent in the presence or absence of a base to obtain compound (T-IV). Examples of ureaing reagents include carbonyldiimidazole, triphosgene, and the like. Examples of the bases include toriethylamine, diisopropylethylamine, and the like. Examples of the solvent include N,N-dimethylformamide, dichloromethane, tetrahydrofuran, and the like. The reaction temperature is usually about 0 to 100°C, and the reaction time is usually about 1 to 48 hours. The compounds produced by the above method can be isolated and purified by known methods such as extraction, precipitation, distillation, chromatography, fractional recrystallization, recrystallization, and the like. Furthermore, when the compound or intermediate in preparation has asymmetric carbon, an optical isomer is present. These optical isomers can be isolated and purified by conventional methods such as fractional recrystallization (saltification) and column chromatography, which recrystallizes and recrystallizes these optical isomers. A reference for methods for resolving optical isomers from racemates can be mentioned in J. Jacques et al. "Enantiomers, Racemates and Resolution, John Wiley And Sons, Inc.". (Dosage form) The administration may be in any form of oral administration using tablets, pills, capsules, granules, powders, liquids, etc., or parenteral administration using intra-articular, intravenous, intramuscular injections, suppositories, eye drops, eye ointments, transdermal solutions, ointments, transdermal patches, transmucosal patches, inhalants, etc. As solid compositions for oral administration, Tablets, powders, granules, etc. are used. Such solid compositions consist of one or more active ingredients and at least one inert excipient such as lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, polyvinylpyneurydone, and / or magnesium aluminate, and the like. The solid composition may contain inert additives, such as lubricants such as magnesium stearate, disintegrants such as carboxymethylstart sodium, stabilizers, and solubility aids, according to conventional methods. The tablets or pills may optionally be coated with a film of sugar-coated or stomach-soluble or enteric material. As a liquid composition for oral administration, Pharmaceutically acceptable emulsions, solutions, suspensions, syrups or elixirs are used. To such liquid compositions, commonly used inert diluents, such as purified water or ethanol, can be added. In addition to inert diluents, the liquid composition may contain auxiliary agents such as solubilizing agents, wetting agents, sweetening agents, flavoring agents, fragrances, and preservatives. As an injection for parenteral administration, Sterile, aqueous or non-aqueous solutions, suspensions, emulsions, and the like are used. The aqueous solvents include, for example, distilled water for injection or physiological saline. Non-aqueous solvents include, for example, vegetable oils such as propylene glycol, polyethylene glycol or olive oil, alcohols such as ethanol, or bolisorbate 80. Such injectable compositions may further include tonicity agents, preservatives, wetting agents, emulsifiers, dispersing agents, stabilizers, or dissolving aids. These injectable compositions can be sterilized, for example by filtration through a bacterial retention filter, blending or irradiation with a fungicide. These injectable compositions can also be used in the manufacture of sterile solid compositions and dissolved or suspended in sterile water or sterile injectable solvents prior to use. As topical agents, Ointments, plasters, creams, jellies, pups, sprays, lotions, eye drops, eye ointments, and the like are used. These topical agents contain commonly used ointment bases, lotion bases, aqueous or non-aqueous liquids, suspensions, emulsions, and the like. For example, polyethylene glycol, propylene glycol, white petrolatum, beeswax, polyoxyethylene hardened castor oil, glycerin monostearate, stearyl alcohol, cetyl alcohol, lauromacrogol, sorbitan sesquioleate, and the like are used as the ointment or lotion base. Transmucosal agents such as inhalants and nasal agents are used in solid, liquid or semi-solid form, and can be produced according to conventionally known methods. For example, known excipients, and pH adjusters, preservatives, surfactants, lubricants, stabilizers, thickeners, etc. may be added as appropriate. These transmucosal agents may use suitable devices for inhalation or blowing as methods of administration. For example, known thevais or nebulizers such as metered inhalation devices can be used to administer the compounds alone, either as powders of formulated mixtures, or in combination with a pharmaceutically acceptable carrier, as solutions or suspensions. The dry powder inhaler, etc. may be for single or multiple administrations, and dry powder or powder-containing capsules may be used. Alternatively, an appropriate ejector may be used. For example, the form may be such as a pressurized aerosol spray using a suitable gas such as chlorofluoroalkane, hydrofluoroalkane, or carbon dioxide. (Dose) In the case of oral administration, the daily dosage is suitably about 0.001-100 mg / kg per body weight, preferably O.1-30 mg / kg, more preferably 0.1-10 mg / kg, and this is administered in one or more doses. When administered intravenously, the daily dosage is appropriately about 0.0001-10 mg / kg per body weight, and is administered once or in multiple doses per day. Furthermore, as a transmucosal agent, approximately 0.001-100 mg / kg per body weight is administered once or in multiple doses per day. The dosage is appropriately determined according to the individual case, taking into account symptoms, age, gender, etc. (Use in combination) In the present invention, it can be used in combination with various therapeutic or preventive agents for diseases that are thought to be effective. The combination may be administered simultaneously, or may be administered separately, consecutively or at a desired time interval. The co-administered formulation may be a compound or may be formulated separately. (Formulation Example 1) Powder A powder is obtained by mixing 5g of the compound of the present invention or a salt thereof, 895g of lactose and 100g of corn starch in a blender. (Formulation Example 2) Granule After mixing 5g of the compound of the present invention or a salt thereof, 865g of lactose and 100g of low-substituted hydroxypropylcellulose, 300g of 10% aqueous hydroxypropylcellulose is added to the mixture. This is granulated using an extrusion granulator and dried to obtain granules. (Formulation Example 3) Tablets Tablets are obtained by mixing 5g of the compound of the present invention or a salt thereof, 90g of lactose, 34g of corn starch, 20g of crystalline cellulose, and 1g of magnesium stearate in a blender, and then tabletting using a tabletting machine. (Formulation Example 4) Ointment 5 g of the compound of the present invention or a salt thereof was dissolved in a mixture of 50 g of propylene glycol, 50 g of polyethylene glycol, and 50 g of glyceryl monooleate (Capmul GMO-50 EP, NF) at 60°C to 80°C. Add 350 g of white petrolatum jelly, stir at 60°C to 80°C for 15 minutes, then slowly cooled with stirring to obtain a 1.0% ointment. The pharmacological activity of the compounds of the present invention prepared according to the following examples or pharmaceutically acceptable salts thereof was confirmed by the following tests. (Test example) Measurement of deacetylation activity The reaction was carried out in duplicate using a white 384 well plate (Corning, 3824 or PerkinElmer, 6008350) with a final reaction liquid volume of 20.1 μL. As a control for calculating enzyme activity, wells with enzyme added (DMSO(+)) and without enzyme added (DMSO(-)) were set at n=8. 5 μL of SIRT6 enzyme (prepared by Daiichi Sankyo RD Novare Co., Ltd., final concentration: 25 ng / mL) was added, diluted with assay buffer (10 mM Tris-HCl pH 8.0, 0.1% BSA, 0.01% Tween 20, 1 mM DTT, 12.5% ​​Glycerol). The enzymatic reaction was started by adding 5 μL of a mixture of [Lys(Ac)9]-Histone H3 (1-21)-NH2, H3K9 (Ac), biotin-labeled, amide (AnaSpec, AS-64190, final concentration: 2 nM) and β-Nicotinamide adenine dinucleotide (Sigma-Aldrich, N8285-15VL, final concentration: 10 μM), and the reaction was carried out at room temperature for 30 minutes. Mixture of Nicotinamide (Sigma-Aldrich, 72340-100G, final concentration: 100 mM), AlphaLISA Anti-unmodified Histone H3 Lysine 9 / Lysine 27 (H3K9 / K27) Acceptor Beads (PerkinElmer, AL138, final concentration: 10 μg / mL) and AlphaScreen Streptavidin Donor beads (PerkinElmer, 6760002, final concentration: 5 μg / mL) prepared in AlphaLISA Epigenetics Buffer (PerkinElmer, AL008C) 10 μL was added and the reaction was allowed to react for 60 minutes at room temperature to detect reaction quenching and acetylation. The emission intensity was measured using EnVision (PerkinElmer). The relative enzyme activity (%) of the test substance was calculated using the following formula: Relative enzyme activity (%) = [(Leaf intensity of the test substance added - DMSO(-) well luminescence intensity) / (DMSO(+) well luminescence intensity - DMSO(-) well luminescence intensity)] x 100 EC of test substance 150 (Compound concentrations showing relative enzyme activity of 150%) were calculated using the relative enzyme activity (%) value at each concentration, and were shown in Tables 1-1 to 1-5. The present invention will be explained in more detail below by referring to examples and test examples, but the scope of the present invention is not limited to these. In the following examples, nuclear magnetic resonance (hereinafter, 1 The H NMR) spectrum was expressed as a δ value (ppm) using tetramethylsilane as a standard material or chemical shift values ​​of deuterated solvents using deuterium. The splitting patterns were denoted by single lines as s, double lines as d, triple lines as t, quadruple lines as q, multiple lines as m, and broads as br. (Example 1) N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-methylurea (1a) 4,4-Difluorocyclohexane-1-carbonitrile 4,4-difluorocyclohexane-1-carbonitrile 4-oxocyclohexane-1-carbonitrile (CAS Registry number: 34916-10-4) (1.0 g) was dissolved in dichloromethane (10 mL), and a solution of (diethylamino)sulfur trifluoride (1.6 g) in dichloromethane (10 mL) was added at 0° C., and the mixture was stirred at 0° C. for 2 hours. The reaction mixture was poured into an aqueous sodium bicarbonate solution, and the reaction mixture was extracted three times with dichloromethane. The combined organic layers were washed with saturated brine and dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography [eluent solvent: petroleum ether / ethyl acetate=20 / 1 (V / V)] to give 0.70 g of the title compound (yield: 50%) as a yellow solid. (1b) 4,4-Difluoro-N'-hydroxycyclohexane-1-carboximidamide 4,4-difluoro-N'-hydroxycyclohexane-1-carboximidamide 4,4-difluorocyclohexane-1-carbonitrile (0.70 g) of Example 1 (1a) was dissolved in tetrahydrofuran (10 mL), hydroxylamine hydrochloride (0.37 g) and triethylamine (1.24 g) were added, and the mixture was stirred at 65° C. for 12 hours. The solvent was distilled off from the reaction mixture under reduced pressure, and water was added to the obtained residue, and the reaction mixture was extracted three times with ethyl acetate. The combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure to give 0.50 g of the title compound (yield: 69%) as a white solid. (1c) N-(5-Cyano-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)-N'-methylurea N-(5-cyano-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)-N'-methylurea N-methyl-N'-(4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)urea (WO 2010 / 024258) (17 g), sodium hydrogen carbonate (13 g) was dissolved in dichloromethane (500 mL) and water (100 mL), and a solution of bromocyan (10 g) in dichloromethane (100 mL) was added dropwise at 0° C. The mixture was stirred at 0° C. for 2 hours and then at room temperature for 13 hours. The reaction mixture was poured into water and the reaction mixture was extracted three times with dichloromethane. The combined organic layers were washed with water and saturated brine and dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure to give 13.0 g of the title compound (yield: 68%) as a yellow solid. (1d) N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-methylurea N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-methylurea 4,4-difluoro-N'-hydroxycyclohexane-1-carboximidamide (150 mg) of Example 1 (1b) was dissolved in N,N-dimethylformamide (5 mL), and N-(5-cyano-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)-N'-methylurea (222 mg), zinc chloride (34.4 mg), and tosylic acid monohydrate (48.0 mg) of Example 1 (1c) were added successively at room temperature, and the mixture was stirred at 80° C. for 12 hours. The reaction mixture was poured into water, and the reaction mixture was extracted three times with ethyl acetate, and the combined organic layers were washed with saturated sodium chloride solution, and then dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the resulting residue was purified by high performance liquid chromatography [column: Phenomenex luna C18; mobile phase: acetonitrile / 0.225% aqueous formic acid solution=30 / 70-60 / 40 (V / V)] to give 111 mg (yield: 32%) of the title compound as a white solid. (Example 2) N-methyl-N'-{5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}urea (2a) N-[5-(1H-imidazole-1-carbothioyl)-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl]-N'-methylurea N-[5-(1H-imidazole-1-carbothioyl)-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl]-N'-methylurea N-methyl-N'-(4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)urea (WO 2010 / 024258) (5.0 g) was suspended in tetrahydrofuran (50 mL), 1,1'-thiocarbonyldiimidazole (4.6 g) was added, and the mixture was left at room temperature for 2 days. The precipitated solid was filtered off and washed with tetrahydrofuran to obtain 7.5 g of the title compound (yield: 99%) as a white solid. (2b) N-[5-(hydrazinecarbothioyl)-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl]-N'-methylurea N-[5-(hydrazinecarbothioyl)-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl]-N'-methylurea N-[5-(1H-imidazole-1-carbothioyl)-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl]-N'-methylurea (7.5 g) from Example 2 (2a) was suspended in ethanol (100 mL), hydrazine monohydrate (3.4 mL) was added, and the mixture was left at room temperature overnight. The precipitated solid was collected by filtration and washed with ethanol to obtain 5.7 g (yield: 86%) of the title compound as a white solid. (2c) N-Methyl-N'-{5-[2-(trifluoroacetyl)hydrazinecarbothioyl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}urea N-methyl-N'-{5-[2-(trifluoroacetyl)hydrazinecarbothioyl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}urea N-[5-(hydrazinecarbothioyl)-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl]-N'-methylurea (6.54 g) from Example 2 (2b) was suspended in dichloromethane (30 mL), trifluoroacetic anhydride (4.80 mL) and trifluoroacetic acid (5.24 mL) were added, and the mixture was stirred at room temperature for 3 hours. The reaction solution was concentrated, azeotroped twice with toluene, and the resulting solid was triturated with ethyl acetate / n-hexane, and filtered to obtain 8.8 g of the title compound (yield: quantitative) as a pale yellow solid. (2d) N-methyl-N'-{5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}urea N-methyl-N'-{5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}urea N-methyl-N'-{5-[2-(trifluoroacetyl)hydrazinecarbothioyl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}urea (8.8 g) of Example 2 (2c) was dissolved in dimethylsulfoxide (100 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (5.3 g) was added, and the mixture was stirred at 70° C. for 2 hours. Water was added to the reaction mixture, and the precipitated solid was collected by filtration and washed with water and ethyl acetate. The resulting solid was suspended in ethyl acetate / ethanol and stirred for a while under heating. The precipitated solid was recovered by heat filtration to give 4.1 g of the title compound (yield: 51%) as a pale yellow solid. (Example 3) N-(5-{5-[(1R)-1-ethoxyethyl]-1,3,4-oxadiazol-2-yl}-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)-N'-methylurea (3a) Methyl (2R)-2-ethoxypropanoate methyl (2R)-2-ethoxypropanoate D-(+)-methyl lactate (CAS Registry number: 17392-83-5) (2.0 g) and iodoethane (5.99 g) were dissolved in diethyl ether (20 mL), silver oxide (8.90 g) was added at room temperature, and the mixture was stirred at room temperature for 12 hours. Furthermore, iodethane (3.00 g) and silver oxide (4.45 g) were added, and the mixture was stirred at room temperature for 24 hours. The reaction mixture was filtered and the solvent was distilled off from the filtrate under reduced pressure to give 1.00 g (yield: 32%) of the title compound as a pale yellow oil. (3b) (2R)-2-ethoxypropanoic acid (2R)-2-ethoxypropanoic acid Methyl (2R)-2-ethoxypropanoate (1.0 g) of Example 3 (3a) was dissolved in tetrahydrofuran (6 mL), methanol (6 mL), and water (3 mL), lithium hydroxide monohydrate (0.79 g) was added, and the mixture was stirred at room temperature for 2 hours. The solvent was distilled off from the reaction mixture under reduced pressure, water was added to the resulting residue, and the reaction mixture was washed with ethyl acetate. The aqueous layer was adjusted to pH 2 with 1 M hydrochloric acid and extracted five times with ethyl acetate. The combined organic layers were washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure to give 0.60 g of the title compound (yield: 67%) as a pale yellow oil. (3c) N-(5-{2-[(2R)-2-ethoxypropanoyl]hydrazinecarbothioyl}-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)-N'-methylurea N-(5-{2-[(2R)-2-ethoxypropanoyl]hydrazinecarbothioyl}-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)-N'-methylurea (2R)-2-ethoxypropanoic acid (112 mg) from Example 3 (3b) was dissolved in N,N-dimethylformamide (5 mL), and 4-methylmorpholine (0.208 mL), 1H-benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (981 mg), and N-[5-(hydrazinecarbothioyl)-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl]-N'-methylurea (150 mg) from Example 2 (2b) was added at room temperature and stirred at 40° C. for 12 hours. The solvent was distilled off from the reaction mixture under reduced pressure, and the resulting residue was purified by silica gel column chromatography [eluent: ethyl acetate / methanol=1 / 0-30 / 1 (V / V)] to give 110 mg of the title compound (yield: 60%) as a yellow solid. (3d) N-(5-{5-[(1R)-1-ethoxyethyl]-1,3,4-oxadiazol-2-yl}-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)-N'-methylurea N-(5-{5-[(1R)-1-ethoxyethyl]-1,3,4-oxadiazol-2-yl}-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)-N'-methylurea N-(5-{2-[(2R)-2-ethoxypropanoyl]hydrazinecarbothioyl}-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)-N'-methylurea (90 mg) of Example 3 (3c) was dissolved in dimethylsulfoxide (3 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (112 mg) was added, and the mixture was stirred at 60° C. for 15 minutes. The filtrate obtained by filtering the reaction mixture was purified by high performance liquid chromatography [column: Phenomenex Gemini C18; mobile phase: acetonitrile / 0.05% aqueous ammonia = 18 / 82-42 / 58 (V / V)] to give 26 mg of the title compound (yield: 32%) as a pale yellow solid. (Example 4) N-methyl-N'-(5-{3-[1-(2,2,2-trifluoroethoxy)ethyl]-1,2,4-oxadiazol-5-yl}-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)urea (4a) 2-(2,2,2-Trifluoroethoxy)propanoic acid 2-(2,2,2-trifluoroethoxy)propanoic acid 2,2,2-trifluoroethanol (6.54 g) was dissolved in tetrahydrofuran (30 mL), and sodium (601 mg) was added at 0° C. After the sodium was dissolved, 2-bromopropanoic acid (CAS Registry number: 598-72-1) (2.00 g) was added, and the mixture was stirred at 50° C. for 12 hours. Water was added to the reaction mixture, the pH was adjusted to 9 with a 2M aqueous sodium hydroxide solution, and washed with ethyl acetate. The aqueous layer was adjusted to pH 2 with 2 M hydrochloric acid and extracted three times with ethyl acetate. The combined organic layers were washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure to give 2.20 g of the title compound (yield: 98%) as a colorless oil. (4b) 2-(2,2,2-trifluoroethoxy)propanamide 2-(2,2,2-trifluoroethoxy)propanamide Thionyl chloride (10 mL) was added to 2-(2,2,2-trifluoroethoxy)propanoic acid (2.2 g) of Example 4 (4a), and the mixture was stirred at room temperature for 12 hours. The solvent was evaporated from the reaction mixture under reduced pressure, and the resulting residue was dissolved in tetrahydrofuran (5 mL), and ammonia (4 mol / L tetrahydrofuran solution, 14.7 mL) was added at 0° C., and the mixture was stirred at room temperature for 12 hours. The reaction solution was concentrated to obtain the residue obtained by trituration with ethyl acetate / petroleum ether and filtering to obtain 0.78 g of the title compound (yield: 36%) as a yellow solid. (4c) 2-(2,2,2-trifluoroethoxy)propanenitrile 2-(2,2,2-trifluoroethoxy)propanenitrile Thionyl chloride (1.0 mL) was added to 2-(2,2,2-trifluoroethoxy)propanamide (0.58 g) of Example 4 (4b), and the mixture was stirred at 90° C. for 12 hours. The solvent was distilled off from the reaction mixture under reduced pressure to give 0.52 g of the title compound (yield: quantitative) as a yellow oil. (4d) N-methyl-N'-(5-{3-[1-(2,2,2-trifluoroethoxy)ethyl]-1,2,4-oxadiazol-5-yl}-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)urea N-methyl-N'-(5-{3-[1-(2,2,2-trifluoroethoxy)ethyl]-1,2,4-oxadiazol-5-yl}-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)urea Using N'-hydroxy-2-(2,2,2-trifluoroethoxy)propaneimidamide (77 mg) synthesized from 2-(2,2,2-trifluoroethoxy)propanenitrile in Example 4 (4c) in the same manner as in Example 1 (1b), and N-(5-cyano-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)-N'-methylurea (100 mg) in Example 1 (1c), the title compound was obtained as a white solid in the same manner as in Example 1 (1d). (Example 5) N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(2R)-1-hydroxypropan-2-yl]urea (5a) tert-Butyl 2-({[(prop-2-en-1-yl)oxy]carbonyl}amino)-6,7-dihydro[1,3]thiazolo[5,4-c]pyridine-5(4H)-carboxylate tert-butyl 2-({[(prop-2-en-1-yl)oxy]carbonyl}amino)-6,7-dihydro[1,3]thiazolo[5,4-c]pyridine-5(4H)-carboxylate tert-Butyl 2-amino-6,7-dihydro[1,3]thiazolo[5,4-c]pyridine-5(4H)-carboxylate (CAS Registry number: 365996-05-0) (10.0 g) and N,N-diisopropylethylamine (19.5 mL) were dissolved in tetrahydrofuran (100 mL), allyl chloroformate (5.90 mL) was added, and the mixture was stirred at room temperature for 12 hours. Methanol was added to the reaction mixture, and the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography [eluent solvent: petroleum ether / ethyl acetate=3 / 1 (V / V)] to give 8.40 g of the title compound (yield: 67%) as a pale yellow solid. (5b) Prop-2-en-1-yl {5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}carbamate prop-2-en-1-yl {5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}carbamate Using prop-2-en-1-yl (5-cyano-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)carbamate (282 mg) synthesized from tert-butyl 2-({[(prop-2-en-1-yl)oxy]carbonyl}amino)-6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-5(4H)-carboxylate of Example 5 (5a) in the same manner as in Example 6 (6h), 1 (1c), and 4,4-difluoro-N'-hydroxycyclohexane-1-carboximidamide (190 mg) in Example 1 (1b), the title compound 160 was obtained in the same manner as in Example 1 (1d). mg (yield: 35%) was obtained as a pale yellow solid. (5c) 5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridine-2-amine 5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-amine Under a nitrogen atmosphere, prop-2-en-1-yl {5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}carbamate (150 mg) and dimedone (240 mg) of Example 5 (5b) were dissolved in dichloromethane (5 mL), tetrakistriphenylphosphine palladium (45 mg) was added, and the mixture was stirred at room temperature for 12 hours. The solvent was distilled off from the reaction mixture under reduced pressure, and the resulting residue was purified by silica gel column chromatography [eluent solvent: petroleum ether / ethyl acetate / methanol=1 / 1 / 0-0 / 100 / 1 (V / V / V)] to give 100 mg of the title compound (yield: 66%) as a yellow solid. (5d) N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(2R)-1-hydroxypropan-2-yl]urea N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(2R)-1-hydroxypropan-2-yl]urea 5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridine-2-amine (100 mg) of Example 5 (5c) was dissolved in N,N-dimethylformamide (5 mL), 1,1'-carbonyldiimidazole (95 mg) was added, and the mixture was stirred at room temperature for 5.5 hours. (R)-(-)-2-amino-1-propanol (0.069 mL) was added to the reaction mixture, and the mixture was stirred at room temperature for 12 hours. The reaction mixture was poured into water and the reaction mixture was extracted three times with ethyl acetate. The combined organic layers were washed with saturated brine and dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the resulting residue was purified by high-performance liquid chromatography [column: Phenomenex Synergi C18; mobile phase: acetonitrile / 0.225% aqueous formic acid solution=28 / 72-58 / 42 (V / V)] to give 23 mg of the title compound (yield: 17%) as a yellow solid. (Example 6) N-methyl-N'-(10-{3-[(1s,4s)-4-(trifluoromethyl)cyclohexyl]-1,2,4-oxadiazol-5-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl)urea (6a) (1s,4s)-4-(trifluoromethyl)cyclohexane-1-carboxamide (1s, 4s)-4-(trifluoromethyl)cyclohexane-1-carboxamide (1s,4s)-4-(trifluoromethyl)cyclohexane-1-carboxylic acid (CAS Registry number: 1202578-27-5) (1.00 g) and triethylamine (1.04 mL) were dissolved in dichloromethane (25 mL), isobutyl chloroformate (0.87 mL) was added dropwise at 0° C., and the mixture was stirred at 0° C. for 1 hour. The reaction mixture was added dropwise to a 28% aqueous ammonia solution (19 mL) at 0° C. and stirred at room temperature for 2 hours. The reaction mixture was poured into water and extracted three times with dichloromethane. The combined organic layers were washed with saturated sodium chloride solution and then dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure to give 1.04 g of the title compound (yield: quantitative) as a white solid. (6b) (1s,4s)-4-(trifluoromethyl)cyclohexane-1-carbonitrile (1s, 4s)-4-(trifluoromethyl)cyclohexane-1-carbonitrile The (1s,4s)-4-(trifluoromethyl)cyclohexane-1-carboxamide (1.04 g) of Example 6 (6a) was suspended in dichloromethane (20 mL), triethylamine (1.41 mL) was added at 0° C., and then trifluoroacetic anhydride (0.785 mL) was added dropwise over 5 minutes, and the mixture was stirred at 0° C. for 2 hours. The reaction solution was diluted with water and extracted twice with dichloromethane. The combined organic layers were washed successively with water and saturated sodium chloride solution, and then dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography [eluent: ethyl acetate / n-hexane=1 / 4-2 / 1 (V / V)] to give 804 mg of the title compound (yield: 89%) as a white solid. (6c) (1s,4s)-N'-Hydroxy-4-(trifluoromethyl)cyclohexane-1-carboximidamide (1s, 4s)-N'-hydroxy-4-(trifluoromethyl)cyclohexane-1-carboximidamide (1s,4s)-4-(trifluoromethyl)cyclohexane-1-carbonitrile (278 mg) of Example 6 (6b) was dissolved in ethanol (8 mL), and 50% aqueous hydroxylamine solution (0.15 mL) was added, and the mixture was stirred at 50° C. for 3.5 hours. The solvent was distilled off from the reaction mixture under reduced pressure, azeotroped with ethanol, then chloroform and water were added to the residue, and stirred, the organic layer was separated by a phase separator (Biotage Co., Ltd.), and the solvent was distilled off under reduced pressure. The resulting residue was dissolved in ethanol (4 mL), and 50% aqueous hydroxylamine solution (2.0 mL) was added, and the mixture was stirred at 60° C. for 4 hours. After cooling the reaction mixture to room temperature, the solvent was distilled off under reduced pressure, azeotroped with ethanol, and then dried in vacuo at 50° C. to obtain 187 mg of the title compound (yield: 57%) as a white solid. (6d) 9-Benzyl-3-oxa-9-azabicyclo[3.3.1]nonane-7-one 9-benzyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-one 3,6-dioxabicyclo[3.1.0]hexane (CAS registry number: 285-69-8) (2.40 kg) was dissolved in water (12 L), concentrated sulfuric acid (25.2 g) was added at 15°C, and the mixture was stirred at 95°C for 16 hours. The reaction mixture was cooled to 15° C., 3 M aqueous sodium hydroxide solution (97 mL) was added, and the pH was adjusted to 7-8. Subsequently, sodium periodate (5.33 kg) was added at 5-10°C over 3 hours, and then stirred at 10-15°C for 16 hours. Acetonitrile (12 L) was added to the reaction mixture, and the mixture was stirred at room temperature for 30 minutes, the precipitated solid was filtered off, the filtrate was concentrated under reduced pressure, and most of the acetonitrile was evaporated. Subsequently, 1,3-acetonedicarboxylic acid (4.47 kg), acetonitrile (8 L), and 12 M hydrochloric acid (719 mL), were cooled to 10°C, and benzylamine (2.98 kg) was added dropwise at 10°C. The mixture was stirred at 10-20° C. for 1 hour, and then stirred at 50° C. for 16 hours. The precipitated solid was filtered off and washed with ethanol (300 mL) to obtain 2.70 kg of the title compound (yield: 33%) as a pale yellow solid. (6e) tert-Butyl 7-oxo-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate tert-butyl 7-oxo-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate Example 6e-1 9-benzyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-one (150 g) of Example 6 (6d) was dissolved in 1 M hydrochloric acid (1.0 L) and ethanol (700 mL), 10% palladium carbon (20 g) was added, and the mixture was stirred at 50° C. under a hydrogen (50 psi) atmosphere for 20 hours. The insoluble matter was removed by filtration, and the filtrate was concentrated under reduced pressure to remove most of the ethanol, resulting in a mixture containing 3-oxa-9-azabicyclo[3.3.1]nonan-7-one hydrochloride. Example 6e-2 To the mixture obtained in Example 6e-1 was added tetrahydrofuran (1.2 L) and sodium hydrogen carbonate (327 g) and stirred at room temperature for 1 hour, then di-tert-butyl dicarbonate (339 g) was added, and stirred at 30-40° C. for 16 hours. The reaction mixture was filtered, and the filtrate was extracted three times with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate, and then the solvent was removed under reduced pressure. The residue was triturated with ethyl acetate / petroleum ether, and filtered to give 190 g of the title compound (yield: 61%) as a yellow solid. (6f) tert-Butyl 2-amino-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate tert-butyl 2-amino-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate The tert-butyl 7-oxo-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate (300 g) of Example 6 (6e) was dissolved in toluene (1.4 L), pyrrolidine (146 mL) and tosylic acid monohydrate (30.0 g) were added at room temperature, and the mixture was stirred at 135° C. for 4 hours using a Dean Stark instrument. The solvent was distilled off from the reaction mixture under reduced pressure, and the resulting residue was dissolved in methanol (1.5 L), sulfur (43.0 g) and cyanamide (68.0 g) were added, and the mixture was stirred at room temperature for 18 hours. The reaction mixture was concentrated under reduced pressure, most of the methanol was distilled off, and dichloromethane was added. The organic layer was washed with saturated aqueous sodium hydrogen carbonate solution and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, and the resulting residue was triturated with ethyl acetate / petroleum ether, and filtered to give 190 g of the title compound (yield: 61%) as a yellow solid. (6g) tert-Butyl 2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate tert-butyl 2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate The tert-butyl 2-amino-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate (95 g) and N,N-diisopropylethylamine (133 mL) of Example 6 (6f) were dissolved in tetrahydrofuran (1 L), and N-methylcarbamoyl chloride (57 g) was added dropwise at 0° C., and the mixture was stirred at 60° C. for 12 hours. The solvent was distilled off from the reaction mixture under reduced pressure, and the resulting residue was triturated with petroleum ether / ethyl acetate, and the precipitated solid was collected by filtration. The resulting solid was dissolved in dichloromethane, washed with water and saturated brine, and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure to give 100 g of the title compound (yield: 84%) as a yellow solid. (6h) N-Methyl-N'-(4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl)urea monohydrochloride N-methyl-N'-(4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl)urea--hydrogen chloride (1 / 1) The tert-butyl 2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate (100 g) of Example 6 (6g) was dissolved in dichloromethane (1 L), 4 M hydrogen chloride-ethyl acetate solution (300 mL) was added, and the mixture was stirred at room temperature for 12 hours. The solvent was distilled off under reduced pressure to give 83 g of the title compound (yield: 95%) as a pale yellow solid. (6i) N-[10-Cyano-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-methylurea N-[10-cyano-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-methylurea Using the N-methyl-N'-(4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl)urea monohydrochloride (2.19 g) of Example 6 (6h), 1.58 g (yield: 75%) of the title compound was obtained as a white solid in the same manner as in Example 1 (1c). (6j) N-methyl-N'-(10-{3-[(1s,4s)-4-(trifluoromethyl)cyclohexyl]-1,2,4-oxadiazol-5-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl)urea N-methyl-N'-(10-{3-[(1s,4s)-4-(trifluoromethyl)cyclohexyl]-1,2,4-oxadiazol-5-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl)urea N-[10-cyano-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-methylurea (120 mg), (1s,4s)-N'-hydroxy-4-(trifluoromethyl)cyclohexane-1-carboximidamide (101 mg), and zinc chloride (77 mg) of Example 6 (6c) were suspended in N,N-dimethylformamide (5 mL), and stirred at 60° C. under a nitrogen atmosphere for 2 hours. Concentrated sulfuric acid (0.1 mL) was added to the reaction mixture, and the mixture was stirred at 80° C. for an additional 3 hours. After cooling to room temperature, the reaction mixture was poured into water and extracted twice with ethyl acetate. The combined organic layers were washed twice with water and once with saturated sodium chloride solution, and then dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography [eluent: ethyl acetate / methanol=1 / 0-9 / 1 (V / V)] to give 105 mg of the title compound (yield: 52%) as a white solid. (Example 7) N-{(4S,8S)-10-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea (7a) tert-Butyl (4S,8S)-2-amino-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate tert-butyl (4S,8S)-2-amino-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate (Optical resolution using a chiral column) tert-butyl 2-amino-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate (160 g) of Example 6 (6f) was applied to chiral SFC (column: CHIRALPAK AD (250mm*30mm, 10μm)) [mobile phase: 0.1% ammonia water / isopropanol / carbon dioxide] and tert-butyl (4S,8S)-2-amino-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate 67 g (yield: 42%) (peak 1, retention time: 2.370 min) was obtained as a yellow solid, and tert-butyl (4R,8R)-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate 69 g (yield: 43%) (peak 2, retention time: 2.573 min) was obtained as a yellow solid. The absolute configuration of tert-butyl (4S,8S)-2-amino-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate was determined by X-ray crystallography of an intermediate synthesized using this compound (Example 20 (20a)). (Optical resolution by diastereomeric salt method) Ethyl acetate (15 L) was added to tert-butyl 2-amino-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate (1.0 kg) and (+)-di-p-toluoyl-D-tartrate (CAS Registry number: 32634-68-7) (580 g) of Example 6 (6f), and the mixture was stirred at 70° C. for 3 hours. The mixture was slowly cooled to room temperature, and the precipitated solid was filtered off and washed with ethyl acetate (1 L). The resulting solid was added to a 1M aqueous sodium hydroxide solution and extracted three times with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was dissolved in ethyl acetate (1 L) at 60° C. and petroleum ether (1 L) was added. After stirring at 60° C. for 0.5 hours, the mixture was slowly cooled to room temperature, and the precipitated solid was filtered off, and washed with ethyl acetate / petroleum ether (100 mL / 100 mL) to obtain 285 g of the title compound (yield: 29%) as a white solid. (7b) N-Methyl-N'-[(4S,8S)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea monohydrochloride N-methyl-N'-[(4S,8S)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea--hydrogen chloride (1 / 1) 6.0 g (yield: quantitative) of the title compound was obtained as a white solid using the tert-butyl (4S,8S)-2-amino-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate (6.0 g) synthesized in the same manner as in Example 6 (6h). (7c) N-{(4S,8S)-10-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea N-{(4S,8S)-10-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea N-[(4S,8S)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea monohydrochloride (80 mg) and 4,4-difluoro-N'-hydroxycyclohexane-1-carboximidamide (50) of Example 1 (1b) 39 mg (yield: 32%) of the title compound was obtained as a white solid in the same manner as in Example 1 (1d). (Example 8) N-methyl-N'-(5-{3-[3-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)urea (8a) N'-Hydroxy-3-(trifluoromethoxy)benzene-1-carboximidamide N'-hydroxy-3-(trifluoromethoxy)benzene-1-carboximidamide 300 mg (yield: 46%) of the title compound was obtained as a white solid in the same manner as in Example 1 (1b) using 3-(trifluoromethoxy)benzonitrile (CAS Registry number: 52771-22-9) (500 mg). (8b) N-methyl-N'-(5-{3-[3-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)urea N-methyl-N'-(5-{3-[3-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)urea N-(5-cyano-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)-N'-methylurea (120 mg) and N'-hydroxy-3-(trifluoromethoxy)benzene-1-carboximidamide (167 mg) of Example 8 (8a) were dissolved in ethyl acetate (3 mL), zinc chloride (124 mg) in tetrahydrofuran (3 mL) was added, and the mixture was stirred at 60° C. for 15 hours. The solvent was distilled off from the reaction mixture under reduced pressure, and the resulting residue was dissolved in ethanol (3 mL), concentrated hydrochloric acid (3 mL) was added, and the mixture was stirred at 80° C. for 1 hour. The solvent was distilled off from the reaction mixture under reduced pressure, and methanol was added to the obtained residue, and the precipitated solid was filtered off and washed with methanol to obtain 46 mg of the title compound (yield: 22%) as a white solid. (Example 9) N-{5-[5-(4-fluoro-3-methylphenyl)-1,3,4-oxadiazol-2-yl]-4,5,6,7-tetrahydro[[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-methylurea N-{5-[5-(4-fluoro-3-methylphenyl)-1,3,4-oxadiazol-2-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-methylurea N-[5-(hydrazinecarbothioyl)-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl]-N'-methylurea (0.40 g) of Example 2 (2b) was dissolved in dimethylsulfoxide (6 mL), 4-fluoro-3-methylbenzoic acid (0.24 g) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.80 g) were added, and the mixture was stirred at 60° C. for 7 hours. Water was added to the reaction mixture, and the precipitated solid was collected by filtration and washed successively with ethanol and ethyl acetate to obtain 162 mg of the title compound (yield: 30%) as a brown solid. (Example 10) N-{(5R * ,8S * )-9-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[d][1,3]thiazol-2-yl}-N'-methylurea (10a) tert-Butyl 2-amino-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[d][1,3]thiazole-9-carboxylate tert-butyl 2-amino-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[d][1,3]thiazole-9-carboxylate tert-butyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate (CAS registry number: 185099-67-6) (110 g) was dissolved in toluene (500 mL), pyrrolidine (49 mL) and tosylic acid monohydrate (8.4 g) were added at room temperature, and the mixture was stirred at 130° C. using a Dean Stark instrument for 18 hours. The solvent was evaporated from the reaction mixture under reduced pressure, and the resulting residue was dissolved in methanol (500 mL) and cooled to 0° C. A methanol solution (100 mL) of sulfur (15.7 g) and cyanamide (22.6 g) was added at 0° C. and stirred at room temperature for 16 hours. The solvent was distilled off from the reaction mixture under reduced pressure, and the resulting residue was purified by silica gel column chromatography [eluent solvent: petroleum ether / ethyl acetate / dichloromethane=20 / 5 / 1-5 / 5 / 1 (V / V / V)] to give 91.8 g of the title compound (yield: 67%) as a yellow solid. (10b) tert-butyl (5R) * ,8S * )-2-amino-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[d][1,3]thiazole-9-carboxylate tert-butyl (5R) * ,8S * )-2-amino-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[d][1,3]thiazole-9-carboxylate The tert-butyl 2-amino-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[d][1,3]thiazole-9-carboxylate (150 g) of Example 10 (10a) was subjected to chiral SFC (column: CHIRALPAK AD (150 mm*4.6 mm, 3 μm)) [mobile phase: 0.05% diethylamine / ethanol / carbon dioxide] to obtain an enantiomer of 80 g of peak 1 (retention time: 1.962 min) and an enantiomer of 78 g of peak 2 (retention time: 2.183 min). To the enantiomer of Peak 2 was added petroleum ether / ethyl acetate / dichloromethane (100 mL / 10 mL / 5 mL), and the mixture was stirred at 50° C. for 20 minutes. The solid that precipitated was collected by filtration to obtain 35 g (yield: 24%) of the title compound as a pale yellow solid. (10c) tert-butyl (5R) * ,8S * )-2-[(methylcarbamoyl)amino]-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[d][1,3]thiazole-9-carboxylate tert-butyl (5R) * ,8S * )-2-[(methylcarbamoyl)amino]-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[d][1,3]thiazole-9-carboxylate tert-butyl of Example 10 (10b) (5R * ,8S *)-2-amino-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[d][1,3]thiazole-9-carboxylate (5.0 g) was used to obtain 5.4 g of the title compound (yield: 95%) as a yellow solid in the same manner as in Example 6 (6 g). (10d) N-Methyl-N'-[(5R) * ,8S * )-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[d][1,3]thiazol-2-yl]urea monohydrochloride N-methyl-N'-[(5R * ,8S * )-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[d][1,3]thiazol-2-yl]urea--hydrogen chloride (1 / 1) tert-butyl of Example 10 (10c) (5R * ,8S * )-2-[(methylcarbamoyl)amino]-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[d][1,3]thiazole-9-carboxylate (5.4 g) was used to obtain 4.2 g of the title compound (yield: 96%) as a yellow solid in the same manner as in Example 6 (6h). (10e) 3-(4-Fluorophenyl)-1,2,4-oxadiazole-5(4H)-one 3-(4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one 4-Fluoro-N'-hydroxybenzene-1-carboximidamide (CAS registry number: 22179-78-8) (24.0 g) was dissolved in tetrahydrofuran (300 mL), N,N-diisopropylethylamine (54.2 mL) was added, followed by a dropwise addition of a solution of triphosgene (18.5 g) in tetrahydrofuran (50 mL). After stirring at room temperature for 1 hour, the mixture was stirred at 60° C. for an additional hour. The reaction mixture was cooled to room temperature, and then the solvent was distilled off under reduced pressure. The resulting residue was dissolved in dichloromethane and extracted three times with 1M aqueous sodium hydroxide solution. The combined aqueous layers were acidified with 1 M hydrochloric acid, and the precipitated solid was collected by filtration, washed with water, and dried under reduced pressure at 50° C. to give 13.9 g of the title compound (yield: 50%) as a pale yellow solid. (10f) 5-Chloro-3-(4-fluorophenyl)-1,2,4-oxadiazole 5-chloro-3-(4-fluorophenyl)-1,2,4-oxadiazole To the 3-(4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one (13.9 g) of Example 10 (10e), phosphorus oxychloride (148 g) and pyridine (7.5 mL) were added at room temperature, and the mixture was stirred at 130° C. for 3 hours. The reaction mixture was cooled to room temperature, and then the solvent was evaporated under reduced pressure, and the resulting residue was dissolved in dichloromethane and washed with water and a saturated aqueous sodium hydrogen carbonate solution. The organic layer was dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure to obtain the residue obtained by column chromatography on silica gel [eluent solvent: n-hexane / ethyl acetate=99 / 1-80 / 20 (V / V)] to give 11.2 g of the title compound (yield: 73%) as a pale yellow solid. (10g) N-{(5R * ,8S * )-9-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[d][1,3]thiazol-2-yl}-N'-methylurea N-{(5R * ,8S * )-9-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[d][1,3]thiazol-2-yl}-N'-methylurea N-methyl-N'-[(5R) of Example 10 (10d) * ,8S * )-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[d][1,3]thiazol-2-yl]urea monohydrochloride (800 mg) was dissolved in N,N-dimethylformamide (10 mL), and 5-chloro-3-(4-fluorophenyl)-1,2,4-oxadiazole (609 mg) and potassium carbonate (2.01 g) of Example 10 (10f) were added, and the mixture was stirred at room temperature for 12 hours. The reaction mixture was poured into water and the reaction mixture was extracted three times with ethyl acetate. The combined organic layers were washed with saturated brine and dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography [eluent: methanol / ethyl acetate=1 / 99-20 / 80 (V / V)] to give 560 mg of the title compound (yield: 48%) as a yellow solid. (Example 11) N-{9-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[d][1,3]thiazol-2-yl}-N'-methylurea (11a) 8-Azabicyclo[3.2.1]octane-3-one monohydrochloride 8-azabicyclo[3.2.1]octan-3-one--hydrogen chloride (1 / 1) tert-butyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate (CAS registry number: 185099-67-6) (103 g) was dissolved in methanol (300 mL), 4 M hydrogen chloride-1,4-dioxane solution (320 mL) was added, and the mixture was stirred at room temperature for 20 hours. The solvent was distilled off from the reaction mixture under reduced pressure to give 81 g of the title compound (yield: quantitative) as a pale yellow solid. (11b) 8-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-8-azabicyclo[3.2.1]octane-3-one 8-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-8-azabicyclo[3.2.1]octan-3-one 8-azabicyclo[3.2.1]octane-3-one monohydrochloride (2.0 g) and N,N-diisopropylethylamine (5.4 mL) of Example 11 (11a) were dissolved in tetrahydrofuran (15 mL), and added dropwise to a 1,1-dibromoformaldoxime (3.7 g) in tetrahydrofuran (15 mL) cooled to -20°C under a nitrogen atmosphere, and the mixture was stirred at 0°C for 30 minutes. Subsequently, a toluene solution (30 mL) was added to triethylamine (5.2 mL) and 1-ethynyl-4-fluorobenzene (CAS registry number: 766-98-3) (1.8 g) and the mixture was stirred at 80° C. for 9.5 hours. The reaction mixture was poured into water and the reaction mixture was extracted three times with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure to obtain the residue obtained by column chromatography on silica gel [eluent solvent: petroleum ether / ethyl acetate=1 / 0-3 / 1 (V / V)] to give 350 mg of the title compound (yield: 8.4%) as a yellow solid. (11c) 9-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[d][1,3]thiazole-2-amine 9-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[d][1,3]thiazol-2-amine 8-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-8-azabicyclo[3.2.1]octan-3-one (0.15 g) of Example 11 (11b) was dissolved in pyridine (15 mL), sulfur (29 mg) and cyanamide (340 mg) were added, and the mixture was stirred at 130° C. for 1.5 hours. The solvent was evaporated from the reaction mixture under reduced pressure, and the resulting residue was purified by thin-layer silica gel chromatography [evolving solvent: petroleum ether / ethyl acetate=1 / 1 (V / V)] to give 20 mg of the title compound (yield: 12%) as a yellow solid. (11d) N-{9-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[d][1,3]thiazol-2-yl}-N'-methylurea N-{9-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[d][1,3]thiazol-2-yl}-N'-methylurea Using 9-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[d][1,3]thiazole-2-amine (50 mg) of Example 11(11c), 4.5 mg (yield: 7.9%) of the title compound was obtained as a pale yellow solid in the same manner as in Example 6 (6g). (Example 12) N-{(5R * ,9S* )-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-5,9-epiminocycloocta[d][1,3]thiazol-2-yl}-N'-methylurea (12a) N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-5,9-epiminocycloocta[d][1,3]thiazol-2-yl}-N'-methylurea N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-5,9-epiminocycloocta[d][1,3]thiazol-2-yl}-N'-methylurea Using tert-butyl 3-oxo-9-azabicyclo[3.3.1]nonane-9-carboxylate (CAS Registry number: 512822-27-4) from tert-butyl 3-oxo-9-azabicyclo[3.3.1]nonane-9-carboxylate (CAS Registry number: 512822-27-4) in the same manner as in Example 6 (6f), 6 (6g), 6 (6h), N-(4,5,6,7,8,9-hexahydro-5,9-epiminocycloocta[d][1,3]thiazol-2-yl)-N'-methylurea monohydrochloride (2.5 g) and 5-chloro-3-(4-fluorophenyl)-1,2,4-oxadiazole (1.5 g) of Example 10 (10f), the title compound 2.8 was used in the same manner as in Example 10 (10g). g (yield: 95%) was obtained as a yellow solid. (12b) N-{(5R * ,9S * )-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-5,9-epiminocycloocta[d][1,3]thiazol-2-yl}-N'-methylurea N-{(5R * ,9S * )-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-5,9-epiminocycloocta[d][1,3]thiazol-2-yl}-N'-methylurea N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-5,9-epiminocycloocta[d][1,3]thiazol-2-yl}-N'-methylurea (3.8 g) from Example 12 (12a) was subjected to chiral SFC (column: CHIRALPAK AD (100 mm*4.6 mm, 3 μm)) [mobile phase: 0.05% diethylamine / isopropanol / carbon dioxide], and the enantiomer of Peak 1 (retention time: 1.827 min) and the enantiomer of Peak 2 (retention time: 4.412 min) were separated. 1.5 g of the title compound (yield: 41%, pale yellow solid) was obtained as the enantiomer of Peak 1. (Example 13) N-{(4S,8S)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea (13a) N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea Using the N-methyl-N'-(4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl)urea monohydrochloride (40 g) and the 5-chloro-3-(4-fluorophenyl)-1,2,4-oxadiazole (32 g) of Example 10 (10f), 25 g (yield: 51%) of the title compound was obtained as a white solid in the same manner as in Example 10 (10 g). (13b) N-{(4S,8S)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea N-{(4S,8S)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea Example 13(13a) is used to make N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea (50 g) into chiral SFC (column: CHIRALCEL OD (100mm*4.6mm, 3 μm)) [Mobile phase: 0.05% diethylamine / methanol / carbon dioxide] and N-{(4R,8R)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea 22 g (yield: 45%) (peak 1, retention time: 1.054 min) was obtained as a white solid and N-{(4S,8S)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea 20 g (yield: 43%) (peak 2, retention time: 1.599 min) was obtained as a white solid. The title compound was also prepared from the compound of Example 7 (7a), which is an intermediate whose absolute configuration has been determined, and therefore it was confirmed that the enantiomer of Peak 2 had the absolute configuration of the title compound. (Example 14) N-(10-{5-[3-(difluoromethyl)phenyl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl)-N'-methylurea (14a) 3-(Difluoromethyl)benzaldehyde 3-(difluoromethyl)benzaldehyde Under a nitrogen atmosphere, 1-bromo-3-(difluoromethyl)benzene (CAS Registry number: 29848-59-7) (2.0 g) was dissolved in tetrahydrofuran (40 mL), and n-butyllithium (2.5 M n-hexane solution, 4.1 mL) was slowly added at -78°C. After stirring at -78° C. for 30 minutes, N,N-dimethylformamide (2 mL) was added, and the mixture was stirred at room temperature for 12 hours. The reaction mixture was poured into a saturated aqueous ammonium chloride solution, and the reaction mixture was extracted three times with ethyl acetate. The combined organic layers were washed with saturated brine and dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography [eluent solvent: petroleum ether / ethyl acetate=1 / 0-10 / 1 (V / V)] to give 0.30 g of the title compound (yield: 20%) as a yellow oil. (14b) 5-[3-(difluoromethyl)phenyl]-1,3-oxazole 5-[3-(difluoromethyl)phenyl]-1,3-oxazole 3-(difluoromethyl)benzaldehyde (0.30 g) of Example 14 (14a) was dissolved in methanol (10 mL), p-toluenesulfonylmethylisocyanide (0.38 g) and potassium carbonate (0.38 g) were added, and the mixture was stirred at 70° C. for 1 hour. The solvent was distilled off from the reaction mixture under reduced pressure, and water was added to the obtained residue, and the reaction mixture was extracted three times with ethyl acetate. The combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure to give 0.29 g of the title compound (yield: 77%) as a yellow oil. (14c) 2-Chloro-5-[3-(difluoromethyl)phenyl]-1,3-oxazole 2-chloro-5-[3-(difluoromethyl)phenyl]-1,3-oxazole Under a nitrogen atmosphere, 5-[3-(difluoromethyl)phenyl]-1,3-oxazole (0.29 g) of Example 14 (14b) was dissolved in tetrahydrofuran (10 mL), and lithium bis(trimethylsilyl)amide (1 M tetrahydrofuran solution, 1.8 mL) was slowly added at -78°C. After stirring at -78° C. for 30 minutes, hexachloroethane (0.42 g) was added, and the mixture was stirred at -78° C. for 30 minutes and at room temperature for 12 hours. The reaction mixture was poured into a saturated aqueous ammonium chloride solution, the reaction mixture was extracted three times with ethyl acetate, and the combined organic layers were dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the resulting residue was purified by thin layer chromatography [evolving solvent: petroleum ether / ethyl acetate=10 / 1 (V / V)] to give 0.16 g of the title compound (yield: 47%) as a white solid. (14d) N-(10-{5-[3-(difluoromethyl)phenyl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl)-N'-methylurea N-(10-{5-[3-(difluoromethyl)phenyl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl)-N'-methylurea The N-methyl-N'-(4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl)urea monohydrochloride (0.24 g) of Example 6 (6h) was dissolved in dimethylsulfoxide (2 mL), and the 2-chloro-5-[3-(difluoromethyl)phenyl]-1,3-oxazole (0.16 g) and N,N-diisopropylethylamine (0.61 mL) of Example 14 (14c) were added, and the mixture was stirred at 100° C. for 12 hours. The reaction mixture was poured into water, the reaction mixture was extracted three times with ethyl acetate, and the combined organic layers were dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the resulting residue was purified by high-performance liquid chromatography [Column: Waters Xbridge; Mobile phase: acetonitrile / 0.05% aqueous ammonia=25 / 75-55 / 45 (V / V)] to give 97 mg of the title compound (yield: 31%) as a white solid. (Example 15) N-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea N-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea 67 mg (yield: 35%) of the title compound was obtained as a pink solid using 2-(2-chloro-1,3-oxazol-5-yl)-6-methoxypyridine (0.10 g) synthesized in the same manner as Example 14 (14b) and N-methyl-N'-[(4S,8S)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea monohydrochloride (0.13 g) from 6-methoxypyridine (CAS Registry number: 54221-96-4) in the same manner as Example 14 (14d). (Example 16) N-{10-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea N-{10-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea The N-methyl-N'-(4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl)urea monohydrochloride (0.65 g) of Example 6 (6h) was synthesized in the same manner as in Example 11 (11b), and 58 mg (yield: 6.3%) of the title compound was obtained as a yellow oil. (Example 17) N-{(4S,8S)-10-[4-(4-fluorophenyl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea (17a) 4-(4-Fluorophenyl)-1,3-oxazole 4-(4-fluorophenyl)-1,3-oxazole 2-bromo-1-(4-fluorophenyl)ethane-1-one (CAS Registry number: 403-29-2) (5.0 g) was dissolved in formic acid (10 mL), ammonium formate (14.5 g) was added, and the mixture was stirred at 130° C. for 8 hours. Water was added to the reaction mixture, and the reaction mixture was extracted three times with ethyl acetate. The combined organic layers were washed with water and saturated brine and dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography [eluent: n-hexane / ethyl acetate=10 / 0-7 / 3 (V / V)] to give 1.2 g of the title compound (yield: 32%) as a yellow solid. (17b) 2-Chloro-4-(4-fluorophenyl)-1,3-oxazole 2-chloro-4-(4-fluorophenyl)-1,3-oxazole The 4-(4-fluorophenyl)-1,3-oxazole (1.2 g) of Example 17 (17a) was synthesized in the same manner as Example 14 (14c) to give 1.4 g of the title compound (yield: 96%) as a pale yellow solid. (17c) (4S,8S)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-2-amine dihydrochloride (4S,8S)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-amine--hydrogen chloride (1 / 2) The tert-butyl (4S,8S)-2-amino-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate (15 g) of Example 7 (7a) was dissolved in ethanol (100 mL), and 4 M hydrogen chloride-1,4-dioxane solution (100 mL) was added, and the mixture was stirred at room temperature for 5 hours. The solvent was distilled off from the reaction mixture under reduced pressure, azeotroped with toluene twice, and the precipitated solid was washed with ethyl acetate / n-hexane to obtain 13.4 g of the title compound (yield: 98%) as a pale yellow solid. (17d) (4S,8S)-10-[4-(4-fluorophenyl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-2-amine (4S,8S)-10-[4-(4-fluorophenyl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-amine The (4S,8S)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-2-amine dihydrochloride (2.0 g) of Example 17(17c) was dissolved in dimethylsulfoxide (20 mL), and the 2-chloro-4-(4-fluorophenyl)-1,3-oxazole (1.4 g) and N,N-diisopropylethylamine (6.4 mL) of Example 17(17b) were added, and the mixture was stirred at 100° C. for 12 hours, and left at room temperature overnight. Thereafter, the mixture was stirred at 100° C. for 11 hours and left at room temperature overnight. The mixture was further stirred at 100° C. for 12 hours, the reaction mixture was poured into water, and the reaction mixture was extracted three times with ethyl acetate. The combined organic layers were washed with water and saturated brine and dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the resulting residue was purified by NH silica gel column chromatography [eluent: methanol / ethyl acetate=0 / 10-1 / 9 (V / V)] to give 0.64 g of the title compound (yield: 24%) as a yellow solid. (17e) N-{(4S,8S)-10-[4-(4-fluorophenyl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea N-{(4S,8S)-10-[4-(4-fluorophenyl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-methylurea Example 17(17d) (4S,8S)-10-[4-(4-fluorophenyl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-2-amine (0.20 g) was dissolved in tetrahydrofuran (4 mL), and 1,1'-carbonyldiimidazole (0.14 g) was added, and the mixture was left at room temperature overnight. Methylamine (2 mol / L tetrahydrofuran solution, 0.84 mL) was added and the mixture was stirred at room temperature for 8 hours. The solvent was distilled off from the reaction mixture under reduced pressure, ethyl acetate was added to the resulting residue, the organic layer was washed with water and saturated brine, and dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography [eluent: methanol / ethyl acetate=0 / 10-1 / 19 (V / V)] to give 0.13 g of the title compound (yield: 57%) as a pale yellow solid. (Example 18) N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(2R)-1-hydroxypropan-2-yl]urea (18a) 2-(Trimethylsilyl)ethyl 7-oxo-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate 2-(trimethylsilyl)ethyl 7-oxo-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate 2-(trimethylsilyl)ethanol (199 g) and triethylamine (240 mL) were dissolved in tetrahydrofuran (800 mL), and a solution of triphosgene (173 g) in tetrahydrofuran (400 mL) was added dropwise at -10°C to -5°C over 40 minutes. The mixture was stirred at the same temperature for 20 minutes, then at room temperature for 2.5 hours. The precipitated white solid was filtered off, and the solvent was evaporated from the filtrate under reduced pressure to obtain a residue. To an aqueous solution (700 mL) of 3-oxa-9-azabicyclo[3.3.1]nonan-7-one hydrochloride (99 g) of Example 6 (6e-1) was added tetrahydrofuran (600 mL) and sodium hydrogen carbonate (234 g), and a tetrahydrofuran solution (450 mL) of the residue obtained above was added over 30 minutes, and the mixture was stirred at room temperature for 16 hours. The reaction mixture was extracted three times with ethyl acetate, and the combined organic layers were dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, and the resulting residue was triturated with ethyl acetate / petroleum ether and filtered to give 93 g of the title compound (yield: 58%) as a pale yellow solid. (18b) 2-(Trimethylsilyl)ethyl 2-amino-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate 2-(trimethylsilyl)ethyl 2-amino-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate The 2-(trimethylsilyl)ethyl 7-oxo-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate (90 g) of Example 18 (18a) was synthesized in the same manner as Example 6 (6f) to give 90 g of the title compound (yield: 61%) as a pale yellow solid. (18c) 2-(Trimethylsilyl)ethyl 2-[(tert-butoxycarbonyl)amino]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate 2-(trimethylsilyl)ethyl 2-[(tert-butoxycarbonyl)amino]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate 2-(trimethylsilyl)ethyl 2-amino-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate (180 g) of Example 18 (18b) was dissolved in tetrahydrofuran (1 L), and triethylamine (102 g) and dimethylaminopyridine (1.5 g) were added. Subsequently, di-tert-butyl dicarbonate (152 g) was slowly added at 35° C. to 40° C. over 5 hours, and then stirred at 40° C. for 16 hours. Saturated brine was added to the reaction mixture, and after stirring at room temperature for 30 minutes, the reaction mixture was extracted three times with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure to obtain the residue obtained by column chromatography on silica gel [eluent solvent: petroleum ether / ethyl acetate=5 / 1-2 / 1 (V / V)] to give 180 g of the title compound (yield: 77%) as a white solid. (18d) tert-Butyl 4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-ylcarbamate tert-butyl 4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-ylcarbamate 2-(trimethylsilyl)ethyl 2-[(tert-butoxycarbonyl)amino]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate (183 g) from Example 18 (18c) was dissolved in tetrahydrofuran (600 mL), tetrabutylammonium fluoride (1 mol / L tetrahydrofuran solution, 580 mL) was added, and the mixture was stirred at 40°C to 45°C for 16 hours. The solvent was distilled off from the reaction mixture under reduced pressure, and water was added to the obtained residue, and the reaction mixture was extracted three times with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate, filtered, and most of the solvent was evaporated under reduced pressure. The precipitated solid was filtered off and washed with ethyl acetate (30 mL) to give 98 g of the title compound (yield: 78%) as a white solid. (18e) 10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-2-amine monohydrochloride 10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-amine--hydrogen chloride (1 / 1) 1.5 g (yield: quantitative) of the title compound was obtained as a white solid using the tert-butyl {10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}carbamate (1.6 g) synthesized from the tert-butyl 4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}carbamate (1.6 g) of Example 18 (18d) in the same manner as in Example 18 (6h). (18f) Phenyl {10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}carbamate phenyl {10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}carbamate The 10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-2-amine monohydrochloride (1.4 g) of Example 18 (18e) was suspended in dichloromethane (50 mL), triethylamine (2.0 mL) and phenyl chloroformate (1.1 g) were added, and the mixture was stirred at 40° C. for 3 hours. Further, phenyl chloroformate (1.1 g) was added and the mixture was stirred at 40° C. for 12 hours. The solvent was distilled off from the reaction mixture under reduced pressure, and water was added to the obtained residue, and the reaction mixture was extracted three times with ethyl acetate. The combined organic layers were washed with saturated brine and dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure to give 3.0 g of the title compound (yield: quantitative) as a brown oil. (18g) N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(2R)-1-hydroxypropan-2-yl]urea N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(2R)-1-hydroxypropan-2-yl]urea The phenyl {10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminoxocino[5,4-d][1,3]thiazol-2-yl}carbamate (192 mg) of Example 18 (18f) was dissolved in 1,4-dioxane (2 mL), pyridine (0.128 mL) and (2R)-2-aminopropan-1-ol (90 mg) were added, and the mixture was stirred at 80° C. for 2 hours. The solvent was evaporated from the reaction mixture under reduced pressure, and the resulting residue was purified by silica gel column chromatography [eluent solvent: petroleum ether / ethyl acetate=5 / 1-1 / 1 (V / V)], and the solvent was evaporated under reduced pressure, and the residue was purified by high-performance liquid chromatography [column: Phenomenex luna C18; mobile phase: acetonitrile / 0.225% aqueous formic acid solution=36 / 64-56 / 44 (V / V)] to give 84 mg (yield: 45%) of the title compound as a white solid. (Example 19) N-{6-acetyl-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl}-N'-methylurea (19a) 2,5-Dihydro-1H-pyrrole Monohydrochloride 2,5-dihydro-1H-pyrrole--hydrogen chloride (1 / 1) The mixture was synthesized in the same manner as in Example 6 (6h) using tert-butyl 2,5-dihydro-1H-pyrrole-1-carboxylate (CAS Registry number: 73286-70-1) (10 g) to give 6.8 g of the title compound (yield: 98%) as a gray solid. (19b) 1-(2,5-dihydro-1H-pyrrole-1-yl)ethane-1-one 1-(2,5-dihydro-1H-pyrrol-1-yl)ethan-1-one 2,5-dihydro-1H-pyrrole monohydrochloride (8.9 g) and triethylamine (23.5 mL) of Example 19 (19a) were dissolved in dichloromethane (150 mL), acetyl chloride (7.3 mL) was added dropwise at 0° C., and the mixture was stirred at 15° C. for 2 hours. The reaction mixture was diluted with dichloromethane, the organic layer was washed with water and saturated brine, and dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the resulting residue was triturated with petroleum ether / ethyl acetate, and filtered to give 8.3 g of the title compound (yield: 80%) as a yellow solid. (19c) 3-acetyl-9-benzyl-3,9-diazabicyclo[3.3.1]nonane-7-one 3-acetyl-9-benzyl-3,9-diazabicyclo[3.3.1]nonan-7-one 1-(2,5-dihydro-1H-pyrrole-1-yl)ethane-1-one (7.0 g) of Example 19 (19b) was dissolved in dichloromethane / methanol (100 mL / 10 mL), and sodium hydrogen carbonate (4.8 g) was added. The reaction mixture was blown with ozone gas for 15 minutes with stirring at -78°C. Next, nitrogen gas was blown at -78° C. for 15 minutes. Subsequently, triphenylphosphine (7.4 g) was added, and the mixture was slowly raised, and the mixture was stirred at room temperature for 12 hours. The reaction mixture was filtered and about half of the solvent was distilled off from the filtrate under reduced pressure. To the resulting residue was added 1,3-acetonedicarboxylic acid (5.6 g), 12 M hydrochloric acid (1.6 mL), and benzylamine (4.2 mL), and the mixture was stirred at 15° C. for 1 hour, and then at 50° C. for 12 hours. The solvent was distilled off from the reaction mixture under reduced pressure, and the resulting residue was purified by silica gel column chromatography [eluent: petroleum ether / ethyl acetate=3 / 1-0 / 1 (V / V)] to give 2.0 g of the title compound (yield: 12%) as a yellow solid. (19d) tert-Butyl 3-acetyl-7-oxo-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate tert-butyl 3-acetyl-7-oxo-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate 3-acetyl-9-benzyl-3,9-diazabicyclo[3.3.1]nonan-7-one (1.4 g) of Example 19 (19c) was dissolved in ethanol (8 mL), 1 M hydrochloric acid (7.1 mL) and 10% palladium carbon (200 mg) were added, and the mixture was stirred at 20° C. under a hydrogen (30 psi) atmosphere for 16 hours. The reaction mixture was filtered, and to the resulting filtrate was added sodium bicarbonate (333 mg) and di-tert-butyl dicarbonate (317 mg) and stirred at 15° C. for 16 hours. The solvent was distilled off from the reaction mixture under reduced pressure, water was added to the resulting residue, and the reaction mixture was extracted three times with ethyl acetate. The combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure to obtain the residue obtained by column chromatography on silica gel [eluent solvent: petroleum ether / ethyl acetate=3 / 1-2 / 1 (V / V)] to give 270 mg (yield: 72%) of the title compound as a colorless oil. (19e) N-{6-acetyl-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl}-N'-methylurea N-{6-acetyl-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azocin-2-yl}-N'-methylurea Using N-(6-acetyl-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azocin-2-yl)-N'-methylurea monohydrochloride (50 mg) and 5-chloro-3-(4-fluorophenyl)-1,2,4-oxadiazole (30 mg) of Example 10 (10f) from the tert-butyl 3-acetyl-7-oxo-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate of Example 19 (19d), the title compound 21 was used in the same manner as Example 10 (10g). mg (yield: 30%) was obtained as a white solid. (Example 20) (5R)-3-{(4S,8S)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-5-methylimidazolidine-2,4-dione (20a) (4S,8S)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-2-amine (4S,8S)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-amine The (4S,8S)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-2-amine dihydrochloride (4.59 g) of Example 17(17c) was dissolved in N,N-dimethylformamide (100 mL), and the 5-chloro-3-(4-fluorophenyl)-1,2,4-oxadiazole (4.04 g) and potassium carbonate (7.04 g) of Example 10(10f) were added, and the mixture was stirred at room temperature for 24 hours. The reaction mixture was poured into water and the reaction mixture was extracted three times with ethyl acetate. The combined organic layers were washed with saturated brine and dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the resulting residue was triturated with ethyl acetate, and the precipitated solid was collected by filtration to obtain 4.08 g of the title compound (yield: 67%) as a pale yellow solid. (20b) N-({(4S,8S)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}carbamoyl)-D-alanine N-({(4S,8S)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}carbamoyl)-D-alanine Example 20(20a) (4S,8S)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-2-amine (0.30 g) was dissolved in N,N-dimethylformamide (6 mL), 1,1'-carbonyldiimidazole (0.20 g) was added, and the mixture was left at room temperature overnight. To the reaction mixture was added D-alanine (0.22 g) and triethylamine (0.58 mL), and the mixture was stirred at 50° C. for 3 hours. Ethyl acetate was added to the reaction solution, and the organic layer was washed with saturated sodium chloride solution, and dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure to give 0.46 g of the title compound (quantitative yield) as a yellow solid. (20c) (5R)-3-{(4S,8S)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-5-methylimidazolidine-2,4-dione (5R)-3-{(4S,8S)-10-[3-(4-fluorophynyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-5-methylimidazolidine-2,4-dione Example 20(20b) was dissolved in N-({(4S,8S)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}carbamoyl)-D-alanine (0.46 g) in N,N-dimethylformamide (8 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.28 g) and 4-dimethylaminopyridine (0.024 g) were added, and the mixture was left at room temperature overnight. Water was added to the reaction mixture, and the reaction mixture was extracted three times with ethyl acetate. The combined organic layers were washed with water and saturated brine and dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography [elution solvent: methanol / ethyl acetate=0 / 10-1 / 9 (V / V)], and the obtained solid was washed with ethyl acetate / n-hexane to obtain 0.21 g of the title compound (yield: 48%) as a pale yellow solid. (Example 21) N-[(4S,8S)-10-{5-[3-(cyclopropanecarbonyl)phenyl]-1,3,4-oxadiazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-methylurea (21a) 4-Nitrophenyl (4S,8S)-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate 4-nitrophenyl (4S,8S)-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate The N-methyl-N'-[(4S,8S)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-methylurea monohydrochloride (70 g) of Example 7 (7b) was suspended in tetrahydrofuran (600 mL), and triethylamine (107 mL) was added. The reaction mixture was stirred for 10 minutes, then 4-nitrophenyl chloroformate (46 g) was added, and the mixture was stirred at room temperature for 12 hours. The reaction mixture was filtered, washed with tetrahydrofuran (200 mL), and the filtrate was concentrated under reduced pressure to give the residue obtained by column chromatography on silica gel [eluent solvent: petroleum ether / ethyl acetate=1 / 1-0 / 1 (V / V)] to give 60 g of the title compound (yield: 60%) as a yellow solid. (21b) N-[(4S,8S)-10-(hydrazinecarbonyl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-methylurea N-[(4S,8S)-10-(hydrazinecarbonyl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-methylurea 4-nitrophenyl (4S,8S)-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate (60 g) of Example 21(21a) was dissolved in tetrahydrofuran (600 mL), hydrazine monohydrate (55.6 mL) was added, and the mixture was stirred at 70° C. for 16 hours. The reaction mixture was cooled to room temperature, and the precipitated solid was filtered off and washed with tetrahydrofuran (150 mL). The resulting solid was triturated with ethyl acetate (150 mL) / methanol (45 mL) and filtered to give 36 g of the title compound (yield: 81%) as a yellow solid. (21c) N-[(4S,8S)-10-{2-[3-(cyclopropanecarbonyl)benzoyl]hydrazinecarbonyl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-methylurea N-[(4S,8S)-10-{2-[3-(cyclopropanecarbonyl)benzoyl]hydrazinecarbonyl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-methylurea N-[(4S,8S)-10-(hydrazinecarbonyl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-methylurea (7.4 g) of Example 21(21b) was dissolved in N,N-dimethylformamide (150 mL), and 3-(cyclopropanecarbonyl)benzoic acid (CAS Registry number: 34916-10-4) (5 g), 1H-benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (11.5 g), triethylamine (10 mL) was added and left to stand at room temperature overnight. The reaction mixture was poured into water and acidified with 1N hydrochloric acid, then neutralized with saturated sodium bicarbonate aqueous solution, and the reaction mixture was extracted twice with dichloromethane. The organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure and the resulting residue was purified by silica gel column chromatography [eluent: methanol / ethyl acetate=0 / 10-1 / 9 (V / V)] to give 12.4 g of the title compound (quantitative yield) as a yellow solid. (21d) N-[(4S,8S)-10-{5-[3-(cyclopropanecarbonyl)phenyl]-1,3,4-oxadiazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-methylurea N-[(4S,8S)-10-{5-[3-(cyclopropanecarbonyl)phenyl]-1,3,4-oxadiazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-methylurea N-[(4S,8S)-10-{2-[3-(cyclopropanecarbonyl)benzoyl]hydrazinecarbonyl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-methylurea (12.4 g) of Example 21(21c) was suspended in dichloromethane (130 mL), tosyl chloride (7.3 g) and triethylamine (10.7 mL) were added, and the mixture was left at room temperature overnight. Water was added to the reaction mixture and the reaction mixture was extracted with dichloromethane. The organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography [eluent: methanol / ethyl acetate=0 / 10-1 / 9 (V / V)] to give 7.5 g of the title compound (yield: 63%) as a pale yellow solid. (Example 22) N-[(4S,8S)-10-{5-[3-(difluoromethoxy)phenyl]-1,3,4-oxadiazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-methylurea N-[(4S,8S)-10-{5-[3-(difluoromethoxy)phenyl]-1,3,4-oxadiazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-methylurea Using N-[(4S,8S)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea monohydrochloride of Example 7(7b), N-[(4S,8S)-10-{2-[3-(difluoromethoxy)benzoyl]hydrazinecarbothioyl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea monohydrochloride in the same manner as Example 2(2d), the title compound 970 was obtained by using the same method as Example 2(2d). mg (yield: 27%) was obtained as a white solid. (Example 23) (-)-N-{(4R) * ,8R * )-6-acetyl-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl}-N'-methylurea (23a) 2-(Trimethylsilyl)ethyl 2,5-dihydro-1H-pyrrole-1-carboxylate 2-(trimethylsilyl)ethyl 2,5-dihydro-1H-pyrrole-1-carboxylate 2-(trimethylsilyl)ethanol (269 g) and triethylamine (330 mL) were dissolved in tetrahydrofuran (1.5 L), and a solution of triphosgene (225 g) in tetrahydrofuran (400 mL) was added dropwise at -10°C to -5°C over 60 minutes. The mixture was stirred at the same temperature for 30 minutes, then at room temperature for 1.5 hours. The precipitated white solid was filtered off, and the solvent was evaporated from the filtrate under reduced pressure to obtain a residue. The 2,5-dihydro-1H-pyrrole monohydrochloride salt of Example 19 (19a) was dissolved in tetrahydrofuran / water (500 mL / 700 mL), sodium hydrogen carbonate (250 g) was added, and a tetrahydrofuran solution (400 mL) of the residue obtained above was added over 60 minutes, and the mixture was stirred at room temperature for 16 hours. The organic layer was separated from the aqueous layer, and the solvent was evaporated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent solvent: petroleum ether) to give 730 g of the title compound (quantitative yield: quantitative) as a yellow oil. (23b) 2-(Trimethylsilyl)ethyl 9-benzyl-7-oxo-3,9-diazabicyclo[3.3.1]nonane-3-carboxylate 2-(trimethylsilyl)ethyl 9-benzyl-7-oxo-3,9-diazabicyclo[3.3.1]nonane-3-carboxylate Example 23b-1 2-(trimethylsilyl)ethyl 2,5-dihydro-1H-pyrrole-1-carboxylate (180 g) of Example 23 (23a) was dissolved in dichloromethane / methanol (1.5 L / 300 mL), and sodium hydrogen carbonate (56.7 g) was added. The reaction mixture was blown with ozone gas for 8 hours with stirring at -70°C. Next, nitrogen gas was blown in to replace the nitrogen, and triphenylphosphine (155 g) was added at -60 to -20° C. over 10 minutes, and the mixture was slowly raised, and stirred at room temperature for 16 hours. The mixture was filtered to give the filtrate (0.84 mol, 1.8 L). Example 23b-2 Example 23b-1 was carried out in two batches, and the filtrate was combined and used in the following reaction. To the filtrate was added 1,3-acetone dicarboxylic acid (244 g) and 12 M hydrochloric acid (40 mL), and the mixture was cooled to 0°C. Benzylamine (200 mL) was added to the reaction mixture, and the mixture was stirred at 10-20° C. for 1 hour, and then at 50° C. for 16 hours. The solvent was distilled off from the reaction mixture under reduced pressure, and petroleum ether / ethyl acetate (3 L / 600 mL) was added to the residue, and the precipitate was filtered, and the solvent was evaporated from the filtrate under reduced pressure. The resulting residue was purified by silica gel column chromatography [eluent solvent: petroleum ether / ethyl acetate=50 / 1-5 / 1 (V / V)] to give 340 g of the title compound (yield: 54%) as a white solid. (23c) 3-acetyl-9-benzyl-3,9-diazabicyclo[3.3.1]nonane-7-one 3-acetyl-9-benzyl-3,9-diazabicyclo[3.3.1]nonan-7-one 2-(trimethylsilyl)ethyl 9-benzyl-7-oxo-3,9-diazabicyclo[3.3.1]nonane-3-carboxylate (296 g) of Example 23 (23b) was dissolved in tetrahydrofuran (100 mL), tetrabutylammonium fluoride (1 mol / L tetrahydrofuran solution, 1.39 L) was added, and the mixture was stirred at 50°C to 55°C for 16 hours under a nitrogen atmosphere. To the reaction mixture was added N,N-diisopropylethylamine (280 mL), and after cooling to 5° C., acetyl chloride (100 mL) was slowly added at 5° C. to 10° C. over 30 minutes, and the mixture was stirred at 15° C. for 16 hours. The solvent was distilled off from the reaction mixture under reduced pressure, and ethyl acetate and water were added to the resulting residue, and the mixture was extracted three times with ethyl acetate. The solvent was evaporated from the combined organic layers under reduced pressure, and the residue was purified by silica gel column chromatography [eluent: petroleum ether / ethyl acetate / =5 / 1-0 / 1 (V / V); dichloromethane / ethyl acetate=1 / 20 (V / V)] to give 298 g of the title compound (yield: quantitative) as a yellow oil. (23d) tert-Butyl 3-acetyl-7-oxo-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate tert-butyl 3-acetyl-7-oxo-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate 3-acetyl-9-benzyl-3,9-diazabicyclo[3.3.1]nonan-7-one (217 g) of Example 23 (23c) was dissolved in ethanol (700 mL), 1 M hydrochloric acid (700 mL) and 10% palladium carbon (20 g) were added, and the mixture was stirred at 40° C. under a hydrogen (50 psi) atmosphere for 16 hours. The reaction mixture was filtered, sodium hydrogen carbonate (134 g) was added to the resulting filtrate, and the mixture was stirred for 30 minutes, then di-tert-butyl dicarbonate (240 g) was added, and the mixture was stirred at 25° C. for 16 hours. Ethanol was distilled off from the reaction mixture under reduced pressure, and the residue was extracted five times with ethyl acetate. The combined organic layers were washed with water and saturated brine and dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography [eluent solvent: petroleum ether / ethyl acetate=3 / 1-1 / 1 (V / V); petroleum ether / ethyl acetate / dichloromethane=1 / 1 / 1 (V / V / V)] to give 180 g of the title compound (yield: 80%) as a white solid. (23e) tert-Butyl 6-acetyl-2-amino-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-10-carboxylate tert-butyl 6-acetyl-2-amino-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azocine-10-carboxylate Using tert-butyl 3-acetyl-7-oxo-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate (180 g) of Example 23 (23d), 115 g of the title compound (yield: 51%) was obtained as a pale yellow solid in the same manner as in Example 6 (6f). (23f) tert-butyl (4R) * ,8R * )-6-acetyl-2-amino-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-10-carboxylate tert-butyl (4R) * ,8R * )-6-acetyl-2-amino-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azocine-10-carboxylate (Optical resolution using a chiral column) The tert-butyl 6-acetyl-2-amino-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-10-carboxylate (115 g) of Example 23 (23e) was subjected to chiral SFC (column: CHIRALPAK OD (250mm*50mm, 10μm)) [mobile phase: 0.1% ammonia water / isopropanol / carbon dioxide] and the enantiomer of peak 1 (retention time: 1.414 min) and peak 2 (retention time: 1.676 min) were collected. 55 g of the title compound (yield: 49%, pale yellow solid) was obtained as the enantiomer of Peak 2. (Optical resolution by diastereomeric salt method) tert-butyl 6-acetyl-2-amino-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-10-carboxylate (80 g) of Example 23 (23e) was dissolved in acetonitrile (800 mL), and ethyl acetate (15 L) was added to (+)-di-p-anisoyl-L-tartrate (CAS Registry number: 50583-51-2) (94 g), and the mixture was stirred at 30° C. for 1 hour, followed by stirring at 70° C. for 2 hours. The mixture was stirred for 16 hours while slowly cooling to room temperature. The precipitated solid was filtered off and washed with acetonitrile (50 mL). The resulting solid (87 g) was dissolved in acetonitrile (500 mL), stirred at 70° C. for 2 hours, and stirred for 10 hours while slowly cooling to room temperature. The precipitated solid was filtered off and washed with acetonitrile (50 mL). Water (250 mL) was added to the resulting solid (80 g) and the pH was adjusted to 7 by adding a 2M aqueous lithium hydroxide solution. The aqueous layer was extracted 10 times with ethyl acetate (400 mL). The combined organic layers were washed with 1 M aqueous lithium hydroxide solution (500 mL), dried over anhydrous sodium sulfate, and then the solvent was distilled off under reduced pressure to give 31.5 g of the title compound (yield: 41%) as a white solid. (23g) tert-butyl (4R) * ,8R * )-6-acetyl-2-[(methylcarbamoyl)amino]-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-10-carboxylate tert-butyl (4R) * ,8R * )-6-acetyl-2-[(methylcarbamoyl)amino]-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azocine-10-carboxylate tert-butyl of Example 23 (23f) (4R * ,8R * )-6-acetyl-2-amino-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-10-carboxylate (20.0 g) was used to obtain 30 g of the title compound (yield: quantitative) as a yellow solid in a similar manner to Example 6 (6g). (23h) N-[(4R * ,8R* )-6-acetyl-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl]-N'-methylurea monohydrochloride N-[(4R * ,8R * )-6-acetyl-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azocin-2-yl]-N'-methylurea--hydrogen chloride (1 / 1) tert-butyl of Example 23 (23g) (4R * ,8R * )-6-acetyl-2-[(methylcarbamoyl)amino]-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-10-carboxylate (30.0 g) was used to obtain 31 g of the title compound (yield: quantitative) as a yellow solid in the same manner as in Example 6 (6h). (23i) (-)-N-{(4R) * ,8R * )-6-acetyl-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl}-N'-methylurea (-)-N-{(4R) * ,8R * )-6-acetyl-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azocin-2-yl}-N'-methylurea N-[(4R) of Example 23 (23h) * ,8R * )-6-acetyl-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl]-N'-methylurea monohydrochloride (31 g) was used to obtain 19 g of the title compound (yield: 47%) as a yellow solid in the same manner as in Example 10 (10 g). (Example 24) (-)-Methyl (4R * ,8R * )-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate (24a) 9-tert-Butyl 3-[2-(trimethylsilyl)ethyl] 7-oxo-3,9-diazabicyclo[3.3.1]nonane-3,9-dicarboxylate 9-tert-butyl 3-[2-(trimethylsilyl)ethyl] 7-oxo-3,9-diazabicyclo[3.3.1]nonane-3,9-dicarboxylate Example 23(23b) 2-(trimethylsilyl)ethyl 9-benzyl-7-oxo-3,9-diazabicyclo[3.3.1]nonane-3-carboxylate (190 g) was dissolved in ethanol (700 mL), 1 M hydrochloric acid (665 mL) and 10% palladium carbon (10 g) were added, and the mixture was stirred at 40° C. under a hydrogen (50 psi) atmosphere for 16 hours. The reaction mixture was filtered, sodium hydrogen carbonate (70 g) was added to the resulting filtrate, and the mixture was stirred for 30 minutes, then di-tert-butyl dicarbonate (152 g) was added, and the mixture was stirred at 15° C. for 16 hours. Ethanol was distilled off from the reaction mixture under reduced pressure, and the precipitated solid was collected by filtration to obtain 190 g of the title compound (yield: 98%) as a white solid. (24b) 10-tert-butyl 6-[2-(trimethylsilyl)ethyl] 2-amino-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6,10(5H)-dicarboxylate 10-tert-butyl 6-[2-(trimethylsilyl)ethyl] 2-amino-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azocine-6,10(5H)-dicarboxylate Using 9-tert-butyl 3-[2-(trimethylsilyl)ethyl] 7-oxo-3,9-diazabicyclo[3.3.1]nonane-3,9-dicarboxylate (190 g) of Example 24 (24a), 150 g of the title compound (yield: 69%) as a white solid was obtained in the same manner as in Example 6 (6f). (24c) Methyl 2-amino-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-10-carboxylate dihydrochloride methyl 2-amino-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azocine-6(5H)-carboxylate--hydrogen chloride (1 / 2) 10-tert-butyl 6-[2-(trimethylsilyl)ethyl] 2-amino-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6,10(5H)-dicarboxylate (50 g) of Example 24 (24b) was dissolved in tetrahydrofuran (50 mL), tetrabutylammonium fluoride (1 mol / L tetrahydrofuran solution) (200 mL) was added, and the mixture was stirred at 50°C to 55°C under a nitrogen atmosphere for 16 hours. To the reaction mixture was added N,N-diisopropylethylamine (30 mL), and after cooling to 5° C., methyl chloroformate (9.4 mL) was slowly added at 5° C. to 10° C. over 30 minutes, and the mixture was stirred at 15° C. for 16 hours. The solvent was distilled off from the reaction mixture under reduced pressure, and ethyl acetate was added to the resulting residue, washed three times with water, and then 4 M hydrogen chloride-ethyl acetate solution (120 mL) was added, and the mixture was stirred at 15° C. for 16 hours. The precipitated solid was filtered off and washed with ethyl acetate to give 38 g of the title compound (yield: quantitative) as a white solid. (24d) Methyl 2-amino-10-cyano-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-10-carboxylate methyl 2-amino-10-cyano-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azocine-6(5H)-carboxylate Example 24c) methyl 2-amino-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-10-carboxylate dihydrochloride (36 g) and sodium hydrogen carbonate (37 g) were dissolved in dichloromethane (300 mL) and water (50 mL), bromocyan (18 g) was added, and the mixture was stirred at 15° C. for 16 hours. The reaction mixture was filtered and washed with dichloromethane / methanol (100 mL / 10 mL). The aqueous layer was extracted four times with dichloromethane, and the combined organic layers were dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography [eluent: dichloromethane / methanol=1 / 0-20 / 1 (V / V)] to give 17 g of the title compound (yield: 60%) as a white solid. (24e) Methyl (4R) * ,8R * )-2-amino-10-cyano-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate methyl (4R) * ,8R * )-2-amino-10-cyano-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azocine-6(5H)-carboxylate Methyl 2-amino-10-cyano-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-10-carboxylate (32 g) of Example 24 (24d) was subjected to chiral SFC (column: CHIRALPAK IC (250mm*30mm, 10μm)) [mobile phase: 0.1% ammonia water / ethanol / carbon dioxide], and the enantiomer of peak 1 (retention time: 0.591 min) and peak 2 (retention time: 0.964 min) were separated. 13.3 g of the title compound (yield: 43%, pale yellow solid) was obtained as the enantiomer of Peak 2. (24f) Methyl (4R) * ,8R * )-10-Cyano-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate methyl (4R) * ,8R * )-10-cyano-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azocine-6(5H)-carboxylate Methyl of Example 24 (24e) (4R * ,8R *)-2-amino-10-cyano-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate (500 mg) and N,N-diisopropylethylamine (0.312 mL) were dissolved in tetrahydrofuran (5 mL), N-methylcarbamoyl chloride (251 mg) was added, and the mixture was stirred at 60° C. for 12 hours. To the reaction mixture was added ethyl acetate and water, and extracted twice with ethyl acetate. The combined organic layers were washed with water and saturated brine and dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the resulting residue was purified by high performance liquid chromatography [column: Phenomenex lina C18; mobile phase: acetonitrile / 0.225% aqueous ammonium hydroxide solution = 3 / 97-33 / 67 (V / V)] to give 321 mg (yield: 53%) of the title compound as a white solid. (24g) (-)-Methyl (4R * ,8R * )-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate (-)-methyl (4R * ,8R * )-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azocine-6(5H)-carboxylate Methyl of Example 24 (24f) (4R * ,8R * )-10-cyano-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate (150 mg) was dissolved in N,N-dimethylformamide (2 mL), and 4-fluoro-N'-hydroxybenzene-1-carboximidamide (CAS Registry Number: 22179-78-8) (89.4 mg), zinc chloride (12.2 mg), and tosylic acid monohydrate (15.4 mg) were added one after another at room temperature, and the mixture was stirred at 80° C. for 12 hours. The reaction mixture was filtered and the filtrate was purified by high performance liquid chromatography [Column: Waters Xbridge; Mobile phase: acetonitrile / 10 mM aqueous ammonium bicarbonate solution = 21 / 79-51 / 49 (V / V)] to give 31.4 mg (yield: 15%) of the title compound as a white solid. (Example 25) N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(1R,2R)-2-hydroxycyclopentyl]urea N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(1R,2R)-2-hydroxycyclopentyl]urea Using 5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-amine (150 mg) and (1R,2R)-2-aminocyclopentan-1-ol hydrochloride (CAS Registry number: 68327-11-7) (242 mg) of Example 5 (5d), the title compound 66.6 mg (yield: 32%) was obtained as a pale yellow solid in a method similar to Example 5 (5d). (Example 26) N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(1r,4r)-4-hydroxycyclohexyl]urea N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(1r,4r)-4-hydroxycyclohexyl]urea 119 mg (yield: 56%) of the title compound was obtained as an orange solid using 5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridine-2-amine (150 mg) and trans-4-aminocyclohexan-1-ol (CAS Registry number: 27489-62-9) (202 mg) of Example 5 (5d). (Example 27) N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-(3-methoxypropyl)urea N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-(3-methoxypropyl)urea 99.5 mg (yield: 50%) of the title compound was obtained as a pale yellow solid using 5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridine-2-amine (150 mg) and 3-methoxypropane-1-amine (CAS Registry number: 5332-73-0) (0.179 mL) of Example 5 (5d). (Example 28) N-{5-[3-(3,3-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-(2-hydroxy-2-methylpropyl)urea N-{5-[3-(3,3-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-(2-hydroxy-2-methylpropyl)urea tert-butyl 4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-ylcarbamate (WO 2013 / 134226) and 3-oxocyclohexanecarbonitrile (CAS Registry number: 17983-30-1) were synthesized in the same manner as Examples 1 (1a), 1(1b), 1(1c), 1(1d), 29(29b) 84.6 mg (yield: 48%) of the title compound was obtained as a white solid in a similar manner to Example 5 (5d) using mg) and 1-amino-2-methylpropan-2-ol (0.146 mL). (Example 29) N-{[(2S)-1,4-dioxan-2-yl]methyl}-N'-{(4S,8S)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}urea (29a) tert-Butyl (4S,8S)-2-[({[(2S)-1,4-dioxan-2-yl]methyl}carbamoyl)amino]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate tert-butyl (4S,8S)-2-[({[(2S)-1,4-dioxan-2-yl]methyl}carbamoyl)amino]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate tert-butyl (4S,8S)-2-amino-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate (2 g) of Example 7 (7a) was dissolved in N,N-dimethylformamide (40 mL), and 1,1'-carbonyldiimidazole (1.64 g) was added, and the mixture was left at room temperature overnight. (S)-(1,4-dioxan-2-yl)methaneamine hydrochloride (2.07 g) and triethylamine (4.69 mL) were added and the mixture was stirred at room temperature for 2 hours. Ethyl acetate was added to the reaction solution and the organic layer was washed with water and saturated brine, and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography [eluent: n-hexane / ethyl acetate=1 / 1-0 / 1 (V / V)] to give 2.9 g of the title compound (yield: 98%) as a pale yellow solid. (29b) N-{[(2S)-1,4-dioxan-2-yl]methyl}-N'-[(4S,8S)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea N-{[(2S)-1,4-dioxan-2-yl]methyl}-N'-[(4S,8S)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea The tert-butyl(4S,8S)-2-[({[(2S)-1,4-dioxan-2-yl]methyl}carbamoyl)amino]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate (2.9 g) of Example 29(29a) was dissolved in dichloromethane (24 mL), trifluoroacetic acid (6 mL) was added, and the mixture was stirred at room temperature for 5 hours. The reaction solution was concentrated and azeotroped with toluene twice, and the resulting residue was purified by NH silica gel column chromatography [elution solvent: methanol / ethyl acetate=0 / 10-25 / 75 (V / V)] to give 1.75 g (yield: 78%) of the title compound as a yellow solid. (29c) N-{[(2S)-1,4-dioxan-2-yl]methyl}-N'-{(4S,8S)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}urea N-{[(2S)-1,4-dioxan-2-yl]methyl}-N'-{(4S,8S)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}urea N-{[(2S)-1,4-dioxan-2-yl]methyl}-N'-[(4S,8S)-4,7,8,9-tetrahydro-5H-4,8-epiminoxocino[5,4-d][1,3]thiazol-2-yl]urea (300 mg) was dissolved in N,N-dimethylformamide (5 mL), and 5-chloro-3-(4-fluorophenyl)-1,2,4-oxadiazole (210 mg) and potassium carbonate (365 mg) of Example 10 (10f) were added and the mixture was stirred at room temperature for 6 hours. Water was added to the reaction mixture and the reaction mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography [eluent: methanol / ethyl acetate=0 / 10-15 / 85 (V / V)] to give 386 mg (yield: 87%) of the title compound as a pale yellow solid. (Example 30) N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-6-(methanesulfonyl)-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl}-N'-oxan-4-ylurea N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-6-(methanesulfonyl)-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azocin-2-yl}-N'-oxan-4-ylurea 2-(trimethylsilyl)ethyl 2-amino-10-cyano-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate and tetrahydro-2H-pyran-4-amine were synthesized in the same manner as in Example 5(5d), 1(1d), 18(18d). N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate and tetrahydro-2H-pyran-4-amine in Example 31(31b) in the same manner as in Example 5(5d), 1(1d), 18(18d). 12.9 mg (yield: 13%) of the title compound was obtained as a white solid in the same manner as in Example 31 (31d). (Example 31) N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-6-(methanesulfonyl)-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl}-N'-methylurea (31a) 2-(Trimethylsilyl)ethyl 2-amino-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate 2-(trimethylsilyl)ethyl 2-amino-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azocine-6(5H)-carboxylate 10-tert-butyl 6-[2-(trimethylsilyl)ethyl] 2-amino-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6,10(5H)-dicarboxylate (2.5 g) of Example 24 (24b) was dissolved in ethanol (11 mL), tosylic acid monohydrate (2.37 g) was added, and the mixture was stirred at 65° C. for 7 hours. Water was added to the reaction mixture and the reaction mixture was extracted three times with chloroform. The combined organic layers were washed with a saturated aqueous sodium hydrogen carbonate solution and a saturated brine solution, and dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure to give 1.45 g of the title compound (yield: 74%) as a pale yellow solid. (31b) 2-(Trimethylsilyl)ethyl 2-amino-10-cyano-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate 2-(trimethylsilyl)ethyl 2-amino-10-cyano-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azocine-6(5H)-carboxylate Using 2-(trimethylsilyl)ethyl 2-amino-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate (1.45 g) of Example 31(31a), 1.55 g of the title compound (quantitative yield) as a light orange solid was obtained in the same manner as in Example 1(1c). (31c) 2-(Trimethylsilyl)ethyl 10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate 2-(trimethylsilyl)ethyl 10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azocine-6(5H)-carboxylate 2-(trimethylsilyl)ethyl 10-cyano-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate and methylamine monohydrochloride of Example 31(31b) were synthesized in the same manner as in Example 5(5d). Registry Number: 22179-78-8) (219 mg) was used to obtain 207 mg of the title compound (yield: 26%) as a pale yellow solid in the same manner as Example 1 (1d). (31d) N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-6-(methanesulfonyl)-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosin-2-yl}-N'-methylurea N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-6-(methanesulfonyl)-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azocin-2-yl}-N'-methylurea 2-(trimethylsilyl)ethyl of Example 31(31c) N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate was synthesized using the same method as in Example 18 (18d) to N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-2-yl}-N'-methylurea (51.1 mg) synthesized using a method similar to Example 18 (18d) The mixture was dissolved in 0° C., triethylamine (0.051 mL) and methanesulfonyl chloride (0.014 mL) were added at 0° C., and the mixture was stirred at 0° C. for 1.5 hours. To the reaction mixture was added triethylamine (0.111 mL) and methanesulfonyl chloride (0.048 mL), and the mixture was stirred at 0° C. for 3.5 hours, then triethylamine (0.111 mL) and methanesulfonyl chloride (0.048 mL), and the mixture was stirred at 0° C. for 2 hours. Water was added to the reaction mixture, extracted three times with chloroform using a phase separator (Biotage Co., Ltd.), and the combined organic layers were dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel chromatography [eluent: hexane / ethyl acetate=88 / 12-0 / 100 (V / V); ethyl acetate / methanol=100 / 0-80 / 20 (V / V)] to give 7.1 mg (yield: 12%) of the title compound as a white solid. (Example 32) Propan-2-yl 10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate propan-2-yl 10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azocine-6(5H)-carboxylate 2-(trimethylsilyl)ethyl of Example 31(31c) N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate was synthesized using the same method as in Example 18 (18d) to N-{10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-2-yl}-N'-methylurea (51.1 mg) synthesized using a method similar to Example 18 (18d) The mixture was dissolved in (mL), triethylamine (0.051 mL) and isopropyl chloroformate (0.021 mL) were added at 0° C., and the mixture was stirred at 0° C. for 16 hours. To the reaction mixture was added triethylamine (0.111 mL) and isopropyl chloroformate (0.070 mL), and the mixture was stirred at 0° C. for 2.5 hours. Water was added to the reaction mixture, extracted three times with chloroform using a phase separator (Biotage Co., Ltd.), and the combined organic layers were dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel chromatography [eluent: hexane / ethyl acetate=88 / 12-0 / 100 (V / V)] to give 26.9 mg (yield: 44%) of the title compound as a white solid. (Example 33) Methyl (4R) * ,8R * )-2-{[(2-hydroxy-2-methylpropyl)carbamoyl]amino}-10-{3-[1-(trifluoromethyl)cyclopropyl]-1,2,4-oxadiazol-5-yl}-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate (33a) Methyl (4R) * ,8R * )-2-[(tert-butoxycarbonyl)amino]-10-{3-[1-(trifluoromethyl)cyclopropyl]-1,2,4-oxadiazol-5-yl}-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate methyl (4R) * ,8R * )-2-[(tert-butoxycarbonyl)amino]-10-{3-[1-(trifluoromethyl)cyclopropyl]-1,2,4-oxadiazol-5-yl}-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azocine-6(5H)-carboxylate Methyl of Example 24 (24e) (4R * ,8R * Methyl synthesized in the same manner as in Example 18 (18c) from )-2-amino-10-cyano-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate (4R) * ,8R * )-2-[(tert-butoxycarbonyl)amino]-10-cyano-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate (400 mg) and N'-hydroxy-1-(trifluoromethyl)cyclopropane-1-carboximidamide of Example 37(37a) (160 mg) were used to obtain 300 mg of the title compound as a yellow solid in the same manner as in Example 1(1d). (33b) Methyl (4R) * ,8R * )-2-{[(2-hydroxy-2-methylpropyl)carbamoyl]amino}-10-{3-[1-(trifluoromethyl)cyclopropyl]-1,2,4-oxadiazol-5-yl}-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate methyl (4R) * ,8R * )-2-{[(2-hydroxy-2-methylpropyl)carbamoyl]amino}-10-{3-[1-(trifluoromethyl)cyclopropyl]-1,2,4-oxadiazol-5-yl}-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azocine-6(5H)-carboxylate Methyl of Example 33 (33a) (4R * ,8R * Methyl synthesized in the same manner as Example 6 (6h) from )-2-[(tert-butoxycarbonyl)amino]-10-{3-[1-(trifluoromethyl)cyclopropyl]-1,2,4-oxadiazol-5-yl}-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate (4R) * ,8R * )-2-amino-10-{3-[1-(trifluoromethyl)cyclopropyl]-1,2,4-oxadiazol-5-yl}-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azosine-6(5H)-carboxylate (130 mg) and 1-amino-2-methylpropan-2-ol (100 mg) were used to obtain 40 mg of the title compound as a white solid in the same manner as in Example 5 (5d). (Example 34) N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[2-(2-hydroxyethoxy)ethyl]urea N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[2-(2-hydroxyethoxy)ethyl]urea Using 5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridine-2-amine (150 mg) and 2-(2-aminoethoxy)ethane-1-ol (0.126 mL) of Example 5 (5c), 71.3 mg (yield: 34%) of the title compound was obtained as a white solid in a similar manner to Example 5 (5d). (Example 35) N-{5-[3-(3,3-difluorocyclopentyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(1r,3r)-3-hydroxycyclobutyl]urea N-{5-[3-(3,3-difluorocyclopentyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(1r,3r)-3-hydroxycyclobutyl]urea Using 5-[3-(3,3-difluorocyclopentyl)-1,2,4-oxazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridine-2-amine (60 mg) and (1r,3r)-3-aminocyclobutan-1-ol (CAS Registry number: 41171-91-9) from 3-oxocyclopentanecarbonitrile (CAS Registry number: 41171-91-9), the title compound 81 was used in the same manner as in Example 5 (5d). mg (yield: 22%) was obtained as a white solid. (Example 36) N-{5-[3-(3,3-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-methylurea N-{5-[3-(3,3-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-methylurea 3,3-difluoro-N'-hydroxycyclohexane-1-carboximidamide (50 mg) synthesized from 3-oxocyclohexanecarbonitrile (CAS Registry number: 17983-30-1) in the same manner as in Example 1 (1a) and 1 (1b) was used to obtain 44 mg of the title compound (yield: 43%) as a white solid in the same manner as in Example 1 (1d). (Example 37) N-[(3R)-oxolan-3-yl]-N'-[(4S,8S)-10-{3-[1-(trifluoromethyl)cyclopropyl]-1,2,4-oxadiazol-5-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea (37a) N'-Hydroxy-1-(trifluoromethyl)cyclopropane-1-carboximidamide N'-hydroxy-1-(trifluoromethyl)cyclopropane-1-carboximidamide 1-(trifluoromethyl)cyclopropane-1-carboxamide (CAS Registry number: 1628184-67-7) (38.3 g) was dissolved in N,N-dimethylformamide (400 mL), 2,4,6-trichloro-1,3,5-triazine (69 g) was added, and the mixture was stirred at room temperature for 12 hours. The reaction mixture was poured into ice water (2 L), extracted three times with tert-butyl methyl ether (150 mL), and the combined organic layers were washed with saturated brine. To the resulting organic layer was added ethanol (500 mL) and 50% aqueous hydroxylamine (53 g) and the mixture was stirred at 60° C. for 12 hours. The reaction mixture was concentrated under reduced pressure, then water (500 mL) was added, and the mixture was extracted three times with ethyl acetate. The combined organic layers were washed with saturated sodium chloride solution and then dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure to give 35.5 g of the title compound (yield: 84%) as a white solid. (37b) N-[(3R)-oxolan-3-yl]-N'-[(4S,8S)-10-{3-[1-(trifluoromethyl)cyclopropyl]-1,2,4-oxadiazol-5-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea N-[(3R)-oxolan-3-yl]-N'-[(4S,8S)-10-{3-[1-(trifluoromethyl)cyclopropyl]-1,2,4-oxadiazol-5-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea N-[(4S,8S)-10-cyano-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate and (R)-3-aminotetrahydrofuran in the same way as Example 5(5d), 6(6h), 1(1c) were synthesized from the tert-butyl (4S,8S)-2-amino-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(3R)-oxolan-3-yl]urea (2.60 g) and N'-hydroxy-1-(trifluoromethyl)cyclopropane-1-carboximidamide (1.31 g) of Example 37 (37a) were used to obtain 1.73 g (yield: 46%) of the title compound as a white solid in a similar manner to Example 1 (1d). (Example 38) N-[(2R)-1-hydroxypropan-2-yl]-N'-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea (38a) 2-Chloro-5-methoxy-1,3-benzoxazole 2-chloro-5-methoxy-1,3-benzoxazole 5-Methoxybenzoxazole (CAS Registry number: 132227-03-3) (2.4 g) was suspended in tetrahydrofuran (50 mL) and lithium bis(trimethylsilyl)amide (1M tetrahydrofuran solution, 16 mL) was slowly added dropwise at -78°C. After stirring at -78° C. for 20 minutes, hexachloroethane (5.7 g) was added and stirred at -78° C. for 10 minutes and at room temperature for 1 hour. Water was added to the reaction mixture and the reaction mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography [eluent: n-hexane / ethyl acetate=1 / 0-7 / 3 (V / V)] to give 2.6 g of the title compound (yield: 88%) as a white solid. (38b) (4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-2-amine (4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-amine The (4S,8S)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-2-amine dihydrochloride (9 g) of Example 17 (17c) was dissolved in dimethylsulfoxide (50 mL), N,N-diisopropylethylamine (25 mL) and 2-chloro-5-methoxy-1,3-benzoxazole (6.2 g) of Example 38 (38a) were added, and the mixture was stirred at 20° C. for 12 hours. The reaction mixture was poured into ice water, and the reaction mixture was extracted three times with ethyl acetate, and the combined organic layers were washed with saturated brine, and then dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography [eluent: petroleum ether / ethyl acetate=1 / 1 (V / V); dichloromethane / methanol=15 / 1 (V / V)] to give 7.3 g of the title compound (yield: 56%) as a brown solid. (38c) N-[(2R)-1-hydroxypropan-2-yl]-N'-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea N-[(2R)-1-hydroxypropan-2-yl]-N'-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea Using (4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-2-amine (3 g) and (R)-2-aminopropan-1-ol (1.25 g) of Example 38(38b), 1.95 g (yield: 52%) of the title compound was obtained as a light gray solid in a similar manner to Example 5(5d). (Example 39) N-[(4S,8S)-10-(5-fluoro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminoxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea (39a) (4S,8S)-10-(5-fluoro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-2-amine (4S,8S)-10-(5-fluoro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-amine Using (4S,8S)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-2-amine dihydrochloride (6.8 g) and 2-chloro-5-fluorobenzoxazole (WO 2016 / 025669) (3.8 g) of Example 17(17c), 4.1 g (yield: 56%) of the title compound was obtained as a brown solid in a similar manner to Example 38(38b). (39b) N-[(4S,8S)-10-(5-fluoro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminoxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea N-[(4S,8S)-10-(5-fluoro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea Using (4S,8S)-10-(5-fluoro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-2-amine (2 g) and (R)-2-aminopropan-1-ol (1 g) of Example 39(39a), 1.5 g (yield: 56%) of the title compound was obtained as a white solid in the same manner as in Example 5(5d). (Example 40) N-[(4S,8S)-10-(5-ethoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-(2-hydroxy-2-methylpropyl)urea (40a) 2-Amino-4-ethoxyphenol 2-amino-4-ethoxyphenol 4-ethoxy-2-nitrophenol (Synthetic Communications (2009), 39(11), 2053-2057.) (0.3 g) was dissolved in ethanol (5 mL), 10% palladium carbon (50 mg) was added, and the mixture was stirred at 25° C. under a hydrogen (15 psi) atmosphere for 3 hours. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to give 0.23 g of the title compound (yield: 92%) as a gray solid. (40b) 5-Ethoxy-1,3-benzoxazole-2-thiol 5-ethoxy-1,3-benzoxazole-2-thiol The mixture of 2-amino-4-ethoxyphenol (1.5 g), potassium carbonodithioate O-ethyl (CAS registry number: 140-89-6) (3.27 g), and ethanol (10 mL) from Example 40 (40a) was stirred at 80° C. for 16 hours. The solvent was distilled off under reduced pressure, and the reaction mixture was diluted with water (20 mL), and further added 2 M hydrochloric acid to make it acidic. The mixture was extracted three times with ethyl acetate, and the combined organic layers were washed twice with saturated aqueous sodium hydrogen carbonate solution, and then dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the resulting residue was triturated with ethyl acetate / petroleum ether, and filtered to give 1.6 g of the title compound (yield: 84%) as a gray solid. (40c) 2-Chloro-5-ethoxy-1,3-benzoxazole 2-chloro-5-ethoxy-1,3-benzoxazole The mixture of 5-ethoxy-1,3-benzoxazole-2-thiol (50 mg) and thionyl chloride (2 mL) from Example 40 (40b) was stirred at 80° C. for 2 hours. The reaction mixture was concentrated under reduced pressure to give 50 mg of the title compound (quantitative yield) as a gray solid. (40d) (4S,8S)-10-(5-ethoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminoxocino[5,4-d][1,3]thiazole-2-amine (4S,8S)-10-(5-ethoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-amine Using (4S,8S)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-2-amine dihydrochloride (68 mg) and 2-chloro-5-ethoxy-1,3-benzoxazole (50 mg) of Example 40 (40c), the title compound was obtained as a gray solid in a similar manner to Example 38 (38b). (40e) N-[(4S,8S)-10-(5-ethoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-(2-hydroxy-2-methylpropyl)urea N-[(4S,8S)-10-(5-ethoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-(2-hydroxy-2-methylpropyl)urea Using (4S,8S)-10-(5-ethoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-2-amine (0.20 g) and 1-amino-2-methylpropan-2-ol (0.20 g) of Example 40 (40d), 101 mg of the title compound (yield: 38%) as a light gray solid. (Example 41) N-{(4S,8S)-10-[5-(dimethylamino)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(2-hydroxy-2-methylpropyl)urea (41a) (4S,8S)-10-(5-nitro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminoxocino[5,4-d][1,3]thiazole-2-amine (4S,8S)-10-(5-nitro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-amine Using (4S,8S)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-2-amine dihydrochloride (1.5 g) and 2-chloro-5-nitro-1,3-benzoxazole (WO 2016 / 207785) (1.3 g) of Example 17(17c), 1.8 g (yield: 77%) of the title compound was obtained as a yellow solid in a similar manner to Example 38(38b). (41b) tert-Butyl [(4S,8S)-10-(5-nitro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]carbamate tert-butyl [(4S,8S)-10-(5-nitro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]carbamate Example 41(41a) (4S,8S)-10-(5-nitro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminoxocino[5,4-d][1,3]thiazole-2-amine (1.7 g) was dissolved in dichloromethane (30 mL), 4-dimethylaminopyridine (200 mg) and di-tert-butyl dicarbonate (1.2 g) were added, and the mixture was stirred at room temperature for 2 hours. The solvent was distilled off from the reaction mixture under reduced pressure, and the resulting residue was purified by silica gel column chromatography [eluent solvent: petroleum ether / ethyl acetate=1 / 0-7 / 3 (V / V)] to give 1.5 g of the title compound (yield: 69%) as a yellow solid. (41c) tert-Butyl [(4S,8S)-10-(5-amino-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]carbamate tert-butyl [(4S,8S)-10-(5-amino-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]carbamate Example 41(41b) tert-butyl[(4S,8S)-10-(5-nitro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]carbamate (1.5 g) was dissolved in methanol (20 mL), 10% palladium carbon (0.2 g) was added, and the mixture was stirred at room temperature under a hydrogen (15 psi) atmosphere for 10 hours. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to give 1 g of the title compound (yield: 71%) as a brown solid. (41d) tert-Butyl {(4S,8S)-10-[5-(dimethylamino)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}carbamate tert-butyl {(4S,8S)-10-[5-(dimethylamino)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}carbamate Example 41(41c) tert-butyl[(4S,8S)-10-(5-amino-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]carbamate (500 mg) was dissolved in methanol (30 mL), formaldehyde (164 mg) and tetraisopropyl orthotitanate (385 mg) were added, and the mixture was stirred at room temperature for 10 hours. Sodium cyanoborohydride (150 mg) was added thereto, and the mixture was stirred at room temperature for 1 hour. The solvent was evaporated from the reaction mixture under reduced pressure, and water was added to the resulting residue, and extracted twice with ethyl acetate. The combined organic layers were washed with saturated sodium chloride solution and then dried over anhydrous sodium sulfate. After filtration, the solvent was evaporated under reduced pressure to give 500 mg of the title compound (yield: 94%) as a gray solid. (41e) (4S,8S)-10-[5-(dimethylamino)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-2-amine (4S,8S)-10-[5-(dimethylamino)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-amine Example 41(41d) tert-butyl{(4S,8S)-10-[5-(dimethylamino)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}carbamate (600 mg) was dissolved in dichloromethane (40 mL), 4 M hydrogen chloride-ethyl acetate solution (18 mL) was added, and the mixture was stirred at room temperature for 1 hour. The solvent was distilled off from the reaction mixture under reduced pressure, and to the resulting residue was added dichloromethane (30 mL) and 3M aqueous sodium hydrogen carbonate solution (20 mL), and the mixture was stirred at 20° C. for 30 minutes. The reaction mixture was poured into water, extracted three times with dichloromethane, and the combined organic layers were washed with saturated brine, and then dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure to give 400 mg of the title compound (yield: 84%) as a light gray solid. (41f) N-{(4S,8S)-10-[5-(dimethylamino)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(2-hydroxy-2-methylpropyl)urea N-{(4S,8S)-10-[5-(dimethylamino)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(2-hydroxy-2-methylpropyl)urea Using (4S,8S)-10-[5-(dimethylamino)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-2-amine (150 mg) and 1-amino-2-methylpropan-2-ol (75 mg) of Example 41(41e), 87 mg (yield: 43%) of the title compound was obtained as a light gray solid in a similar manner to Example 5 (5d). (Example 42) N-[(4S,8S)-10-(5,6-difluoro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea (42a) (4S,8S)-10-(5,6-difluoro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminoxocino[5,4-d][1,3]thiazole-2-amine (4S,8S)-10-(5,6-difluoro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-amine 150 mg (yield: 74%) of the title compound was obtained as a yellow solid using (4S,8S)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-2-amine dihydrochloride (180 mg) and 2-chloro-5,6-difluoro-1,3-benzoxazole (WO 2018 / 037223) (110 mg) of Example 17 (17c). 150 mg (yield: 74%) in a yellow solid. (42b) N-[(4S,8S)-10-(5,6-difluoro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea N-[(4S,8S)-10-(5,6-difluoro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea Using (4S,8S)-10-(5,6-difluoro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-2-amine (150 mg) and (R)-2-aminopropan-1-ol (35 mg) of Example 42(42a), 96 mg of the title compound (yield: 49%) as a white solid was obtained in the same manner as in Example 5(5d). (Example 43) N-{(4S,8S)-10-[5-(methanesulfonyl)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(2-methylpropyl)urea (43a) (4S,8S)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-2-amine (4S,8S)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-amine The tert-butyl (4S,8S)-2-amino-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazole-10-carboxylate (30 g) of Example 7 (7a) was dissolved in dichloromethane (240 mL), trifluoroacetic acid (60 mL) was added, and the mixture was stirred at room temperature for 2 hours. The reaction solution was concentrated and azeotroped twice with toluene, and the resulting residue was purified by NH silica gel column chromatography [elution solvent: methanol / ethyl acetate=0 / 1...

Claims

1. A compound of formula (1) or a pharmaceutically acceptable salt thereof.

2. R 1 and R 2 are all hydrogen atoms or R 1 and R 2 are bonded to each other to form a substituent, and represent any group selected from the following: R 12 R: methyl group, hydroxyethyl group, acetyl group, methoxycarbonyl group, or methanesulfonyl group 3 The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein represents a hydrogen atom or a methyl group.

3. R 1 and R 2 are all hydrogen atoms or R 1 and R 2 are bonded to each other to form a substituent, and represent any group selected from the following: R 13 : acetyl group or methoxycarbonyl group R 3 The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein: represents a hydrogen atom.

4. R 1 and R 3 Both of these represent methyl groups, and R 2 The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein represents a hydrogen atom.

5. R 6 represents any group selected from the following: a C1-C6 alkyl group, a hydroxy C1-C6 alkyl group, a hydroxy C3-C6 cycloalkyl group, a C1-C6 alkoxy C1-C6 alkyl group, a tetrahydrofuranyl group, a tetrahydropyranyl group, or a dioxanylmethyl group; R 7 The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein represents a hydrogen atom.

6. R 6 is any group selected from the following: a methyl group, an isobutyl group, a 2-hydroxy-1-methylethyl group, a 2-hydroxy-2-methylpropyl group, a 3-hydroxybutyl group, a 2-hydroxycyclopentyl group, a 4-hydroxycyclohexyl group, a 2-methoxypropyl group, a 3-tetrahydrofuranyl group, a 4-tetrahydropyranyl group, or a 1,4-dioxan-2-ylmethyl group, R 7 The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein: is a hydrogen atom.

7. The compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein Q represents any group selected from the following: R Q4 a C3-C6 cycloalkyl group substituted with 1 to 3 groups selected from the group consisting of Q4 a phenyl group substituted with 1 to 3 groups selected from the group consisting of Q4 a pyridyl group substituted with 1 to 3 groups selected from the group consisting of Q4 a 1,3-benzoxazol-2-yl group R substituted with 1 to 3 groups selected from Q4 : halogen atom, cyano group, C1-C6 alkyl group, C1-C6 alkoxy group, halo C1-C6 alkyl group, halo C1-C6 alkoxy group, C1-C6 alkylsulfonyl group, di C1-C6 alkylamino group, or C3-C6 cycloalkylcarbonyl group 8. The compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein Q represents any group selected from the following: a cyclohexyl group substituted with two fluorine atoms, a phenyl group substituted with a fluorine atom or a cyclopropylcarbonyl group, a pyridyl group substituted with one group selected from the group consisting of a methoxy group, an ethoxy group, and a difluoromethoxy group, or a 1,3-benzoxazol-2-yl group substituted with one or two groups independently selected from the group consisting of a fluorine atom, a methyl group, a methoxy group, an ethoxy group, a dimethylamino group, and a methanesulfonyl group.

9. Y represents a single bond or any group selected from the following:

9. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the group can be oriented either left or right.

10. The compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein Q represents a 1,3-benzoxazol-2-yl group substituted with one or two groups independently selected from the group consisting of a fluorine atom, a methyl group, a methoxy group, an ethoxy group, a dimethylamino group, and a methanesulfonyl group, and Y represents a single bond.

11. Q represents a cyclohexyl group substituted with two fluorine atoms, a phenyl group substituted with a fluorine atom or a cyclopropylcarbonyl group, or a pyridyl group substituted with one group selected from the group consisting of a methoxy group, an ethoxy group, and a difluoromethoxy group, and Y represents any group selected from the following:

7. The compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof.

12. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, selected from the following compounds: N-[(4S,8S)-10-{5-[3-(cyclopropanecarbonyl)phenyl]-1,3,4-oxadiazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-methylurea, (-)-N-{(4R * ,8R * )-6-acetyl-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7,8,9-hexahydro-4,8-epimino[1,3]thiazolo[5,4-d]azocin-2-yl}-N'-methylurea, (-)-methyl (4R * ,8R * )-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-[(methylcarbamoyl)amino]-4,7,8,9-tetrahydro-4,8-epimino[1,3]thiazolo[5,4-d]azocine-6(5H)-carboxylate, N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(1R,2R)-2-hydroxycyclopentyl]urea, N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-[(1r,4r)-4-hydroxycyclohexyl]urea, N-{5-[3-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-5-yl]-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}-N'-(3-methoxypropyl)urea N-{[(2S)-1,4-dioxan-2-yl]methyl}-N'-{(4S,8S)-10-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}urea, N-[(2R)-1-hydroxypropan-2-yl]-N'-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-[(4S,8S)-10-(5-fluoro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-[(4S,8S)-10-(5-ethoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-(2-hydroxy-2-methylpropyl)urea, N-{(4S,8S)-10-[5-(dimethylamino)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(2-hydroxy-2-methylpropyl)urea, N-[(4S,8S)-10-(5,6-difluoro-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-{(4S,8S)-10-[5-(methanesulfonyl)-1,3-benzoxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(2-methylpropyl)urea, N-(2-hydroxy-2-methylpropyl)-N'-[(4S,8S)-10-(5-methoxy-6-methyl-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-[(4S,8S)-10-(5-methoxy-6-methyl-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(3R)-oxolan-3-yl]urea, N-(2-hydroxy-2-methylpropyl)-N'-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(3R)-oxolan-3-yl]urea, N-[(4S,8S)-10-(5-methoxy-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-methylurea, N-methyl-N'-[(4S,8S)-10-(5-methyl-1,3-benzoxazol-2-yl)-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-(2-hydroxy-2-methylpropyl)-N'-[(4S,8S)-10-{5-[(, 2 H3) [methyloxy]-1,3-benzoxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-{(4S,8S)-10-[5-(4-fluorophenyl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(1s,4s)-4-hydroxycyclohexyl]urea, N-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,2-oxazol-3-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-oxan-4-ylurea, N-[(4S,8S)-10-{5-[6-(difluoromethoxy)pyridin-2-yl]-1,3-oxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-[(2R)-1-hydroxypropan-2-yl]-N'-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}urea, N-{(4S,8S)-10-[5-(6-ethoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(2R)-1-hydroxypropan-2-yl]urea, N-[(2R)-1-hydroxypropan-2-yl]-N'-{5-[5-(methanesulfonyl)-1,3-benzoxazol-2-yl]-6,6-dimethyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}urea, N-(2-hydroxy-2-methylpropyl)-N'-{5-[5-(methanesulfonyl)-1,3-benzoxazol-2-yl]-6,6-dimethyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl}urea, N-[(2R)-1-hydroxypropan-2-yl]-N'-[(4S,8S)-10-{5-[(, 2 H3) methyloxy]-1,3-benzoxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]urea, N-[(4S,8S)-10-{5-[( 2 H3) methyloxy]-1,3-benzoxazol-2-yl}-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl]-N'-[(3R)-oxolan-3-yl]urea, N-[(1r,3S)-3-hydroxycyclobutyl]-N'-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}urea, N-{(4S,8S)-10-[5-(6-ethoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-(2-hydroxy-2-methylpropyl)urea, N-{(4S,8S)-10-[5-(6-ethoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-[(1r,3S)-3-hydroxycyclobutyl]urea, N-{(4S,8S)-10-[5-(6-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-4,7,8,9-tetrahydro-5H-4,8-epiminooxocino[5,4-d][1,3]thiazol-2-yl}-N'-oxan-4-ylurea 13. A SIRT6 activator comprising, as an active ingredient, the compound according to any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition comprising, as an active ingredient, a compound according to any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof.

15. The pharmaceutical composition according to claim 14, which is an oral preparation.

16. The pharmaceutical composition according to claim 14, which is an external preparation.

17. A pharmaceutical composition according to any one of claims 14 to 16 for treating and / or preventing peripheral inflammatory diseases.

18. Peripheral inflammatory diseases include rheumatoid arthritis, systemic lupus erythematosus, scleroderma, bronchial asthma, asthmatic bronchitis, diffuse interstitial pneumonia, chronic obstructive pulmonary disease, ulcerative colitis, Crohn's disease, acute hepatitis, chronic hepatitis, fulminant hepatitis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, alcoholic hepatitis, non-alcoholic steatohepatitis, liver cirrhosis, peripheral neuritis, and ankylosing spondylitis. , acute eczema, subacute eczema, chronic eczema, contact dermatitis, sun dermatitis caused by sunlight and / or ultraviolet rays, radiation dermatitis, atopic dermatitis, seborrheic dermatitis, psoriasis vulgaris, arthritic psoriasis, erythrodermic psoriasis, pustular psoriasis, lichen planus, erythroderma, rosacea, urticaria, alopecia areata, pemphigus, erythroderma, acne vulgaris, pressure ulcers, wounds, burns, conjunctivitis, keratitis, scleritis, acute and chronic otitis media, perennial alopecia Allergic rhinitis, hay fever, sinusitis, laryngitis, esophagitis, intractable stomatitis, glossitis, acute and chronic sialadenitis, angular cheilitis, cheilitis, Behcet's disease, multiple sclerosis, type I diabetes, type II diabetes, atherosclerosis, pancreatitis, chronic heart failure, vitiligo, common warts, diabetic ulcers, leg ulcers, keloids, hypertrophic scars, seborrheic keratosis, male pattern baldness, female pattern baldness, senile 18. The pharmaceutical composition according to claim 17, wherein the symptom is any one selected from the group consisting of alopecia, acne scars, pigmentation, actinic keratosis, gray hair, chronic hand eczema, chronic pruritus, generalized pruritus, glaucoma, cataracts, age-related macular degeneration, idiopathic pulmonary fibrosis, acute glomerulonephritis, chronic glomerulonephritis, diabetic nephropathy, hypertrophic cardiomyopathy, osteoporosis, neurogenic muscular atrophy, myogenic muscular atrophy, and hypertension.

19. Peripheral inflammatory diseases include rheumatoid arthritis, systemic lupus erythematosus, scleroderma, bronchial asthma, acute hepatitis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, alcoholic hepatitis, non-alcoholic steatohepatitis, ankylosing spondylitis, contact dermatitis, sun dermatitis caused by sunlight and / or ultraviolet rays, radiation dermatitis, atopic dermatitis, seborrheic dermatitis, psoriasis vulgaris, psoriatic arthritis, erythrodermic psoriasis, pustular psoriasis, lichen planus, erythroderma, rosacea, urticaria, alopecia areata, pemphigus, erythroderma, acne vulgaris, and pressure ulcers.

18. The pharmaceutical composition according to claim 17, wherein the treatment is any one selected from the group consisting of wounds, burns, sinusitis, laryngitis, esophagitis, intractable stomatitis, glossitis, acute / chronic sialadenitis, angular cheilitis, cheilitis, Behcet's disease, vitiligo, common warts, diabetic ulcers, leg ulcers, keloids, hypertrophic scars, seborrheic keratosis, male pattern baldness, female pattern baldness, senile alopecia, acne scars, pigmentation disorders, actinic keratosis, candy hair, chronic hand eczema, chronic pruritus, generalized pruritus, and idiopathic pulmonary fibrosis.

20. Peripheral inflammatory diseases include rheumatoid arthritis, systemic lupus erythematosus, alcoholic hepatitis, non-alcoholic steatohepatitis, contact dermatitis, sun dermatitis caused by sunlight and / or ultraviolet rays, radiation dermatitis, atopic dermatitis, seborrheic dermatitis, psoriasis vulgaris, psoriatic arthritis, erythrodermic psoriasis, pustular psoriasis, lichen planus, erythroderma, rosacea, urticaria, alopecia areata, pemphigus, erythroderma, acne vulgaris, pressure ulcers, wounds, and fever.

18. The pharmaceutical composition according to claim 17, wherein the condition is any one selected from the group consisting of wounds, intractable stomatitis, glossitis, Behcet's disease, vitiligo vulgaris, common warts, diabetic ulcers, leg ulcers, keloids, hypertrophic scars, seborrheic keratosis, male pattern baldness, female pattern baldness, senile alopecia, acne scars, pigmentation disorders, actinic keratosis, candy hair, chronic hand eczema, chronic pruritus, generalized pruritus, and idiopathic pulmonary fibrosis.

21. A method for treating and / or preventing peripheral inflammatory diseases, comprising administering an effective amount of the pharmaceutical composition according to any one of claims 14 to 16.

22. Peripheral inflammatory diseases include rheumatoid arthritis, systemic lupus erythematosus, scleroderma, bronchial asthma, asthmatic bronchitis, diffuse interstitial pneumonia, chronic obstructive pulmonary disease, ulcerative colitis, Crohn's disease, acute hepatitis, chronic hepatitis, fulminant hepatitis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, alcoholic hepatitis, non-alcoholic steatohepatitis, liver cirrhosis, peripheral neuritis, and ankylosing spondylitis. , acute eczema, subacute eczema, chronic eczema, contact dermatitis, sun dermatitis caused by sunlight and / or ultraviolet rays, radiation dermatitis, atopic dermatitis, seborrheic dermatitis, psoriasis vulgaris, arthritic psoriasis, erythrodermic psoriasis, pustular psoriasis, lichen planus, erythroderma, rosacea, urticaria, alopecia areata, pemphigus group, erythroderma, acne vulgaris, pressure ulcers, wounds, burns, conjunctivitis, keratitis, scleritis, acute and chronic otitis media, perennial Allergic rhinitis, hay fever, sinusitis, laryngitis, esophagitis, intractable stomatitis, glossitis, acute and chronic sialadenitis, angular cheilitis, cheilitis, Behcet's disease, multiple sclerosis, type I diabetes, type II diabetes, atherosclerosis, pancreatitis, chronic heart failure, vitiligo, common warts, diabetic ulcers, leg ulcers, keloids, hypertrophic scars, seborrheic keratosis, male pattern baldness, female pattern baldness, senility 22. The method of claim 21, wherein the condition is any one selected from the group consisting of alopecia areata, acne scars, pigmentation disorders, actinic keratosis, gray hair, chronic hand eczema, chronic pruritus, generalized pruritus, glaucoma, cataracts, age-related macular degeneration, idiopathic pulmonary fibrosis, acute glomerulonephritis, chronic glomerulonephritis, diabetic nephropathy, hypertrophic cardiomyopathy, osteoporosis, neurogenic muscular atrophy, myogenic muscular atrophy, and hypertension.

23. Peripheral inflammatory diseases include rheumatoid arthritis, systemic lupus erythematosus, scleroderma, bronchial asthma, acute hepatitis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, alcoholic hepatitis, non-alcoholic steatohepatitis, ankylosing spondylitis, contact dermatitis, sun dermatitis caused by sunlight and / or ultraviolet rays, radiation dermatitis, atopic dermatitis, seborrheic dermatitis, psoriasis vulgaris, psoriatic arthritis, erythrodermic psoriasis, pustular psoriasis, lichen planus, erythroderma, rosacea, urticaria, alopecia areata, pemphigus, erythroderma, and psoriasis vulgaris.

22. The method of claim 21, wherein the condition is any one selected from the group consisting of acne vulgaris, bedsores, wounds, burns, sinusitis, laryngitis, esophagitis, intractable stomatitis, glossitis, acute / chronic sialadenitis, angular cheilitis, cheilitis, Behcet's disease, vitiligo, common warts, diabetic ulcers, leg ulcers, keloids, hypertrophic scars, seborrheic keratosis, male pattern baldness, female pattern baldness, senile alopecia, acne scars, pigmentation disorders, actinic keratosis, candy hair, chronic hand eczema, chronic pruritus, generalized pruritus, and idiopathic pulmonary fibrosis.

24. Peripheral inflammatory diseases include rheumatoid arthritis, systemic lupus erythematosus, alcoholic hepatitis, non-alcoholic steatohepatitis, contact dermatitis, sun dermatitis caused by sunlight and / or ultraviolet rays, radiation dermatitis, atopic dermatitis, seborrheic dermatitis, psoriasis vulgaris, psoriatic arthritis, erythrodermic psoriasis, pustular psoriasis, lichen planus, erythroderma, rosacea, urticaria, alopecia areata, pemphigus, erythroderma, acne vulgaris, pressure ulcers, and wounds.

22. The method of claim 21, wherein the condition is any one selected from the group consisting of burns, intractable stomatitis, glossitis, Behcet's disease, vitiligo vulgaris, common warts, diabetic ulcers, leg ulcers, keloids, hypertrophic scars, seborrheic keratosis, male pattern baldness, female pattern baldness, senile alopecia, acne scars, pigmentation disorders, actinic keratosis, gray hair, chronic hand eczema, chronic pruritus, generalized pruritus, and idiopathic pulmonary fibrosis.

25. A compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, for use in the treatment and / or prevention of peripheral inflammatory diseases.

26. Peripheral inflammatory diseases include rheumatoid arthritis, systemic lupus erythematosus, scleroderma, bronchial asthma, asthmatic bronchitis, diffuse interstitial pneumonia, chronic obstructive pulmonary disease, ulcerative colitis, Crohn's disease, acute hepatitis, chronic hepatitis, fulminant hepatitis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, alcoholic hepatitis, non-alcoholic steatohepatitis, liver cirrhosis, peripheral neuritis, ankylosing spondylitis, acute eczema, and Eczema, subacute eczema, chronic eczema, contact dermatitis, sun dermatitis caused by sunlight and / or ultraviolet rays, radiation dermatitis, atopic dermatitis, seborrheic dermatitis, psoriasis vulgaris, arthritic psoriasis, erythrodermic psoriasis, pustular psoriasis, lichen planus, erythroderma, rosacea, urticaria, alopecia areata, pemphigus, erythroderma, acne vulgaris, pressure ulcers, wounds, burns, conjunctivitis, keratitis, scleritis, acute and chronic otitis media, perennial allergic rhinitis , hay fever, sinusitis, laryngitis, esophagitis, intractable stomatitis, glossitis, acute and chronic sialadenitis, angular cheilitis, cheilitis, Behcet's disease, multiple sclerosis, type I diabetes, type II diabetes, atherosclerosis, pancreatitis, chronic heart failure, vitiligo, common warts, diabetic ulcers, leg ulcers, keloids, hypertrophic scars, seborrheic keratosis, male pattern baldness, female pattern baldness, senile alopecia, acne scars, pigmentation 26. The compound according to claim 25, or a pharmaceutically acceptable salt thereof, wherein the compound is any one selected from the group consisting of glomerulonephritis, actinic keratosis, canities of hair, chronic hand eczema, chronic pruritus, generalized pruritus, glaucoma, cataracts, age-related macular degeneration, idiopathic pulmonary fibrosis, acute glomerulonephritis, chronic glomerulonephritis, diabetic nephropathy, hypertrophic cardiomyopathy, osteoporosis, neurogenic muscular atrophy, myogenic muscular atrophy, and hypertension.

27. Peripheral inflammatory diseases include rheumatoid arthritis, systemic lupus erythematosus, scleroderma, bronchial asthma, acute hepatitis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, alcoholic hepatitis, non-alcoholic steatohepatitis, ankylosing spondylitis, contact dermatitis, sun dermatitis caused by sunlight and / or ultraviolet rays, radiation dermatitis, atopic dermatitis, seborrheic dermatitis, psoriasis vulgaris, psoriatic arthritis, erythrodermic psoriasis, pustular psoriasis, lichen planus, erythroderma, rosacea, urticaria, alopecia areata, pemphigus, erythroderma, acne vulgaris, pressure ulcers, and wounds.

26. The compound according to claim 25, or a pharmaceutically acceptable salt thereof, which is any one selected from the group consisting of wounds, burns, sinusitis, laryngitis, esophagitis, refractory stomatitis, glossitis, acute / chronic sialadenitis, angular stomatitis, cheilitis, Behcet's disease, vitiligo, common warts, diabetic ulcers, leg ulcers, keloids, hypertrophic scars, seborrheic keratosis, male pattern baldness, female pattern baldness, senile alopecia, acne scars, pigmentation disorders, actinic keratosis, candy hair, chronic hand eczema, chronic pruritus, generalized pruritus, and idiopathic pulmonary fibrosis.

28. Peripheral inflammatory diseases include rheumatoid arthritis, systemic lupus erythematosus, alcoholic hepatitis, non-alcoholic steatohepatitis, contact dermatitis, sun dermatitis caused by sunlight and / or ultraviolet rays, radiation dermatitis, atopic dermatitis, seborrheic dermatitis, psoriasis vulgaris, psoriatic arthritis, erythrodermic psoriasis, pustular psoriasis, lichen planus, erythroderma, rosacea, urticaria, alopecia areata, pemphigus complex, erythroderma, acne vulgaris, pressure ulcers, wounds, burns, and refractory oral diseases.

26. The compound according to claim 25, or a pharmaceutically acceptable salt thereof, which is any one selected from the group consisting of internal inflammation, glossitis, Behcet's disease, vitiligo vulgaris, common warts, diabetic ulcers, leg ulcers, keloids, hypertrophic scars, seborrheic keratosis, male pattern baldness, female pattern baldness, senile alopecia, acne scars, pigmentation disorders, actinic keratosis, candy hair, chronic hand eczema, chronic pruritus, generalized pruritus, and idiopathic pulmonary fibrosis.

29. Use of a compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, in the manufacture of a pharmaceutical composition for use in treating and / or preventing peripheral inflammatory diseases.

30. Peripheral inflammatory diseases include rheumatoid arthritis, systemic lupus erythematosus, scleroderma, bronchial asthma, asthmatic bronchitis, diffuse interstitial pneumonia, chronic obstructive pulmonary disease, ulcerative colitis, Crohn's disease, acute hepatitis, chronic hepatitis, fulminant hepatitis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, alcoholic hepatitis, non-alcoholic steatohepatitis, liver cirrhosis, peripheral neuritis, and ankylosing spondylitis. , acute eczema, subacute eczema, chronic eczema, contact dermatitis, sun dermatitis caused by sunlight and / or ultraviolet rays, radiation dermatitis, atopic dermatitis, seborrheic dermatitis, psoriasis vulgaris, arthritic psoriasis, erythrodermic psoriasis, pustular psoriasis, lichen planus, erythroderma, rosacea, urticaria, alopecia areata, pemphigus group, erythroderma, acne vulgaris, pressure ulcers, wounds, burns, conjunctivitis, keratitis, scleritis, acute and chronic otitis media, perennial Allergic rhinitis, hay fever, sinusitis, laryngitis, esophagitis, intractable stomatitis, glossitis, acute and chronic sialadenitis, angular cheilitis, cheilitis, Behcet's disease, multiple sclerosis, type I diabetes, type II diabetes, atherosclerosis, pancreatitis, chronic heart failure, vitiligo, common warts, diabetic ulcers, leg ulcers, keloids, hypertrophic scars, seborrheic keratosis, male pattern baldness, female pattern baldness, senility 30. The use according to claim 29, wherein the condition is any selected from the group consisting of alopecia areata, acne scars, pigmentation, actinic keratosis, gray hair, chronic hand eczema, chronic pruritus, generalized pruritus, glaucoma, cataracts, age-related macular degeneration, idiopathic pulmonary fibrosis, acute glomerulonephritis, chronic glomerulonephritis, diabetic nephropathy, hypertrophic cardiomyopathy, osteoporosis, neurogenic muscular atrophy, myogenic muscular atrophy, and hypertension.

31. Peripheral inflammatory diseases include rheumatoid arthritis, systemic lupus erythematosus, scleroderma, bronchial asthma, acute hepatitis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, alcoholic hepatitis, non-alcoholic steatohepatitis, ankylosing spondylitis, contact dermatitis, sun dermatitis caused by sunlight and / or ultraviolet rays, radiation dermatitis, atopic dermatitis, seborrheic dermatitis, psoriasis vulgaris, psoriatic arthritis, erythrodermic psoriasis, pustular psoriasis, lichen planus, erythroderma, rosacea, urticaria, alopecia areata, pemphigus, erythroderma, and psoriasis vulgaris.

30. The use according to claim 29, wherein the condition is any selected from the group consisting of acne vulgaris, pressure ulcers, wounds, burns, sinusitis, laryngitis, esophagitis, intractable stomatitis, glossitis, acute / chronic sialadenitis, angular cheilitis, cheilitis, Behcet's disease, vitiligo, common warts, diabetic ulcers, leg ulcers, keloids, hypertrophic scars, seborrheic keratosis, male pattern baldness, female pattern baldness, senile alopecia, acne scars, pigmentation disorders, actinic keratosis, gray hair, chronic hand eczema, chronic pruritus, generalized pruritus, and idiopathic pulmonary fibrosis.

32. Peripheral inflammatory diseases include rheumatoid arthritis, systemic lupus erythematosus, alcoholic hepatitis, non-alcoholic steatohepatitis, contact dermatitis, sun dermatitis caused by sunlight and / or ultraviolet rays, radiation dermatitis, atopic dermatitis, seborrheic dermatitis, psoriasis vulgaris, psoriatic arthritis, erythrodermic psoriasis, pustular psoriasis, lichen planus, erythroderma, rosacea, urticaria, alopecia areata, pemphigus, erythroderma, acne vulgaris, pressure ulcers, and wounds.

30. The use according to claim 29, wherein the condition is any selected from the group consisting of burns, intractable stomatitis, glossitis, Behcet's disease, vitiligo, common warts, diabetic ulcers, leg ulcers, keloids, hypertrophic scars, seborrheic keratosis, male pattern baldness, female pattern baldness, senile alopecia, acne scars, pigmentation disorders, actinic keratosis, gray hair, chronic hand eczema, chronic pruritus, generalized pruritus, and idiopathic pulmonary fibrosis.